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Background: Dopamine is a key modulator of striatal function and learning, and may improve motor
recovery after stroke. Seven small trials of dopamine agonists after stroke have provided equivocal
evidence of the clinical effectiveness of dopamine agonists in improving motor recovery.
Design: Dopamine Augmented Rehabilitation in Stroke was a multicentre, randomised, double-blind,
placebo-controlled trial with stroke patients randomised to receive 6 weeks of co-careldopa (Sinemet®,
Merck Sharp & Dohme Ltd) or placebo in combination with occupational and physical rehabilitation.
Methods: The primary outcome measure was the proportion of patients walking independently at 8 weeks
[Rivermead Mobility Index (RMI) score of ≥ 7 points and ‘yes’ to item 7 on the RMI]. Secondary outcome
measures assessed physical functioning, pain, cognition, mood, fatigue and carer burden at 8 weeks,
6 months and 12 months.
Results: Between May 2011 and March 2014, 593 patients (mean age 68.5 years) and 165 carers
(mean age 59.7 years) were recruited from stroke rehabilitation units; 308 patients were randomised to
co-careldopa and 285 to placebo at a median of 15 days following stroke onset. The study drug was
to be taken 45–60 minutes before therapy, which included motor activities (mean 23.2 and 24.8 sessions
in the co-careldopa and placebo groups, respectively). The mean number of investigational medicinal
product doses taken was 20.6 in the co-careldopa group and 22.4 in the placebo group. Ability to walk
independently was not improved at 8 weeks [40.6% (co-careldopa) vs. 44.6% (placebo); odds ratio 0.78,
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95% confidence interval (CI) 0.53 to 1.15], 6 months [51.6% (co-careldopa) vs. 53.3% (placebo)] or
12 months [51.6% (co-careldopa) vs. 56.8% (placebo)]. There were no significant differences for Barthel
Index, Nottingham Extended Activities of Daily Living, ABILHAND Manual Ability Measure or Modified
Rankin Scale, pain or fatigue at any time point. Montreal Cognitive Assessment scores did not significantly
differ; the majority of participants had cognitive impairment at baseline, which improved during 12 months’
follow-up. No difference was observed in General Health Questionnaire 12-item version scores between
groups at 8 weeks and 12 months but, at 6 months, those in the co-careldopa group reported significantly
better general health [mean difference (MD) –1.33, 95% CI –2.57 to –0.10]. Mortality at 12 months was
not significantly different. Carers in the placebo group reported significantly greater burden at 6 months
(MD 5.05, 95% CI 0.10 to 10.01) and 12 months (MD 7.52, 95% CI 1.87 to 13.18).
Conclusion: Co-careldopa in addition to routine NHS occupational and physical therapy is not clinically
effective or cost-effective in improving walking, physical functioning, mood or cognition following stroke.
We recommend further research to develop imaging and clinical markers that would allow identification of
promising drug therapies that would enhance motor therapy in improving walking ability and arm function.
Further research is needed to compare strategies of giving drug therapy intermittently immediately prior to
therapy sessions or as continuous background daily administration.
Limitations: In total, 10.3% of patients were lost to follow-up at 8 weeks and < 10% of patients met the
strict per-protocol definition. Despite this, the findings are robust and generalisable to patients with limited
mobility in the first few weeks after stroke.
Trial registration: Current Controlled Trials ISRCTN99643613.
Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical
Research Council and National Institute for Health Research partnership.
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Carer An individual identified by the patient as their main informal carer who provides the patient with
practical support a minimum of once per week.
Code-break envelopes Contain coded documents that enable unblinding of the treatment allocation of
an individual patient. They are held by the Clinical Trials Research Unit safety team and the NHS trust
pharmacy responsible for the backup of this process as per the protocol.
Investigational medicinal product Defined in the Directive 2001/20/EC, Article 2 (d) as:
. . . a pharmaceutical form of an active substance or placebo being tested or used as a reference in a
clinical trial, including products already with a marketing authorization but used or assembled
(formulated or packaged) in a way different from the authorised form, or when used for an
unauthorised indication, or when used to gain further information about the authorised form.
Reproduced with permission from Directive 2001/20/EC of the European Parliament and of the Council
of 4 April 2001. URL: https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2001_20/
dir_2001_20_en.pdf (accessed July 2018); © European Union, 1995–2018
Kit number A random code used to identify each treatment code allocation and container of investigational
medicinal product (e.g. vial, box, bottle).
Rehabilitation Occupational/physical therapy that addresses physical functioning (e.g. sitting practice,
standing, dressing, kitchen skills).
Researcher The research nurse/therapist at each trust who is responsible for the outcome assessment.
This person may be a Dopamine Augmented Rehabilitation in Stroke researcher or be employed by a local
National Institute for Health Research Stroke Research Network.
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A&E accident and emergency
ABILHAND ABILHAND Manual Ability Measure
AE adverse event
AISCT Acute Ischaemic Stroke
Classification Template
BI Barthel Index
CACE complier-average causal effect





CRAG Consumer Research Advisory
Group
CRF case report form
CT computerised tomography
CTRU Clinical Trials Research Unit
DARS Dopamine Augmented
Rehabilitation in Stroke
DICOM Digital Imaging and
Communication in Medicine
DMEC Data Monitoring and Ethics
Committee
DVD digital versatile disc
DWI diffusion-weighted imaging
EQ-5D EuroQol-5 Dimensions
FAS Fatigue Assessment Scale
FIM Functional Independence Measure
FLAIR fluid-attenuated inversion recovery
fMRI functional magnetic resonance
imaging
GHQ-12 General Health Questionnaire
12-item version
GP general practitioner
HRQoL health-related quality of life
ICER incremental cost-effectiveness ratio
ICF International Classification of
Functioning, Disability and Health
IMP investigational medicinal product
IST-3 Third International Stroke Trial
ITT intention to treat
LACI lacunar infarction
MCA middle cerebral artery
MD mean difference
MedDRA Medical Dictionary for Regulatory
Activities
MoCA Montreal Cognitive Assessment
MRI magnetic resonance imaging
mRS Modified Rankin Scale
MSK-SSP musculoskeletal – symptoms/signs
and pain
NEADL Nottingham Extended Activities of
Daily Living
NICE National Institute for Health and
Care Excellence
NIHR National Institute for Health
Research
NMB net monetary benefit
OLS ordinary least squares
OR odds ratio
OT occupational therapy
PACI partial anterior circulation infarction
PI principal investigator
POCI posterior circulation infarction




RCT randomised controlled trial
RMI Rivermead Mobility Index
SAE serious adverse event
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SAR site achievement report
SD standard deviation
SE standard error
SRN Stroke Research Network
SSRI selective serotonin
reuptake inhibitor
TACI total anterior circulation infarction
TSC Trial Steering Committee
WHO World Health Organization
WTP willingness to pay
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Plain English summary
S troke has a huge impact, and more than one-third of affected people will have moderate or severedisability that has an impact on quality of life and self-care. Rehabilitation, in the form of routine NHS
physical or occupational therapy, promotes recovery of mobility through relearning to use the affected
body parts and/or learning to compensate with the less affected side. However, many people are not able
to walk despite physiotherapy. Small studies have found that certain drugs that affect the learning process
may improve functional recovery and that this improvement occurs when the drugs are given at the same
time as the therapy session. The Dopamine Augmented Rehabilitation in Stroke trial was designed to
measure if combining these drugs with routine therapy leads to an improvement in the ability to walk
independently 8 weeks after a stroke.
We allocated at random 593 patients with a stroke who were unable to independently walk ≥ 10 metres
indoors to receive either a drug called co-careldopa or a placebo for 6 weeks, in addition to their routine
therapy. We measured function and ability to walk at 8 weeks to see if the drug had an impact on recovery.
We found that adding co-careldopa to routine physical and occupational therapy was not effective in
improving walking following stroke. Further studies might consider using daily drug administration and
more-intensive therapy. Future studies are needed to identify measures that identify new treatments to
improve stroke recovery.
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In England, there are 110,000 new cases of stroke annually and 900,000 stroke survivors, of whom
300,000 are moderately or severely disabled. Physical therapy (PT) and occupational therapy (OT) promote
the recovery of function following stroke and early access to multidisciplinary rehabilitation is recommended
for all patients to improve function and quality of life; however, many patients remain disabled and unable
to walk despite PT.
Most rehabilitation interventions focus on the patient’s ability to learn or relearn motor skills. Studies of
the brain structures involved in learning suggest that the basal ganglia and dopamine play a key role in the
acquisition of motor skills. Dopamine is a key modulator of striatal function and may contribute to the
selection and termination of motor programmes for skilled movements. This suggests that pharmacological
manipulation of neurotransmitter systems could be used to enhance the reacquisition of motor skills
after stroke.
A number of drugs increase brain dopaminergic activity, but some, such as amphetamines, are associated
with significant adverse effects. Levodopa is an orally administered precursor of dopamine that crosses
the blood–brain barrier before being metabolised to dopamine. Co-careldopa (Sinemet®, Merck Sharp &
Dohme Ltd) is a combined preparation of 100 mg of levodopa with a peripheral DOPA decarboxylase
inhibitor, carbidopa. Carbidopa reduces peripheral levodopa metabolism, thereby maximising the central
bioavailability of levodopa, and is a well-established treatment for Parkinson’s disease, a condition
associated with marked reductions in basal ganglia dopamine activity.
Seven small trials of dopamine agonists after stroke, with a combined total of 249 patients, have provided
equivocal evidence on motor recovery, and a larger trial to establish the effects of increasing dopaminergic
activity after stroke on motor recovery is required. Administering oral levodopa prior to motor therapy
to enhance brain dopamine concentrations during therapy is a logical strategy to optimise efficacy of
dopaminergic therapy and minimise adverse effects. This approach requires co-ordination of drug
administration with planned therapy, and differs from that used for treatment of Parkinson’s disease
and drug administration in most clinical trials. This novel approach of co-ordinating drug administration
with motor therapy was utilised in the Dopamine Augmented Rehabilitation in Stroke (DARS) trial.
Aim and objectives
Aim
To determine if combining co-careldopa with routine PT and OT during early rehabilitation in people with
new stroke admitted to a stroke unit enhances the effect of conventional rehabilitation treatments in terms
of physical functioning.
Primary objective
The primary objective compared the proportion of patients in both treatment groups walking
independently at 8 weeks post randomisation.
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Secondary objectives
Secondary objectives were to assess the impact on physical functioning, mood and cognition at 8 weeks,
6 months and 12 months post randomisation, comparing between treatment groups:
l proportion of patients walking at 6 months and 12 months
l activities of daily living, mobility and dependency
l psychological distress/mood
l carer burden.
Additional objectives were to:
l Determine the cost-effectiveness of co-careldopa and conventional rehabilitation treatment compared
with usual care within NHS stroke services.
l Investigate potential moderators and mediators of effect at 8 weeks, namely (1) whether or not
baseline patient clinical characteristics and investigations predict those who might benefit from
co-careldopa-augmented rehabilitation, and (2) whether or not fatigue, concurrent musculoskeletal
symptoms, signs and pain, and cognitive function influence the short- and long-term effect of
co-careldopa on physical functioning.
l Investigate the feasibility of implementation of timed drug administration with therapy within routine
NHS services.
l Assess the adverse event (AE) profile associated with co-careldopa administered with NHS stroke motor
rehabilitation therapy.
l Investigate the practical implications of delivering this intervention within routine NHS acute and early
community care of people with stroke.
l Assess the acceptability of co-careldopa treatment to stroke patients.
Methods
The DARS trial was a multicentre, randomised, double-blind, placebo-controlled trial with stroke patients
who were randomised, while inpatients, to receive 6 weeks of co-careldopa or placebo in combination
with physical occupational rehabilitation.
Participants had new or recurrent clinically diagnosed ischaemic or haemorrhagic stroke within 5 to
42 days prior to randomisation, could not independently walk ≥ 10 metres indoors [Rivermead Mobility
Index (RMI) score of < 7 points], did not have Parkinson’s disease and required rehabilitation.
A total of 51 UK NHS stroke services with an acute inpatient stroke rehabilitation unit and a service
allowing rehabilitation treatments within the community setting participated in the DARS trial.
Patients were randomised to receive either co-careldopa or a matched placebo tablet, taken before
receiving routine NHS PT and OT involving motor therapy for 6 weeks. Patients were required to take the
study drug 45–60 minutes before PT or OT sessions. Patients were randomised in permuted block sizes
balanced for centre, type of stroke and baseline RMI score. Treatment adherence and therapy sessions
received were recorded.
The primary outcome was the proportion of patients walking independently at 8 weeks (RMI score of
≥ 7 points). Secondary outcomes assessed physical functioning [Nottingham Extended Activities of Daily
Living (NEADL), Barthel Index (BI), ABILHAND Manual Ability Measure (ABILHAND) and modified Rankin
Scale (mRS)], pain (musculoskeletal – symptoms/signs and pain manikin), cognition [Montreal Cognitive
Assessment (MoCA)], mood [General Health Questionnaire 12-item version (GHQ-12)], fatigue [Fatigue
Assessment Scale (FAS)] and carer burden [Carer Burden Scale (CBS)] at 8 weeks, 6 months and 12 months.
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The sample size calculation of 572 patients was based on the proportion of people walking independently at
8 weeks reported in previous Levodopa and placebo studies and it provided 90% power at 5% significance
to detect a 50% relative difference between the placebo and active treatment groups in the proportion of
participants independently walking at 8 weeks.
Ongoing monitoring during the trial indicated that the combined death rate and loss to follow-up was
likely to exceed the assumed rate of 10%; therefore, a decision was taken to increase the required sample
size to 590 to account for this.
Potential predictors of response to co-careldopa via moderators and mediators were explored. Moderator
analyses explored whether or not the size of the treatment effect depended on baseline characteristics of
the patients. Mediator analyses explored the extent to which the treatment effect could be explained by
an intermediate mechanistic outcome. Analyses focused on RMI at 8 weeks. Potential mediator variables
related to the period prior to the outcome but post randomisation and included therapy sessions received,
study medication taken, and assessments of fatigue, pain, cognitive function and activities of daily living.
A health economic analysis was undertaken using quality-adjusted life-years (QALYs) as the main outcome
measure, captured using the EuroQol-5 Dimensions at baseline, 8 weeks, 6 months and 12 months after
randomisation. Health-care resource utilisation was captured using questionnaires covering primary and
secondary care use over the trial period. The primary health economic analysis was a cost–utility analysis
with a secondary cost-effectiveness analysis.
Results
Between May 2011 and March 2014, 593 patients [mean age 68.5 years, 187 (61%) male] and 165 carers
(mean age 59.7 years) were recruited; 308 patients were randomised to co-careldopa and 285 to placebo
at a median of 15 days (range 3–59 days) following stroke onset. Most participants had cerebral infarction:
270 (87.7%) in the co-careldopa group and 238 (83.5%) in the placebo group. A total of 91 participants
withdrew from the trial: 58 (18.8%) in the co-careldopa group and 33 (11.6%) in the placebo group.
The mean number of therapy sessions that included motor activities was 23.2 in the co-careldopa group
and 24.8 in the placebo group, with a mean length of 43 minutes in both groups. The mean number of
investigational medicinal product (IMP) doses taken was 20.6 in the co-careldopa group and 22.4 in the
placebo group, and the IMP was taken as per protocol in 55% of therapy sessions.
The proportion of patients who can walk independently at 8 weeks was 40.6% in the co-careldopa
group and 44.6% in the placebo group [odds ratio (OR) 0.78, 95% confidence interval (CI) 0.53 to 1.15],
indicating no statistical evidence of a significant difference between the treatment groups. At 8 weeks,
the follow-up rate in the co-careldopa group was 88.0% and in the placebo group was 91.6%. The results
at 6 months and 12 months also failed to demonstrate any statistically significant differences between the
groups [51.6% (co-careldopa) vs. 53.3% (placebo) and 51.6% (co-careldopa) vs. 56.8% (placebo) at 6
and 12 months, respectively]. The ability to walk independently did not differ between males and females.
Participants who suffered an infarction were significantly less likely to walk independently than those who
had a primary haemorrhage [206 (40.6%) vs. 46 (54.1%), respectively; OR 0.382, 95% CI 0.219 to 0.667].
Sensitivity analyses confirmed the results of the primary end-point analysis of no evidence of a statistically
significant difference between the treatment groups.
There was no significant difference between the two groups in the number of AEs reported: in the
co-careldopa group, 195 participants (63.3%) reported a mean of 3.5 AEs each and in the placebo group
170 participants (59.6%) reported a mean of 3.6 AEs each. Fifty-seven participants (18.5%) in the
co-careldopa group reported 74 serious adverse events (SAEs) and 50 participants (17.5%) in the placebo
group reported 58 SAEs. The majority of SAEs reported in both the co-careldopa group and the placebo
group were not suspected to be related to the IMP. Thirty-nine participants (6.6%) died within 12 months
of randomisation: 22 (7.1%) in the co-careldopa group and 17 (6.0%) in the placebo group. The median
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number of days from randomisation to discharge was 25 in the co-careldopa group and 27 in the placebo
group, with the majority of participants discharged to their own home or a relative’s home: 174 (56.5%)
in the co-careldopa group and 170 (59.6%) in the placebo group.
There was no evidence of statistically significant differences between treatment groups in NEADL, BI,
ABILHAND or mRS, pain or fatigue at any time point. MoCA scores did not significantly differ between
groups; the majority of participants had cognitive impairment at baseline (77% with a score of
< 26 points), which improved during the 12-month follow-up period (41% with a score of < 26 points).
No statistically significant differences were observed in GHQ-12 scores between groups at 8 weeks and
12 months but, at 6 months, those in the co-careldopa group reported significantly better general health
[mean difference (MD) –1.33 points, 95% CI –2.57 to –0.10 points]. Mortality at 12 months was not
significantly different between groups (7.1% in co-careldopa vs. 6.0% in placebo). SAEs occurred in
18.5% of the co-careldopa group and 17.5% of the placebo group. Carers in the placebo group reported
statistically significantly greater burden at both 6 months and 12 months (MD 5.05 points, 95% CI 0.10
to 10.01 points and MD 7.52 points, 95% CI 1.87 to 13.18 points, respectively) on the CBS.
In the health economic analyses, co-careldopa patients incurred higher costs and gained fewer QALYs than
placebo patients, indicating that co-careldopa is not cost-effective. The mean number of QALYs was 0.397
[standard deviation (SD) 0.002] for the co-careldopa group and 0.420 (SD 0.002) for the placebo group.
Conclusions
There is no evidence that co-careldopa administered before routine NHS PT or OT during stroke rehabilitation
in NHS services is clinically effective or cost-effective in improving walking, physical functioning, mood or
cognition in the first year following stroke, and it would not be a cost-effective therapy.
The DARS trial is larger than all previous randomised controlled trials to evaluate dopaminergic drug therapy
during recovery from stroke. In that context, the DARS trial has established that there is no case for
administering co-careldopa during rehabilitation of stroke patients who do not have Parkinson’s disease.
Recommendations for future research
Future clinical trials of other pharmacotherapies that act on motor learning should consider comparing
strategies of continuous dosing and intermittent dosing prior to motor therapy and different doses of drug
therapy. Clinical trials of pharmacotherapy to improve stroke recovery may need to consider using a greater
intensity of therapy than was used in the DARS trial. Future research should consider incorporation of
emerging imaging markers, such as functional magnetic resonance imaging, as proof-of-concept biomarkers
into early-phase trials of pharmacotherapy to improve recovery from stroke. Future research is needed
into the development of more sensitive clinical markers of motor recovery that would demonstrate
proof-of-concept efficacy on neurological impairment in early-phase trials before undertaking large
pragmatic trials using disability measures as the primary trial outcome.
Trial registration
This trial is registered as ISRCTN99643613.
Funding
This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research
Council and National Institute for Health Research partnership.
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Chapter 1 Introduction
Up to one in five people in the UK will suffer a stroke,1 with approximately 110,000 new cases annuallyin England.2 There are 900,000 stroke survivors in England, 300,000 of whom are moderately or
severely disabled.2 The cost of stroke care to the NHS is around £3B annually, with wider economic costs
of £8B.3 It is anticipated that the number of disabled stroke survivors will increase as a result of an ageing
population. Physical therapy4 (PT) and occupational therapy5 (OT) have been shown to promote the
recovery of function following stroke, and early access to multidisciplinary rehabilitation is recommended
for all patients to improve function and quality of life.6,7
What is ‘rehabilitation’?
The World Health Organization (WHO) definition of rehabilitation focuses on the enablement of people in
order to reduce the impact that a disabling condition may have on a person’s life.8
The cornerstone of rehabilitation is the WHO’s International Classification of Functioning, Disability and
Health9 (ICF). This model postulates that an underlying health condition (such as stroke) may cause
impairment in bodily structures and function, limitation of activities and restriction of participation.10
Clinically important impairments following stroke may include changes in gait pattern and intellectual
functions, inability to sequence complex movements, and alterations in muscle tone and power.11 Activity
limitations and participation restrictions may include difficulties in problem-solving, transferring oneself,
maintaining family and personal relationships, and acquiring and keeping a job.11 However, an individual’s
functional abilities are also profoundly influenced by wider contextual factors,8 both environmental and
personal. Environmental factors comprise not only the built environment but also legislation and societal
attitudes.8 Depending on circumstances, they may serve as barriers to, or facilitators of, individual
function.8 Personal factors are intrinsic to the individual but may not be directly related to the underlying
health condition.8 They include sex, age, race and physical fitness.8
Therefore, in ICF terms, ‘disability’ is constructed as an interaction between an individual and their
environment and personal factors.10,12 ‘Rehabilitation’ typically comprises a complex package of measures
targeting multiple levels of the ICF. The precise nature of the intervention required varies depending on the
extent of cerebral damage caused by the stroke and the patient’s goals, and with the passage of time from
the stroke. Within the first few hours, optimum acute care minimises the extent of tissue injury and secondary
complications (impairment in structure) and, therefore, maximises preservation of function.13 As planning
for discharge progresses, environmental assessment and, if necessary, provision of assistive technologies
(contextual factors) may help to enhance safety and personal independence on leaving hospital. In the long
term, a combination of rehabilitation interventions at impairment, activities and environmental levels may be
necessary to address specific goals such as return to work (participation).14 Many stroke survivors require not
only intermittent discrete periods of time-limited rehabilitation to address particular functional goals, but
also longer-term monitoring and support to prevent long-term complications and to mitigate the effects of
changing disability (such as deterioration in mobility due to accelerated joint ageing).13
Rehabilitation interventions may be restorative (e.g. encouraging use of a hemiplegic limb) or compensatory
(such as the teaching of new techniques or provision of orthoses or assistive technologies).14 Since the
1950s, a variety of rehabilitation approaches have been developed, each based on differing theories
about how patients recover from stroke.4 National Institute for Health and Care Excellence (NICE) quality
standards15 state that a minimum of 45 minutes of each active therapy should be offered to stroke
patients for a minimum of 5 days per week. The dose of active therapy is such to allow patients to meet
their rehabilitation goals, and active therapy should continue as long as the patient benefits and can tolerate
the therapy. More recently, the provision by the therapist of active feedback on the quality of movements
has been emphasised.16 A recent Cochrane review17 has demonstrated no clear evidence in favour of any
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one approach. Although many rehabilitation strategies are in clinical use,18 most restorative interventions
share one crucial commonality: their reliance on the patient’s ability to learn (or to relearn) motor skills.
Brain structures involved in motor learning
Motor learning is fundamental not only to rehabilitation but also to daily life,19 from a baby learning
to walk to a musician practising a symphony. Becoming skilled in a motor task requires us not only to
learn the correct order of movements but also to develop an awareness of the sensory input that guides
decisions, such as timing of the movement, trajectory and what force should be applied.20 Often, acquiring
a skill also requires the learner to manipulate or interact with objects in his or her environment.21 Although
there is no universally accepted definition of ‘motor learning’, it has been conceptualised as ‘a change in
motor behaviour, specifically referring to the increased use of novel, task-specific joint sequences and
combinations, resulting from practice and/or repetition’.22
Many studies have sought to define the brain structures involved in motor learning. Whether or not it is
reasonable to extrapolate theoretical frameworks for motor learning derived in healthy individuals to those
with stroke is debatable. However, stroke patients participating in rehabilitation demonstrate increased
activation of the ipsilesional primary motor cortex, pre-motor cortex and supplementary motor areas.23
This suggests that functional reconfiguration is possible after stroke, allowing lost functions to be
recovered using partially spared pathways.23 The cellular basis for this is axonal remodelling, changes
in the number and morphology of dendrites,24–26 and long-term potentiation or depression of synaptic
transmission both adjacent to and remote from the original stroke,24,25 a process termed ‘neuroplasticity’.
Magnetic resonance imaging (MRI) has been the mainstay of attempts to understand learning processes,
both in healthy participants20,21,27,28 and in those recovering from stroke.23 Attention has focused on the
role of the basal ganglia. These contain the striatum (caudate, putamen and nucleus accumbens) and the
globus pallidus.29,30 They are now known to form part of wider corticobasal and corticocerebellar loop
circuits. The striatum receives white matter projections from almost all cortical areas. It sends projections
to the thalamus and cerebellum, which, in turn, project to the cortex29–31 (Figure 1). Although the precise
function of these pathways remains opaque, it is clear that they are crucial to a variety of cognitive and
motor processes.32–34 Lesions at any point in these pathways may mimic deficits resulting from cortical
injury:31 a phenomenon that has been termed ‘disconnection syndrome’.31 For example, discrete lesions to
the basal ganglia may result in a spectrum of clinical manifestations more typically associated with frontal
lobe insult due to the extensive projections these structures receive from the prefrontal cortex.31
The indirect pathway (light-green arrow) projects from the cortex via a complex web of connections
between the globus pallidus externa and the subthalamic nucleus, to the substantia nigra and globus
pallidus interna and, thence, to the thalamus. The direct pathway (light-blue arrow) projects from the
cortex to the striatum, and thence to the thalamus. The hyperdirect pathway (grey arrow) bypasses the
striatum and projects directly to the substantia nigra and globus pallidus interna. Dopaminergic projections
from the substantia nigra (black arrows) exert an inhibitory effect on GABAergic interneurons of the
indirect pathway, and an excitatory effect on GABAergic interneurons of the direct pathway.
The role of dopamine in learning processes
There has recently been a growing appreciation of the central role that dopamine plays in learning.
Dopamine is a key modulator of striatal function; through its selective action on striatal projection
interneurones, dopamine is able to inhibit the indirect striato-thalamic pathway and excite the direct
pathway.35 By directly influencing the activity of these pathways, dopamine may contribute to the selection
and termination of motor programmes for skilled movements.35,36 In conditioned learning, dopamine may
potentiate drive and arousal, encode the ‘value’ of a reward, or ‘stamp in’ associations between stimulus
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and response.37 More recently, it has been proposed that phasic dopamine release dopamine acts as an
‘alerting signal’, prompting the orientation of conscious attention and cognitive processing towards salient
environmental cues and increasing general arousal and motivation.38 Together with other neurotransmitters
(noradrenaline, serotonin and acetylcholine), dopamine up-regulates excitatory glutamatergic transmission,
which in turn stimulates activation of N-methyl-D-aspartate receptors.39 It is the activity of these receptors
that promotes long-term potentiation or long-term depression of synaptic efficacy.39 These long-term
synaptic changes are thought to mediate consolidation of memory traces (e.g. of the association between
stimulus and reward,29 or motor memories40).
‘Pharmacorehabilitation’: a new frontier in stroke rehabilitation?
Taken together, these disparate findings present an intriguing possibility: might pharmacological manipulation
of neurotransmitter systems be used to enhance the reacquisition of motor skills after stroke? Several drugs
influence directly the levels of key neurotransmitters. Dextroamphetamine and metamphetamine inhibit reuptake
of dopamine, noradrenaline and serotonin into the presynaptic terminal, thereby increasing their bioavailability
within the synaptic cleft.39 Methylphenidate, similarly, blocks presynaptic reuptake of dopamine and
noradrenaline.39 As all of these neurotransmitters are known to enhance excitatory glutamatergic transmission in
the corticostriatal pathways, using drugs that act on these systems may present an opportunity to manipulate
neuroplasticity, thereby enhancing the effectiveness of conventional rehabilitation.39 An early-phase trial41 in rats
with a unilateral experimental lesion of the motor cortex reported an immediate improvement the animals’
ability to run along a rotating beam following a single dose of dextroamphetamine. This finding has been
replicated in other trials in both rats42–46 and primates47 (albeit with some dissenting findings).48 The treatment































FIGURE 1 Connectional pathway and neurotransmitter systems of the corticobasal ganglia thalamic pathway.
GABA, gamma-aminobutyric acid.
DOI: 10.3310/eme06050 EFFICACY AND MECHANISM EVALUATION 2019 VOL. 6 NO. 5
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ford et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3
Encouraged by these findings, there have been several trials of amphetamines to enhance recovery in
human stroke survivors.39,49 Although there is a trend towards improved motor outcomes in those treated
with amphetamine,39 many trials are of small scale, with considerable heterogeneity in the dosing
regimens, timing between dose and therapy, follow-up period and outcome measures.39 Several showed
differences in the baseline characteristics of the intervention and placebo groups (age, consciousness level),
which may account for a trend towards higher mortality rates in those treated with amphetamine.39
Therefore, positive findings must be interpreted with caution39 and clinical use of amphetamine has been
limited as a result of the concern about sympathomimetic effects.49
Drugs that promote dopaminergic activity directly may be more appropriate targets for pharmacological
enhancement of rehabilitation.50 Levodopa, an orally administered precursor of dopamine, crosses the
blood–brain barrier before being metabolised to dopamine centrally resulting in a rise in brain dopamine
levels.39 Around 5% of the levodopa that enters the central nervous system is further metabolised to
noradrenaline, raising the possibility that its effects may be mediated at least in part by noradrenaergic
transmission.51 Co-careldopa (Sinemet®, Merck Sharp & Dohme Ltd) is a combined preparation of 100 mg
of levodopa with a peripheral DOPA decarboxylase inhibitor, carbidopa. Carbidopa reduces peripheral
levodopa metabolism, thereby maximising the central bioavailability of levodopa.51 Peak plasma levels of
levodopa occur between 30 minutes and 2 hours after a single oral dose of co-careldopa, with a plasma
half-life of 1–3 hours.
Only one systematic review has examined the use of dopamine agonists to enhance motor recovery from
stroke in humans. Berends et al.39 assessed the evidence for a number of candidate drug classes, including
amphetamine, selective serotonin reuptake inhibitors (SSRIs) and levodopa. Two papers52,53 concerning the
use of levodopa met their inclusion criteria. The evidence of a positive treatment effect with this agent
was judged to be lacking.39 A number of other trials54–62 that they did not cite also address this question.
These are of variable quality and report mixed results. Many were limited by small sample sizes56,58 or
comparatively short follow-up,58,60 or administered only single doses of co-careldopa.58,59 Some recruited
patients months or years after stroke.56,58 Several demonstrated benefit with dopamine on motor outcomes
including the Barthel index54 (BI), the National Institutes of Health Stroke Scale,54 the Functional Independence
Measure (FIM),55 walking speed and manual dexterity,56 procedural motor learning,57 motor memory,59
the Fugel-Mayer Assessment60 and the Rivermead Motor Assessment.62 However, others have found no
improvement in length of stay,61 cognitive and motor domains of the FIM61 or upper limb function.58
A systematic search was carried out to identify relevant studies and emerging data as the trial progressed.
An overview of identified randomised controlled trials (RCTs) is given in Table 1 and the search strategy is
in Appendix 1.
These equivocal results may perhaps be explained by dopamine’s complex and multiple actions in vivo and
the heterogeneous groups of patients involved in these trials. Any link between administration of dopamine
and recovery of function may be attenuated by injury to pathways involved in motor learning and cognitive
function, or by reduced motivation to participate in rehabilitation. However, it is clear that co-careldopa is
well tolerated, with no serious adverse events (SAEs) reported with the dosing regimens used. Therefore,
there is a need for a larger RCT to address the question of whether or not administering levodopa is
beneficial in enhancing recovery from stroke.
The Dopamine Augmented Rehabilitation in Stroke (DARS) trial set out to evaluate the effect of administering
co-careldopa for up to 6 weeks on patients’ ability to walk ≥ 10metres independently at up to 8 weeks
after stroke.64
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NIHSS, National Institutes of Health Stroke Score; RMA, Rivermead Motor Assessment; SD, standard deviation.
Notes
RMA consists of test items in three sections that test (1) gross function (13 items), for example walking with and without
out an aid, negotiating stairs with and without the rail, walking, turning and retrieving an object, and running; (2) leg and
trunk movements (10 items), for example standing on one leg and flexing the knee in a weight-bearing position; and
(3) arm movements (15 items).
Notes
Fugl-Meyer Assessment assesses activities of daily living, functional mobility and pain.
BI assesses the ability of an individual with a neuromuscular or musculoskeletal disorder to care for him/herself.
NIHSS measures the severity of symptoms associated with cerebral infarcts; used as a quantitative measure of neurological
deficit post stroke.
Gait velocity or 10-metre timed walk assesses walking speed over a short distance.
Nine-hole Peg Test measures finger dexterity.
Grip strength is a quantitative and objective measure of isometric muscular strength of the hand and forearm.
Action Research Arm Test assesses upper limb functioning using observational methods.
Serial reaction time task appears to be a specific paradigm adopted by Rösser et al.,57 rather than a standardised outcome measure.
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The aim of this trial was to determine if combining co-careldopa with routine PT and OT during early
rehabilitation in people with new stroke admitted to a stroke unit enhances the effect of conventional
rehabilitation treatments in terms of physical functioning.
Primary objective
The primary objective related to physical functioning and was to compare the proportion of patients in
both treatment groups who could walk independently (≥ 10 metres with an aid if necessary but with no
standby help) at 8 weeks post randomisation.
Physical functioning was assessed using the Rivermead Mobility Index (RMI),65 which assesses functional
mobility in gait, balance and transfers after stroke. It is a 15-item scale comprising 14 self-reported items
and one direct observation item. Items increase in difficulty and the higher the score, the better the
mobility. Scores range from 0 to 15 points, where 0 is given for a ‘no’ response and 1 is given for a
‘yes’ response.
To meet the primary end point in the DARS trial, participants had to have a RMI score of ≥ 7 points and
had to answer ‘yes’ to item 7 (‘Do you walk 10 metres with an aid or furniture if necessary but with no
standby help?’) to confirm that they could walk independently.
Secondary objectives
l Assess the impact on physical functioning and mood at 8 weeks, 6 months and 12 months to:
¢ compare the proportion of patients who are walking at 6 months and 12 months post
randomisation in the two groups
¢ compare activities of daily living, mobility and dependency [assessed using the RMI (continuous),
BI,66 modified Rankin Scale (mRS),67 Nottingham Extended Activities of Daily Living (NEADL) scale,68
ABILHAND Manual Ability Measure (ABILHAND)69] between groups
¢ compare psychological distress/mood between the two groups [assessed using the General Health
Questionnaire 12-item version (GHQ-12)70]
¢ compare carer burden between groups using the Caregiver Burden Scale (CBS)71
¢ investigate cost-effectiveness of co-careldopa and conventional rehabilitation treatments
[assessed using the EuroQol-5 Dimensions (EQ-5D) to quantify care costs].
l Investigate potential moderators and mediators of effect at 8 weeks, to investigate whether or not:
¢ baseline patient clinical characteristics and investigations [e.g. routine brain computerised tomography
(CT)] help to predict those who might benefit from co-careldopa-augmented rehabilitation
¢ key factors {e.g. fatigue [using the Fatigue Assessment Scale (FAS)72], concurrent musculoskeletal –
symptoms/signs and pain (MSK-SSP) (using the MSK-SSP manikin73,74) and cognitive function [using
the Montreal Cognitive Assessment (MoCA)75]} influence the short-term effect of co-careldopa on
physical functioning.
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l Investigate the implementation within routine NHS services to:
¢ assess the adverse event (AE) profile associated with the combination treatment (NHS stroke
rehabilitation treatment linked with co-careldopa)
¢ investigate the practical implications of delivering this intervention within routine NHS acute and
early community care of people with stroke
¢ assess the acceptability of co-careldopa treatment to stroke patients (study drug adherence
will be measured and a semistructured interview will be undertaken with participants at the
8-week assessment).
l Investigate the cost-effectiveness of co-careldopa-augmented rehabilitation for stroke compared with
usual care within stroke services.
Trial design
The DARS trial was a multicentre, prospective, randomised, double-blinded, placebo-controlled trial
of NHS PT and OT treatment alone compared with NHS PT and OT treatment in addition to up to
6 weeks of co-careldopa treatment for patients admitted to acute stroke services after new or
recurrent stroke.64 Outcome measures were obtained at 8 weeks, 6 months and 12 months following
randomisation.
Changes to trial design
Recruitment into the trial was lower than anticipated. Screening logs were reviewed during the early
stages of recruitment, and after approximately 11 months of recruitment the following relaxations were
made to the eligibility criteria to increase the number of potential patients who could participate in the
trial without compromising the scientific validity of the research: (1) inclusion of patients with new or
recurrent stroke (previously new stroke only) and (2) extension of the recruitment window from 2 weeks
to 42 days post stroke.
Trial timelines
The original project plan was to deliver the project in 45 months. However, the recruitment and
implementation of the project were more challenging than anticipated and the funder granted a 21-month
funded extension. The main reasons for the extension are outlined below:
(a) The initial setup time was prolonged as a result of a worldwide lack of availability of the
investigational medicinal product (IMP) (Sinemet), which delayed drug procurement for the recruiting
sites. Thus, trial setup increased from 9 months to 16 months because of a global shortage of the
active drug.
(b) Challenges in identifying and recruiting suitable people with stroke led to much lower recruitment
estimates per centre than those envisaged by the sites at trial setup. Thus, many more centres than
planned were required in order to recruit 572 patients within a reasonable time frame.
(c) Implementation of the DARS trial was challenging for the following reasons – the need to deliver
seamless trial intervention across acute and community NHS trusts, the need to administer medication
with therapy sessions in both hospital and community settings, and service reconfiguration during the
recruitment period.
The impact of these challenges was not fully realised at the outset of the trial. These issues led to a delay
in the start of the site setup and poor recruitment rates for the first few months.
METHODS




Patients admitted to participating NHS stroke services after experiencing a new or recurrent stroke were
screened for trial entry from admission up to 42 days post stroke. It is possible that a patient’s condition
could improve during the 42 days post stroke and the patient was reviewed during this period to reassess
eligibility. Screening logs were maintained for all patients admitted to stroke services after a new or
recurrent stroke.
Potential patients were identified by local Stroke Research Network (SRN) staff in liaison with ward nurses and
therapists, and were provided with verbal information about the trial. Patients interested in receiving further
information were provided with a detailed patient information booklet and a patient digital versatile disc
(DVD) that provided an overview of the trial and a visual aid to increase understanding of the implications
of participating in the trial. The principal investigator (PI) (or medically qualified member of the trial team)
obtained written informed consent. When the patient was able to comprehend but unable to sign or date
the consent form, provision was made for completion of the consent form by an independent person.
Carer recruitment
Carers of eligible and consenting patients were approached and consented at the time of patient
enrolment to provide information relating to carer burden.
Eligibility
Inclusion criteria
l New or recurrent clinically diagnosed ischaemic or haemorrhagic (excluding subarachnoid
haemorrhage) stroke within 5 to 42 days prior to randomisation.
l Could not independently walk (that is, without the use of physical assistance) ≥ 10 metres indoors.
l Achieved a score of < 7 points on the RMI, scored by a professional.
l Were expected to need rehabilitation treatment.
l Were ≥ 18 years of age.
l Were able to give informed consent.
l Were able to access continuity of rehabilitation treatment following discharge from hospital
(i.e. continuity of rehabilitation available within 5 days following discharge).
l Were expected to be able to comply with the treatment schedule.
l Were expected to be in hospital for at least their first two doses of trial medication.
Coenrolment into another trial was permitted if it had been agreed with the chief investigator of the
relevant studies and provided that it would not confound the results of the DARS trial nor overburden the
patient, attribution of AEs was not compromised and there were no potential interactions.
Exclusion criteria
l Not expected to survive for 2 months following stroke.
l A diagnosis of Parkinson’s disease, severe medical or surgical illness, or severe psychosis.
l Known hypersensitivity or contraindications to co-careldopa.
l Symptomatic orthostatic hypotension.
l Required physical assistance from at least one person to walk prior to stroke due to pre-existing
comorbidities (e.g. heart failure or osteoarthritis).
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l Pregnancy, lactation or, in the case of women of child-bearing potential, unwillingness to use medically
approved contraception during treatment and for 1 month after treatment had finished.
l Participation in another interventional drug or treatment therapy trial.
l Inability to walk ≥ 10 metres indoors prior to stroke [with a walking aid if necessary, but without
physical assistance, which, in this context, means help from one or more person(s)].
Potential trials for coenrolment with the DARS trial were considered by the chief investigator and trial
management team if (1) it was agreed with the chief investigator of the relevant studies, (2) it did not
confound the results of the DARS trial, (3) it did not overburden the patient, (4) attribution of causality
to AEs was not compromised and (5) there were no potential interactions of trial interventions.
Carer eligibility
A carer was defined as an individual identified by the patient as their main informal carer who provides
the patient with practical support a minimum of once per week. Carers had to provide written informed
consent to be eligible for participation. Presence of a carer was not a prerequisite for patient enrolment.
Trial settings
A total of 51 NHS stroke services across the UK with an acute inpatient stroke rehabilitation facility and
a service allowing rehabilitation treatments within the community setting that could consist of early
supported discharge or community stroke teams/services obtained NHS permissions to take part in the
DARS trial. A further five stroke services participated as repatriation sites for participants recruited from
other services.
Face-to-face follow-up was conducted by a blinded researcher in the participant’s home, at hospital or at a
community facility. When it was not possible to complete a face-to-face assessment, telephone follow-up
was conducted.
Interventions
Patients were randomised to receive either co-careldopa (Sinemet) or a matched placebo tablet in addition
to routine NHS PT and OT. The initial two doses of co-careldopa were 62.5 mg (50 mg of levodopa and
12.5 mg of carbidopa) and the remaining doses were 125mg (100 mg of levodopa and 25 mg of carbidopa).
Patients were required to take a single oral tablet 45–60 minutes before PT or OT sessions (this also includes
programmed rehabilitation delivered by rehabilitation assistants). Rehabilitation treatment appropriate for
drug administration within the DARS trial was defined as active physical treatment (i.e. most PT and OT
directed at motor skills such as walking, transfers and dressing, but not psychological input sessions or
speech and language therapy).
The dose and timing of the medication reflects current evidence on the use of co-careldopa in this
context.52,57,76,77 A pragmatic approach to taking the IMP was chosen; although the IMP should optimally
be taken 45–60 minutes prior to the rehabilitation treatment session, it was recognised that, on occasions,
the therapist was unable to contact the patient to remind them to take the tablet or the patient forgot
and it was acceptable for the tablet to be taken 0–15 minutes before the start of therapy in these
situations. The reasons for any deviations from the optimal timing were recorded. If the participant was
scheduled to have two therapy sessions either one directly after the other or within 3 hours of a dose
then a repeat dose was not given before the second therapy session. If the participant was scheduled to
have more than two PT or OT sessions, the dose was not administered more than twice during any one
24-hour period.
METHODS
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Co-careldopa or placebo in addition to NHS PT or OT was given for a maximum of 6 weeks and assuming a
maximum of two sessions of therapy per day for 30 days over a 6-week period. The duration of treatment
could be < 6 weeks if the patient was clinically deemed to not require further rehabilitation treatment. The
decision about need for rehabilitation intervention was made by the treating clinicians, therapists and nurses
in consultation with patients and families.
A pack of 62 tablets (two 62.5-mg tablets and 60 125-mg tablets), each with a unique kit number,
was dispensed to each participant by the hospital pharmacy on the day of randomisation. The first two
co-careldopa or placebo doses were administered in the hospital setting, allowing the participant to be
observed in case of early AEs. Blood pressure was checked before administering the first dose and, if the
systolic blood pressure was < 90 mmHg, the decision whether or not to administer the IMP was discussed
with the local PI. Subsequent doses were administered in the hospital setting by the attending nursing staff
or within the home setting post discharge.
Following discharge into the community, telephone reminders were given to the participant approximately
1 hour prior to the therapy visit by the treating community rehabilitation staff to remind the patient to take
the medication.










































FIGURE 2 Treatment pathways. a, Rehabilitation treatment appropriate for drug administration within DARS is defined
as an active physical treatment (i.e. most physical and occupational therapy directed at motor skills such as walking,
transfers and dressing, but not psychological input sessions or speech and language therapy, swallowing, splinting).
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Adherence to medication
Stroke survivors may have significant residual impairments that may affect their ability to comply with trial
medication, and ensuring pharmaco-adherence in the community setting is a challenge. To maximise
compliance, patients, clinicians, pharmacy staff and the manufacturer were consulted during the design of
the IMP packaging to ensure that it was usable by people with hemiparesis and included clear instructions
as to when the trial medication should be taken in relation to the NHS PT and OT provision. A DVD was
developed for participants and carers to use as a visual aid to complement the other patient information.
This content was presented in a manner accessible to patients with aphasia or hemisensory neglect and
used graphics to illustrate abstract concepts. A telephone reminder was also implemented, whereby the
treating community rehabilitation staff contacted the participant approximately 1 hour prior to their
community-based therapy session to prompt them to take the trial medication.73
Outcomes
Primary outcome
The primary outcome was the ability to walk independently at 8 weeks post randomisation, defined as a
score of ≥ 7 points and an answer of ‘yes’ to item 7 on the RMI (‘Do you walk 10 metres with an aid or
furniture if necessary but with no standby help?’).65
Secondary outcomes
Patient outcomes (measured at 8 weeks, 6 months and 12 months)
l Physical functioning was assessed using the RMI,65 BI,66 mRS,67 NEADL68 and ABILHAND.69
l Mood was assessed using the GHQ-12.70
l Fatigue (measured using the FAS72), concurrent musculoskeletal symptoms, signs and pain (using the
MSK-SSP manikin74,78), activities of daily living (using the BI and NEADL), cognitive function (using the
MoCA75), and number of therapy sessions and IMP doses were assessed for influence on the short-term
effect of co-careldopa on physical functioning.
l Cost-effectiveness was assessed using the EQ-5D79 and patient NHS resource use data (see
Economic evaluation).
Carer outcomes (measured at 8 weeks, 6 months and 12 months)
l Caregiver burden was assessed using the CBS.71
Potential moderators and mediators of treatment effect (at 8 weeks)
l Baseline clinical characteristics and investigations (e.g. routine brain neuroimaging) were recorded for
use in later analysis to determine if they predict those who might benefit from co-careldopa-
augmented rehabilitation.
Investigation of implementation within the NHS (including safety)
l The AE profile associated with the combination treatment (NHS stroke rehabilitation treatment linked
with co-careledopa) was recorded.
l The practical implications of delivering the intervention within routine NHS acute and early community
care of people with stroke were investigated.
l The acceptability of co-careldopa treatment to stroke patients (study drug adherence) was measured
at 8 weeks.
METHODS
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Data collection methods
Baseline data were collected by the clinical research team from clinical records and via face-to-face
administration of the questionnaires, and participants also self-completed a baseline RMI measure.
All baseline data were collected prior to randomisation.
Follow-up data were collected at 8 weeks, 6 months and 12 months via face-to-face administration by
an independent blinded researcher in the participant’s home, at the hospital or at a community facility
and documented on paper case report forms (CRFs) provided by the Clinical Trials Research Unit (CTRU).
Completion of the primary outcome measure (RMI) was via telephone when it was not possible to arrange
a face-to-face visit.
The researcher could choose to send the questionnaires to the patient in advance to allow time to prepare
for the interview. Carer-completed outcomes were collected at the same time as the patient’s outcomes,
when possible, and documented.
Assessment instruments
Table 2 summarises the measures used at each assessment time point and a summary of each instrument
used is provided below:
l The RMI assesses the ability to walk independently. It was completed by researchers prior to
randomisation to inform the stratification of patients and by participants at baseline and follow-up to
see how they assessed their own mobility. It has 15 items (score range of 0–15 points), with higher
scores indicating an increased ability to walk independently.
l The ABILHAND questionnaire measures upper limb impairment by asking participants to rate 23 items
relating to their manual ability on a three-level scale (1, impossible; 2, difficult; and 3, easy). The raw
scores are converted into a linear measure of ability using Rasch analysis. The scores are, thus,
expressed as logits on an interval scale ranging from plus to minus with the centre of the scale set to
zero; a higher number logit indicates greater patient-perceived ability. The baseline score in the DARS
trial is based on participants’ own assessment of their manual ability in the month before their stroke
and at the time of assessment at the follow-up.
l Physical and social independence were assessed using the NEADL. This assesses aspects of physical
and social independence performance across 22 items (score range of 0–66 points) grouped into
four categories [(1) mobility, (2) kitchen, (3) domestic and (4) leisure activities]. A higher score indicates
greater independence. At baseline, participants were asked to consider their independence before
their stroke and at the follow-up they were asked to consider their indepencence in the previous month.
l The GHQ-12 assesses emotional health. It contains 12 questions (score range of 0–36) addressing
issues of decision-making, loss of sleep and confidence, feelings of strain, enjoyment of daily activities,
confidence and happiness. A higher score indicates worse emotional health. The scores can also be
categorised into no sign of psychological distress (score of ≤ 15 points), evidence of distress (score of
> 15 points but ≤ 20 points), or severe problems and psychological distress (score of > 20 points).
l Activities of daily living, disability and mobility were assessed using the BI. Ten items (score range of
0–20 points) evaluate the patient’s functional ability; higher scores indicate a greater degree of
functional independence.
l Joint, neck or back pain was measured using the MSK-SSP manikin. Combinations of locations of
(1) pain in upper limbs, (2) pain in lower limbs, (3) central post-stroke pain, (4) thumb, hand, finger or
wrist joint pain and (5) spinal pain were based on the previous work with MSK-SSP.74,78
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Eligibility and consent ✗
Baseline data (researcher/nurse completed from routinely collected data and ward staff)
RMI (professional perspective on patient’s ability for
stratification)
✗
Past medical history ✗
Lesion location and type (CT) ✗
MoCA ✗
Randomisation (within 5–42 days post stroke) ✗
Patient questionnaires (completed via researcher interview with patient)
RMI (patient’s perspective on ability) ✗ ✗ ✗ ✗
ABILHAND ✗a ✗ ✗ ✗
NEADL ✗a ✗ ✗ ✗
GHQ-12 ✗ ✗ ✗ ✗
EQ-5D ✗ ✗ ✗ ✗
BI (postal version but collected face to face) ✗ ✗ ✗ ✗
MSK-SSP manikin ✗a ✗ ✗ ✗
FAS ✗ ✗ ✗
Health economics resource use questionnaire ✗ ✗ ✗ ✗
Carer questionnaires (carer completed)
CBS ✗ ✗ ✗
EQ-5D ✗ ✗ ✗ ✗
Health economics resource use questionnaire ✗ ✗ ✗ ✗
Qualitative follow-up
Patient/therapist perspective regarding use of the IMP ✗
Clinical follow-up data (researcher/therapist/nurse completed)
Treatment data (rehabilitation and drug compliance) ✗
mRS ✗ ✗
MoCA ✗ ✗ ✗
Serious and non-serious AE monitoring Continuous reporting
New significant medical/surgical illness (e.g. for stroke,
myocardial infarction, cancer, fracture, elective surgical
procedures)
✗ ✗
a The baseline measure relates to the pre-stroke period.
METHODS
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l The FAS contains 10 items (score range of 10–50 points); higher scores indicate more severe fatigue.
l The mRS is used to assess global outcome after stroke and is scored from 0 (no symptoms at all) to
5 (severe disability, bedridden); patients who die are given a score of 6.
l The MoCA is a researcher-administered instrument that assesses cognitive function. It contains
10 items (score range of 0–30 points); a score of < 26 points indicates cognitive impairment.
l The CBS is a 22-item scale (score range of 22–88 points) assessing various aspects of caregiver burden,
including general strain, isolation, disappointment, emotional involvement and environment; higher
scores indicates higher burden.
Strategies to maximise data collection
Site achievement reports (SARs) were developed to provide sites with clear communication of accomplishments
against trial-specific targets to assist sites in understanding their own performance. SAR benchmarks were
based on recruitment, screening, baseline and consent data, intervention delivery monitoring and return of
data essential for primary end-point reporting. RAG ratings indicated predefined target completion. Site-specific
SARs were sent to site researchers (nurses and PIs); monthly and regional summaries were sent to the National
Institute for Health Research (NIHR) SRN managers.80
Several methods were implemented to allow flexibility in the collection of follow-up data to maximise return
rate. This included a research nurse visiting the participant’s home to complete the questionnaires or
completion at a hospital visit. The research nurse could also choose to send the questionnaires to the
participant in advance of the scheduled appointment to allow the patient some time to prepare for the visit.
To maximise completion of the primary end-point data, the research nurse could complete the RMI
questionnaire via telephone when it was not possible to arrange a face-to-face visit.
Sample size
The sample size calculations were based on the primary outcome of the proportion of people walking
independently 8 weeks after randomisation. Independent walking is a robust and easily identifiable
objective clinical outcome; according to Scheidtmann et al.,52 42% of levodopa patients (11/26) were
walking independently at 6 weeks, compared with 26% of placebo-group patients (7/27). Based on these
published data, the sample size calculations indicated that 572 patients should be recruited in total. This
provides 90% power at 5% significance to detect a 50% relative difference (< 15% absolute difference)
between the placebo and active treatment groups in the proportion walking independently at 8 weeks
post randomisation (as measured by an RMI score of ≥ 7 points and answer ‘yes’ to item number 7). This
assumes a control rate of 26% independently walking by 8 weeks and ensures sufficient power to detect a
rate of at least 39% in the active treatment group. This is slightly more conservative than the proportion
improved in the Scheidtmann et al.52 study. The calculations assume that the primary intention-to-treat
(ITT) analysis includes all randomised patients and that patients who died or were lost to follow-up were
unable to walk independently.
The DARS trial sample size also provides 80% power to detect a small to moderate effect size of 0.3 in key
secondary outcomes (e.g. ABILHAND and NEADL). It was important that the trial had sufficient power to
detect a real change in these secondary outcomes given that they are (1) important functional parameters in
addition to walking and (2) likely to change if the treatment is effective. For all secondary analyses, loss to
follow-up was estimated at 10% at 8 weeks, rising to 20% by 12 months, and accounted for intercurrent
illness, late mortality and trial withdrawal. Loss to follow-up was minimised by collecting data via a face-to-face
interview with a researcher.
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Interim analyses and stopping guidelines
Outcome data were analysed once only, although statistical monitoring of safety data was conducted
throughout the trial and reported at agreed intervals to the Data Monitoring and Ethics Committee (DMEC).
Strategies to maximise recruitment
Recruitment in to a pharmacorehabilitation stroke trial is challenging and the barriers to achieving target
recruitment are multifaceted. A responsive approach was implemented to ensure issues in recruitment and
implementation were identified in a timely manner so that the trial could adapt processes accordingly.
Table 3 provides a summary of the strategies implemented and the perceived benefit.
TABLE 3 Strategies to maximise recruitment
Strategy Rationale
Liaison with sites and
NIHR SRNs
l Establish effective working relationships with participating sites
l Raise and maintain heightened awareness of the trial
l Identify issues in securing relevant permissions
l Understand the service pathway and how the trial is implemented within existing services
l Understand how potential patients will be identified
l Determine staffing or capacity issues
l Provide a mechanism for continuous feedback on the delivery and conduct of the trial
l Provide a mechanism to share best practice in trial conduct




l Identify reasons why participants are not eligible
l Identify reasons why eligible patients do not enter the trial
l Identify potential resource issues
l Establish accurate recruitment rates
l Identify potential protocol amendments
l Determine if new sites are required
Trial champions at local
and national level
l Facilitate implementation of the trial
l Provide ongoing promotion of the trial
l Reinforce the importance of the trial
l Ensure adherence to, and implementation of, the trial protocol
l Achieve ‘buy-in’
Central trial team l Allow a co-ordinated approach to identifying and resolving queries and issues/barriers
l Ensure clear communication to all involved in the trial
l Ensure prompt response to queries through use of a dedicated trial e-mail account and
trial team
Newsletters/publicity l Promote and maintain engagement and acknowledge contribution
l Maintain awareness of the trial
l Promote ongoing importance of the trial
l Share best practice
l Clear communication
l Encourage ‘healthy competition’ between participating sites
l Promote good will at sites
Regular trial oversight
committee meetings
l TMG, TSC and DMECs provide clear guidance for the resolution of issues with trial
recruitment and implementation
Addition of new sites l Increase the pool of potentially eligible patients
TMG, Trial Management Group; TSC, Trial Steering Committee.
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The randomisation sequence was created by the safety statistician using Stata® version 11.1 (StataCorp,
College Station, TX, USA) statistical software. Random permuted block sizes of four were used to ensure
that treatment groups were well balanced for the following stratification factors:
l centre
l type of stroke (primary intracranial haemorrhage or infarction)
l RMI (score of 0–3 points, > 3 but < 7 points).
Eligible patients who had given written informed consent and completed baseline assessments were
randomised on a 1 : 1 basis via the CTRU automated 24-hour telephone randomisation system to receive
either co-careldopa or placebo.
Allocation concealment
A placebo tablet was manufactured to match the commercial co-careldopa (Sinemet) and the final assembly,
packaging and labelling of the co-careldopa/placebo kit was undertaken by Sharp Clinical Services, UK. The
composition of the placebo was approved by the Medicines and Healthcare products Regulatory Agency.
Co-careldopa and the matching placebo were labelled with a unique random five-digit kit number, which
was assigned to a participant on randomisation by the central randomisation system at the CTRU.
Two sets of code-break envelopes were provided by Sharp Clinical Services one set was shipped with the
study medication to the participating site pharmacy and a second set was held securely at the CTRU for
use in case of an emergency.
Blinding
The trial was double blind. Participants, clinicians, research staff and trial personnel at the CTRU involved
in the day-to-day running of the trial were blinded to group allocation until the final database lock.
Outcomes were collected by assessors masked to the treatment allocation. All analyses until the final
analysis were undertaken blinded to treatment allocation. A trial safety team had access to the treatment
allocation for the purposes of emergency unblinding and preparation of unblinded reports to the DMEC.
Emergency unblinding
Unblinding was permitted only when information about the participant’s trial treatment was clearly
necessary and could alter the appropriate medical management of the patient.
Unblinding could be requested on the grounds of safety by the chief investigator, local PI or authorised
delegate or treating physician. Requests for unblinding were first handled by the local PI, who explored
the reason for the request and evaluated the importance of knowledge of treatment assignment for
participant safety. In the event of a SAE, all patients were treated as though they were receiving the
active medication.
Emergency unblinding was carried out using the code-break envelopes by the CTRU during office hours,
and this was delegated to the local pharmacy department at the appropriate centre at all other times.
Withdrawal from treatment and data collection
Participants could withdraw from further trial treatment and/or data collection.
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Participants did not continue to receive co-careldopa or the placebo after randomisation if they developed
contraindications to the co-careldopa treatment, if the treating physician deemed that the patient was at a
significant health risk from continued participation in the trial or if the participant decided that they no
longer wished to take part in the trial.
If treatment was stopped, participants were still followed up unless they had withdrawn consent to
follow-up. The primary reason for discontinuation was recorded.
Participants were made aware (through the information sheet and consent form) that, should they
withdraw, safety data would still be collected after their last dose and all data collected prior to the
withdrawal date would be used in the final analysis.
Patient and public involvement
We consulted with the Consumer Research Advisory Group (CRAG), which is a local Yorkshire-based
group comprising stroke survivors and caregivers who give advice on research projects. Their advice was
sought on the design of the IMP packaging and the proposal to invite patients to participate in more than
one research project.
Mr Ossie Newell (Joint Chairperson of the Nottingham Stroke Research Consumer Group) reviewed the
original research idea from a patient perspective and reviewed the patient information sheets and proposed
outcome measures to ensure that they were appropriate for the patient population. Mr Michael Bonner, a
member of the Trial Steering Committee (TSC), ensured that the patients’ perspective was considered during
the progress of the trial. He also reviewed the patient information sheet and proposed outcome measures.
Statistical methods
The statistical analysis plan was finalised and approved by the Trial Management Group and TSC.
Significance was tested at the 5% level for all analyses. Analyses were completed in SAS® version 9.2
(SAS Institute Inc., Cary, NC, USA). Analyses were pragmatic, based on an ITT sample.
Screening data
A flow diagram summarised the course of all patients through the screening process, including the number
of patients approached, reasons for ineligibility, issues with consent and other reasons why the patient was
not randomised. Age, sex and ethnicity data of the screening population were also summarised.
Baseline characteristics
Baseline characteristics of recruited participants were summarised by treatment group and overall. Baseline
characteristics included stratification factors [centre, type of stroke (primary intracranial haemorrhage or
infarction) and RMI (summarised as a continuous measure based on the researcher-completed questionnaire)],
classification of stroke (if infarction) [total anterior circulation infarction (TACI), lacunar infarction (LACI),
partial anterior circulation infarction (PACI) or posterior circulation infarction (POCI) classification], age, sex
and ethnicity.
Baseline characteristics of carers were summarised by treatment group and overall, and included age, sex,
ethnicity, relationship to the patient and whether or not they provided care before the patient’s stroke.
Continuous variables were reported as means and SDs, and categorical variables were presented as
frequencies (n) and percentages. Only descriptive statistics were presented; no formal statistical testing
was carried out on these data.
METHODS
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Primary end-point analysis
The primary end point was independent walking ability at 8 weeks post randomisation (defined by a RMI
score of ≥ 7 points and answer ‘yes’ to item number 7 of the RMI).
For the ITT analysis of the primary outcome, it was assumed that patients who died or were lost to
follow-up were unable to walk independently. The planned analysis for estimating differences in walking
ability between treatment groups (co-careldopa and placebo) was to use a multilevel logistic regression model
adjusted for stratification variables: sex, type of stroke, researcher-completed RMI baseline score (continuous)
and centre (the last fitted as a random effect). However, inspection of the residuals, influence and model fit
statistics and the diagnostic plots suggested poor model fit; therefore, stepwise regression was used to build a
more robust model and included additional variables as agreed within the research team (age, baseline scores
for BI, ABILHAND, NEADL, MoCA and GHQ-12, number of days between stroke and randomisation, and total
number of sufficient motor therapy sessions). There were 13 missing values for baseline NEADL and BI; as the
proportion of missing data was < 5%, missing data were imputed using mean imputation.81 All stratifying
variables were included in the stepwise model and a significance level of 0.05 was used to retain baseline
variables. The final model contained, in addition to the stratifying variables, baseline NEADL and BI scores,
age and the number of days from stroke to randomisation.
Parameter estimates or odds ratios (ORs) are reported, together with 95% confidence intervals (CIs) and
p-values (fixed effects) or standard errors (SEs) (random effects).
Sensitivity and per-protocol analyses
A series of sensitivity analyses were conducted to test the robustness of the conclusions of the primary
ITT analysis:
l assuming that participants who died or were lost to follow-up were able to walk independently
at 8 weeks
l complete-case analysis
l fitting centre as a fixed effect
l using researcher-completed RMI score at baseline in place of score at 24-hour randomisation
l using patient-completed RMI score at baseline instead of score at 24-hour randomisation
l including only participants for whom the 8-week questionnaire was received by 12 weeks
post randomisation
l assuming that participants who had no primary outcome data because they were too unwell were
unable to walk independently, and participants who had died, had withdrawn, were unwilling to be
visited, refused to complete the questionnaire, had moved out of the area, those we could not get
hold of and questionnaires that were lost at site or in the post were classed missing.
A per-protocol analysis was planned but could not be undertaken because of the small numbers remaining
in the per-protocol population.
Patient secondary end points
Independent walking ability (primary outcome, defined by item 7 of the RMI and a RMI score of ≥ 7 points
overall) at 6 months and 12 months post randomisation was analysed using a stepwise multilevel logistic
regression model adjusted for stratifying variables. As with the primary end-point analysis, the planned
analysis for other secondary end points including RMI (as a continuous measure), BI, ABILHAND, NEADL,
MoCA and GHQ-12 at 8 weeks, 6 months and 12 months resulted in poor model fit and the same strategy
of using stepwise multilevel regression (in this case linear) was employed. However, for secondary outcomes,
the baseline outcome measurement was kept in the model with the stratifying variables, and the random
effect was removed from the GHQ-12 model because the variance component was negative. mRS was
analysed at 8 weeks and 6 months using a stepwise multilevel proportional odds logistic regression model
adjusting for the same covariates; score test to check proportional odds assumption is reported. For dealing
with missing items within individual outcome measures, the strategy was thus: mean imputation was used
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for the BI; NEADL, GHQ-12, FAS and CBS were prorated. No data were imputed for RMI as a continuous
variable, MSK-SSP manikin or mRS.
Additionally, RMI at 12 months was analysed using repeated measures to investigate long-term trajectory
using a random coefficients model to focus on difference between treatments in change in outcome over
time. Only cases for which data were available at all time points were included in the model.
Parameter estimates, predicted mean values or ORs (ordinal logistic regression only) are reported with
95% CI and p-values.
Carer secondary end points
The carer burden using CBS was analysed at each follow-up by linear regression, adjusting for patient
stratification factors (type of stroke and patient-completed RMI at baseline) and carer characteristics (age,
sex and relationship to participant). Centre was not included in the model because of the small number of
observations. Parameter estimates and predicted mean values with 95% CI and p-values are presented.
Safety
The number of AEs (reported up to the 8-week post-randomisation follow-up visit), the number of patients
with AEs, the suspected relationship of all SAEs (reported up to 30 days beyond the last drug dose) to
co-careldopa/placebo, the number of resolved SAEs and the proportion of patients with all SAEs resolved,
the cause, Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classification, seriousness
criteria and outcome of SAEs are summarised by treatment group.
New, significant medical or surgical events from 8 weeks to 6 months and from 6 months to 12 months
are summarised by treatment group.
The number, primary cause and timings of deaths are summarised by treatment group. The percentage
of patients and carers who die from any cause between randomisation and 12 months follow-up are
summarised by arm and centre.
The number of participants who vomited once or more often between taking the dose of protocol
treatment and the end of therapy and the number of therapy sessions in which the participants vomited
are presented by treatment arm.
Content of occupational and physical therapy
The number of participants being discharged to the community during treatment is summarised by
treatment group. For patients discharged within 6 weeks of therapy, the time to discharge is also
summarised by treatment group. The number of patients who commenced therapy > 5 days post
discharge is summarised by treatment group.
The number of therapy sessions undertaken per patient from randomisation to the end of the 6-week
treatment period, the average length of therapy sessions and therapist present is summarised by treatment
group. The number of therapy sessions per week for each patient in hospital and in the community is
summarised by treatment group.
The number of patients receiving sufficient motor therapy (i.e. those who received at least 20 minutes of
motor therapy in at least 80% of therapy sessions) is summarised by treatment group.
Treatment compliance
The number of co-careldopa/placebo doses received during the 6 weeks of treatment is presented using
summary statistics by treatment group as well as the proportion of patients receiving the same number of
treatments as therapy sessions. If the numbers of therapy sessions and treatments are not consistent,
a table summarises how much they differ by treatment group.
METHODS
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The proportion of all motor therapy sessions and the number of therapy sessions per patient in which
the drug is taken as per protocol, in which the drug is taken but not 45–60 minutes before the therapy
session and in which the drug is not taken at all are summarised. The timing of when each drug is taken is
summarised, including those that are taken 45–60 minutes before the start of the therapy session. Reasons
for not taking the drug at all are summarised. The proportion of times the drug was taken as per protocol
(45–60 minutes before a motor therapy session) is summarised when the patient was still in hospital and
when the patient received or did not receive a telephone call reminder for motor therapy sessions held in
the community.
The number of patients with kit replacements and the total number of kit replacements are presented by
treatment group and by centre.
Definitions of treatment compliance
The primary analysis was by ITT; subsequently, further analyses assessed the sensitivity of the conclusions
of this analysis to non-compliance using a staged definition of ‘compliance’ (binary: yes or no). This
definition was used for the purpose of complier-average causal effect (CACE) analyses. This was based on
whether or not the drug was taken and the timing of this, the amount of motor therapy and the number
of sessions:
1. Strict compliance – randomised drug taken 45–60 minutes before therapy, involving ≥ 20 minutes of
motor therapy for ≥ 80% of the sessions.
2. Relaxed timing compliance – randomised drug taken 0–60 minutes or within 3 hours of a dose of drug
(if patient had two therapy sessions directly one after the other) before therapy, involving ≥ 20 minutes
of motor therapy for ≥ 80% of the sessions.
3. Relaxed timing and motor therapy compliance – randomised drug taken 0–60 minutes or within
3 hours of a dose of drug (if patient had two therapy sessions directly one after the other) before
therapy for ≥ 80% of the motor sessions.
4. Drug intake compliance – missed ≤ 20% of drug within therapy sessions involving ≥ 20 minutes of
motor therapy for ≥ 80% of the motor sessions.
If < 5 therapy sessions had been arranged, the definitions of compliance were set to missing. Treatment
withdrawals were handled within the above definitions.
Patient perspective regarding the use of the investigational medicinal product with
rehabilitation treatment
Responses to questions regarding the patient’s perspective of the use of the IMP measured at 8 weeks’
follow-up are summarised by treatment group, including how easy it was to take the tablet, how easy
it was to remember to take it, how easy it was to get it out of the packet and how easy it was to
understand the instructions on the packaging.
Unblinding requests
A summary of requests for unblinding was produced, including whether or not the patient was
subsequently unblinded, reasons for this and whether or not the research team was unblinded.
Exit poll
An exit poll was completed by the patient and researcher at 12 months post randomisation. If patients had
not completed an unblinding request, both the patient and the researcher were asked to guess which
treatment the patient was randomised to.
This analysis was conducted on patient and researcher responses separately. A summary is included that
looks at the proportion of patient and researcher guesses that are consistent by treatment group.
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A blinding index has been calculated for each treatment group with 95% CI.82 Reasons for the patient’s/
researcher’s choice are summarised by treatment group and whether or not their choice was correct.
Other reasons are listed.
Further analyses
The number of patients who watched the DARS trial information DVD is summarised by treatment group.
Results from the questionnaire to establish whether or not the DVD was easy to understand and its
usefulness for other trials are summarised by treatment group.
The correlations between watching the DVD, treatment compliance and questionnaire completion were
calculated to explore if the DVD had a positive impact in the trial as well as for the patient. Logistic
regression models are used while controlling for RMI at baseline, age, sex and type of stroke.
The level of assistance with patient-completed questionnaires and the person that provided assistance
are summarised at baseline, 8 weeks, 6 months and 12 months, overall and by treatment group. The
proportion of patients who received at least some help is compared between treatment groups using the
chi-squared test. The difference between the two groups and corresponding 95% CI are reported.
Moderator and mediator analyses
Potential predictors of response to co-careldopa via moderators and mediators were explored.
Moderator analyses explored whether or not the size of the treatment effect depended on baseline
characteristics of the patients. Moderator variables included baseline RMI score, depression (measured
using the GHQ-12), pain (measured using the MSK-SSP manikin pre stroke), patient baseline medical
history, neuroimaging and cognitive function (measured using the MoCA). Each moderator was tabulated
by treatment and outcome, and analyses included moderator-by-treatment interaction effects one at a
time into the final primary outcome multilevel model.
Mediator analyses explored the extent to which the treatment effect could be explained by an intermediate
mechanistic outcome. Analyses focused on RMI at 8 weeks. Potential mediator variables related to a period
prior to the outcome but post randomisation. At 8 weeks, these included the number of motor therapy
sessions, number of IMP doses, fatigue (measured using the FAS), pain (measured using the MSK-SSP
manikin), cognitive function (measured using the MoCA) and activities of daily living (measured using the BI
and NEADL). Summary statistics of the mediators were tabulated by treatment and outcome, and the analyses
followed the traditional approach of Baron and Kenny83 to establish mediation.84 Each model was fitted as a
multilevel model with centre as a random intercept and adjusting for the covariates included in the primary
outcome model. The planned analyses also included investigation of departures from randomised treatment as
a mediator through CACE analysis using the definitions of compliance as outlined in Definitions of treatment
compliance. However, on inspection of the data, all patients received the treatment they were randomised to
and, therefore, analysis focused on descriptive statistics of the different levels of compliance.
Radiological review
The influence of the stroke lesion itself (as seen via imaging) was explored as part of the secondary
analysis. All available CT and MRI scans obtained during the index admission were obtained for
participants who had provided informed consent. Participating sites copied the images to CD (compact
disc) USB (universal serial bus) memory stick in Digital Imaging and Communication in Medicine (DICOM)
format,85 and sent them to the CTRU for centralised review. Participating sites were instructed to remove
patient-identifiable information (name, NHS number and treating clinician) from the scans before they
METHODS
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were sent to the CTRU. If this was not possible, sites were required to encrypt the scan data. The
possibility that scans would be incompletely anonymised was explained to participants in the patient
information sheet and as part of the informed consent process.
The use of a standardised classification system for interpreting scans has been shown to minimise the risk
of missing subtle changes.86 A number of systems have been developed.87–89 When selecting a system
for the DARS trial, it was desirable to use an existing protocol with proven interobserver agreement that
could be applied to both CT and MRI scans. As motor learning is thought to depend on the interaction of
several cortical areas and the basal ganglia,20,21,28 the template was required to accurately code the location
and extent of subcortical infarcts as well as the cortical lesions. The Acute Ischaemic Stroke Classification
Template (AISCT)87 was developed by Professor Wardlaw et al. of the University of Edinburgh Brain
Research Imaging Centre and is available to download from www.ed.ac.uk/files/imports/fileManager/
CT%20and%20MR%20reading%20form.pdf (accessed 6 July 2018). It was used in DARS with permission
of Professor Wardlaw (2015, personal communication).
The AISCT was developed in 1994 as a system that reliably codes both the site and size of an infarct, as well as
the degree of swelling and any haemorrhagic transformation.87 Following review of over 100 scans, Wardlaw90
constructed standardised templates to illustrate the different patterns of infarction and tissue swelling. The
AISCT shows good interobserver agreement between experienced neuroradiologists for infarct size and type
(K = 0.78), excellent agreement for infarct swelling (K = 0.8) and moderate agreement for haemorrhagic
transformation of the infarct.87 Among radiology trainees, it has moderate to good agreement for infarct
size and site, fair to moderate agreement for infarct swelling and poor to fair agreement for haemorrhagic
transformation.87 The interobserver agreement of this system has subsequently been evaluated by the Acute
Cerebral CT Evaluation of Stroke Study (ACCESS): a large online validation, which has now been ongoing for
several years.86,91 Neuroradiologists tended to spot more subtle signs of ischaemia than non-radiologists91 and
took longer to read each scan than non-radiologists.86 More severe ischaemia (hypodensity and swelling) was
more reliably detected than subtle signs and a longer time from presentation to scan also improved detection
rates for ischaemic change.86 Detection of acute ischaemia was not influenced by scan quality or by the
presence of an old ischaemic lesion.86 The AISCT has been used in the Third International Stroke Trial (IST-3)92
and also a subsidiary study of IST-3 to determine if CT or MRI angiography might be used to guide
administration of tissue plasminogen activator at up to 6 hours after stroke.93
The AISCT begins with an overall subjective judgement on the quality of images (trichotomised as
good, moderate or poor). The presence of any visible abnormality (an acute stroke lesion or any other
pre-existing abnormality) is then documented. For those scans judged to be abnormal, the presence or
absence and laterality of any ischaemic change is documented. Features of early ischaemia were classified on
CT as loss of definition between the cortical grey matter and underlying white matter; loss of the outline of
the basal ganglia; and frank hypodensity.86,91,93 For MRI, signs of early ischaemic change were classified as a
faint hyperintensity on diffusion-weighted imaging (DWI) sequences but no lesion visible on T2-weighted or
fluid-attenuated inversion recovery (FLAIR) images; bright hyperintensity on DWI but no/pale lesion visible on
T2 or FLAIR images; or a lesion clearly visible on T2 or FLAIR images as well as on DWI.93 Acute swelling was
classified using the AISCT framework and reference diagrams.86 Middle cerebral artery (MCA) lesions were
classified as involving less than or more than one-third of this territory.86,88 Using the reference diagrams
developed for the AISCT, MCA territory lesions were then further classified as small cortical; basal ganglia
striatocapsular; lateral to ventricle striatocapsular; anterior cortical MCA territory; posterior cortical MCA
territory; whole of cortical MCA territory; whole of cortical MCA territory with lateral part of basal ganglia;
and whole MCA territory.86 Lesions in the anterior cerebral artery and posterior cerebral artery territories
were each defined as involving < 50% of that territory, > 50%, or complete.86 Lacunar lesions were classified
as involving the internal capsule or lentiform, internal border zone, centrum semiovale, or thalamus.86 Infarcts
involving the anterior and posterior border zones were noted.86 Cerebellar lesions were classified as lacunar
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infarcts or as involving < 50% or > 50% of the hemisphere.86 Similarly, brain stem lesions were classified as
lacunar or as involving < 50% or > 50% of the brain stem.86 The Alberta Stroke Proforma Early CT Score
(ASPECTS)89 was recorded for all lesions involving the MCA territory.86 Only the primary acute ischaemic
lesion was coded in this way. When two acute ischaemic lesions were present, we utilised clinical judgement
when deciding which was likely to be the most clinically significant. Any second (minor) acute ischaemic
lesion was coded simply as present or absent.93
The AISCT categorises the presence of haemorrhage as petechial, significant haemorrhagic transformation
of an underlying infarct parenchymal haematoma with no infarct visible, parenchymal haematoma clearly
remote from infarct, subdural haematoma, subarachnoid haemorrhage and extradural haemorrhage.93 It
also records the maximum diameter of the lesion (< 3 cm, 3–5 cm, 5–8 cm or > 8 cm).93 If blood is present
in more than one location (e.g. a primary parenchymal haematoma with rupture in the subarachnoid
space), then the presence of both was recorded93 and a clinical judgement was exercised to place them in
rank order of likely significance.93 The following variables were documented for the DARS trial analysis: the
location of haematoma (frontal, temporal, parietal, occipital, basal ganglia/thalamus, internal capsule, brain
stem, cerebellum);94 the extent of midline shift (in millimetres); the presence or absence of hydrocephalus;
and the presence or absence of intraventricular extension. Haematoma volume was calculated using
the equation:
Volume =
A × B × C
2
, (1)
where A is the greatest diameter of the haemorrhage on axial imaging, B is the greatest diameter at 90° to
A and C is the approximate number of axial imaging slices on which the haematoma is visible, multiplied by
slice thickness.95,96 Haematoma diameter and volume were calculated for confluent haematomas only and no
attempt was made to assess these parameters for petechial haemorrhage or for subarachnoid blood.
The presence and extent of white matter lesions were documented using the same validated systems97,98 as
were used by Wardlaw et al.93 Old vascular lesions were classified as old cortical infarct(s), old striatocapsular
infarct(s), old borderzone infarct(s), old lacunar infarct(s), old brain stem/cerebellar infarct(s) or probable old
haemorrhage.93 Finally, non-stroke lesions were classified as cerebral tumour, encephalitis, cerebral abscess
and demyelination.93 Brain atrophy was recorded as present or absent.
All scans were co-reported by the clinical research fellow and one of two experienced consultant
neuroradiologists (Dr Jeremy Macmullen-Price and Dr Tufail Patankar) on a CRF using the standardised
reporting system using AISCT or ASPECTS. Images were reviewed blinded to the original study report from
the recruiting centre, clinical information (stroke laterality, administration of thrombolysis and Oxford
Community Stroke Project clinical stroke syndrome),99 and trial treatment allocation. Images were reviewed in
DICOM format. The time taken to review each case was not recorded; reviewers were free to take as long as
they deemed necessary.
It was expected that all scans would be subjected to routine reporting by local radiologists in order to
guide the clinical management of the patient. As the review of scans for the DARS trial could be delayed
by several months from the point of a patient’s enrolment in the trial, the DARS trial analysis could not
provide clinically significant information in a timely manner. It was also important that the trial team did
not seek to influence or guide the clinical management of participants in any way. Clinical feedback was
not provided to local sites. However, when clinically significant and unexpected findings arose, they were
communicated to the local PI, who was then responsible for ensuring that they were noted and acted on
if necessary.100
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An economic evaluation was conducted to estimate the cost-effectiveness of DARS compared with placebo.
To enable cross-analyses comparisons, decision-making and efficient distribution of scarce health-care
resources, health economic analyses often follow prescribed methods. Thus, the proposed analyses followed
the reference case set out by NICE in its guidance for technology appraisals.101 The economic evaluation was
conducted alongside the clinical trial analysing the data gathered therein; such economic evaluations are
commonplace among stroke rehabilitation trials (e.g. Logan et al.102 and Forster et al.103).
The protocol stated that a decision-analytic model would be developed to model the costs and benefits of
the interventions forward beyond the trial period. However, the decision model development was halted
as the results from the statistical analysis indicated that co-careldopa did not confer incremental benefits
over placebo at 8 weeks and, hence, there were no benefits to propagate forward. Despite these initial
results, it was still considered necessary to conduct the economic evaluation based on the trial data.
Methods
End points, perspectives and discounting
The primary analysis was a cost–utility analysis with the primary end point of cost per quality-adjusted
life-year (QALY) gained from a 6-week course of co-careldopa for rehabilitation post stroke versus placebo
at 12 months. A secondary cost-effectiveness analysis (CEA) was conducted to establish the cost per
incremental achievement of ≥ 7 points on the RMI. Although values from this may be less interpretable,
it was incorporated to be consistent with the main trial statistical analysis, which employed this as the
primary end point.64
The cost perspective for the primary, base-case analysis was that of the Health and Personal Social
Services (i.e. the health-care provider). However, a supplementary analysis considered a wider perspective
encompassing costs to carers and patients. Given that the duration of the trial was 12 months, discounting
of either costs or benefits was not required.
Measurement of effectiveness
The analysis used QALYs as the main outcome measure. QALYs represent a quality-weighted survival
value where 1 QALY is the equivalent of 1 year of full health. The health-state utility values required for
QALY calculation were captured using the EQ-5D, three-level version,104 at baseline, 2 months, 6 months
and 12 months after randomisation. The EQ-5D is a commonly used generic measure of health-related
quality of life (HRQoL) comprising five domains [(1) mobility, (2) self-care, (3) usual activities, (4) pain/
discomfort and (5) anxiety/depression], each with three response levels (1, no problems; 2, some problems;
and 3, severe problems). The EQ-5D is NICE’s101 preferred measure of health benefit and has been
validated in stroke105 and incorporated in many stroke trials (e.g. Palesch et al.106 and Sackley et al.107).
Patient responses were converted to utility values using the UK time trade-off tariff.108 Caregivers also
reported on their own HRQoL using EQ-5D at the same time intervals. The RMI was completed via an
interview with the patients at the same time as the EQ-5D. The RMI has 15 items that measure the ability
of patients to make postural adjustments, transfer and walk and is scored from 0 to 15 points, with higher
scores reflecting better mobility.
Measurement of costs
Health-care resource utilisation was captured using specially developed questionnaires covering primary care
[e.g. general practitioner (GP) and nurse visits] and secondary care [e.g. hospital stays and accident and
emergency (A&E) visits] use over the trial period. The questionnaires also included items capturing costs to
the patient (e.g. travel, aid and home adaptation expenses) and impact on their income (i.e. earning losses).
Caregivers responded separately with costs they had incurred (including earning losses) in the course of
caring for the patient. The resource use questionnaires were completed alongside other outcome measures
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at 8 weeks, 6 months and 12 months after randomisation. The recall period for the measures was ‘Since
you joined the study’ at 2 months and ‘In the last 3 months’ for the remaining two follow-ups. As the last
two completions did not cover the full trial period, monthly resource counts were calculated and then
multiplied by the number of months between the follow-up periods (i.e. by 4 and by 6 for the 6-month and
12-month follow-ups, respectively). Unit costs for health service staff and resources were obtained mainly
from the Personal Social Services Research Unit (PSSRU)109 report and NHS Reference Cost databases.110,111
The market price for co-careldopa was assigned using the electronic market information tool (eMit).112
All costs were inflated to 2015 prices (Great British pounds) using an online inflator (see Appendix 2 for
more details on unit costs).113
Analysis
The primary analysis was a cost–utility analysis with a secondary CEA considering a RMI score of ≥ 7 points
as the effect of interest. In line with the clinical efficacy analysis, an ITT analysis was the primary method for
analysing and summarising the health economic trial data. A supplementary per-protocol analysis (using
criteria set out by the clinical trial team) had been planned but, as very few patients met the strict compliance
criteria, this analysis was not considered feasible. EQ-5D responses were converted to health-state utility
values and multiplied by the proportion of a year the time period represented (baseline to 8 weeks = 0.167;
2–6 months = 0.333; 6–12 months = 0.5) to calculate QALYs. Average QALYs between adjacent time points
were calculated to generate smoothed estimates between time points. If an individual died during the trial,
their utility was assumed to be ‘0’ at that point and QALYs were calculated in the usual way.
Quality-adjusted life-years were calculated using an area under the curve approach:
QALY= f½(EQ5D_Baseline+ EQ5D_2month)/2 0:167g+ f½(EQ5D_2month+ EQ5D_6month)/2
0:333g + f½(EQ5D_6month + EQ5D_12month)/2 0:50g. (2)
Total costs and QALYs were calculated for each arm. For the supplementary analysis, the former included
the costs to the patient and caregiver. If required, adjustments were made to account for differences in
baseline utility.
In the event that one intervention was more costly and more effective or cheaper and less effective than
the other, incremental cost-effectiveness ratios (ICERs) were calculated:
ICER = (costDopamine− costStandard)/(QALYDopamine−QALYStandard). (3)
We used the NICE willingness to pay (WTP) per incremental QALY threshold [lambda (λ) = £20,000] to
determine cost-effectiveness. Interventions with an ICER of < £20,000 per QALY are generally considered
cost-effective. A non-parametric bootstrapping analysis (with replacement) was employed to determine the
level of sampling uncertainty around the ICER by generating 10,000 estimates of incremental costs and
benefits. The bootstrapped estimates were plotted on the cost-effectiveness plane. Estimates of net monetary
benefit (NMB) were generated and used to estimate the probability that co-careldopa was cost-effective given
a range of WTP per incremental QALY values (λ). This was presented as the cost-effectiveness acceptability
curve (CEAC).114,115 Therapies with average incremental NMB of > £0 should be adopted (assuming
λ = £20,000). NMB was derived for each patient, thus:
NMB = (λ × QALYs)− costs: (4)
We also ran a net benefit regression model to allow parametric analysis of the costs and benefits of the
interventions.116 Controlling for any baseline sample heterogeneity and significant baseline differences
between groups, we determined whether or not treatment arm was a significant predictor of net benefit.
This analysis was also used to determine whether or not the effects of co-careldopa were heterogeneous
across different subgroups (including age, sex and stroke severity as indicated by 8-week mRS and infarct
type). An additional NMB regression explored whether or not treatment compliance affected trial results.
METHODS
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Deterministic sensitivity analysis of the ICER was undertaken to test the robustness of the results.
Outcomes and costs were altered by ± 20% (in both arms) to determine the effect of input parameter
variation on the cost-effectiveness results. Multiple Imputation117 was used to generate estimates of
missing cost and utility values. This approach is recommended for economic analyses conducted alongside
clinical trials as it reflects the uncertainty inherent in replacing missing data.118 Imputation was conducted
using baseline characteristics (e.g. age and sex) and available health status measures, such as mRS,
as these were considered to be important predictors of both EQ-5D and costs (for more details on the
predictors see Chapter 4, Missing data). A complete-case sample was also presented, referring to those
patients with no missing costs and no missing utility values over the trial. All analyses were conducted
in Stata® version 13 (StataCorp LP, College Station, TX, USA) and Microsoft Excel® (2010; Microsoft
Corporation, Redmond, WA, USA).
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Chapter 3 Trial results
Screening and recruitment
During the recruitment period of May 2011 to March 2014, 19,509 patients were screened for eligibility.
Of those screened, 1547 (7.9%) were deemed eligible, 599 (3.1%) were consented and 593 (3.0%) were
randomised. Figure 3 shows the monthly, cumulative and target accrual and Figure 4 shows the flow of
patients through the trial. The number of participants recruited per site ranged from 1 to 50.
A comparison of screening data for randomised and non-randomised patients is presented in Table 4.
Compared with screened patients, randomised patients were younger and more likely to be male, of white
ethnicity and screened at a later date post stroke.
Eligibility violations
Table 5 provides details of the 10 eligibility violations that were identified during the trial: five in each
randomised group. In the placebo group, one participant was unable to comply with the treatment
schedule and four were not randomised within the eligible time period post stroke.
Initially, the eligibility criteria stated that participants must be diagnosed with stroke within 2 weeks prior
to randomisation, which was subsequently changed to 42 days. One participant violated eligibility early on
in the trial by being diagnosed > 2 weeks before randomisation; the remaining were diagnosed > 42 days
after randomisation.
In the co-careldopa group, one participant was taking part in another trial, two had known hypersensitivity
or contraindications to co-careldopa and two had their diagnosis of stroke revised (one to demyelination
and one to traumatic brain injury). With the exception of the participant who was unable to comply with
treatment (because they were nil by mouth), all participants received some protocol treatment.
Participant baseline characteristics
Overall, patient baseline characteristics and questionnaire scores were balanced between the randomised
groups, as shown by the demographic characteristics (see Table 6), hospital admission and current stroke
data (see Table 7) and neuroimaging data (see Table 8).
The mean age was 67.5 years for co-careldopa participants and 69.6 years for placebo participants. More
males than females were randomised: 187 (60.7%) in the co-careldopa group and 177 (62.1%) in the
placebo group. The majority of participants were of white ethnic origin: 289 (93.8%) in the co-careldopa
group and 270 (94.7%) in the placebo group. With regard to education, 134 co-careldopa participants
(43.5%) and 139 placebo participants (48.8%) spent ≤ 12 years in formal, full-time education (Table 6).
Participants were randomised at around 2 weeks post stroke (median of 14 and 15 days in the co-careldopa
and placebo groups, respectively). The cause of stroke was cerebral infarction in the majority of cases:
in 270 participants (87.7%) in the co-careldopa group and in 238 participants (83.5%) in the placebo group.
Thrombolysis was received by 62 co-careldopa participants (23.0%) and 59 placebo participants (24.8%)
(Table 7). The proportion of patients with total anterior circulation infarcts was higher in the co-careldopa
group than in the placebo group (36.3% vs. 26.5%, respectively; see Table 7), although baseline walking/
mobility did not differ between the two groups (see Table 13). This difference was due to chance.
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[n = 948 (61.3% of eligible)]
• Patient refused, n = 495 (32.0%)
• Patient discharged before consent, 
   n = 216 (14.0%)
• Patient died, n = 187 (12.1%)
• Other, n = 46 (3.0%)
• Not completed/missing, n = 7 (0.5%)









[n = 17,962 (92.1% of screened)]
• The patient can walk ≥10 metres indoors
   independently, n = 8445 (43.3%)
• Unable to consent, n = 2404 (26.5%)
• No continuity of rehabilitation, n = 1426 (15.7%)
• Could not walk pre stroke, n = 1362 (15.0%)
• Survival of < 2 months expected, n = 1151 (12.7%)
• Other comorbidity, n = 1093 (12.1%)
• Cannot swallow tablets/capsules, n = 1044 (11.5%)
• Not stroke, n = 989 (10.9%)
• [Not new stroke,a n = 361 (4.0%)]
• Rehabilitation not required, n = 551 (6.1%)
• Participating in another trial, n = 432 (4.8%)
• Hypersensitivity or contraindications, n = 337 (3.7%)
• [Concurrent medications,a n = 9 (0.1%)]
• Pregnancy, lactation, contraception, n = 6 (0.1%)









[n = 6/599 (1.0% of consented)]
• Could not walk pre stroke, n = 1 (0.2%)
• Not new stroke,a n = 1 (0.2%)
• Not completed, n = 4 (0.7%)
Lost to follow-up 
[n = 37/308 (12.0%)]
• Died, n = 6 (2.0%)
• Withdrawn, n = 24 (7.8%)
• Moved out of area, n = 1 (0.3%)
• Too unwell, n = 1 (0.3%)
• Lost at site, n = 4 (1.3%)
• Other, n = 1 (0.3%)
Lost to follow-up 
[n = 24/285 (8.4%)]
• Died, n = 1 (0.4%)
• Withdrawn, n = 11 (3.9%)
• Could not contact, n = 2 (0.7%)
• Moved out of area, n = 1 (0.4%)
• Too unwell, n = 2 (0.7%)
• Lost in post, n = 1 (0.4%)
• Refused to complete, n = 2 (0.7%)
• Other, n = 2 (0.7%)
• Unknown, n = 2 (0.7%)
Analysed at 8 weeks
(n = 261)
Analysed at 8 weeks
 (n = 271)
Lost to follow-up 
[n = 66/308 (21.4%)]
• Died, n = 13 (4.2%)
• Withdrawn, n = 30 (9.7%)
• Could not contact, n = 10 (3.3%)
• Moved out of area, n = 4 (1.3%)
• Too unwell, n = 4 (1.3%)
• Refused to complete, n = 1 (0.3%)
• Unwilling for visit, n = 1 (0.3%)
• Other, n = 2 (0.7%)
• Unknown, n = 1 (1.5%)
Lost to follow-up 
[n = 35/285 (12.2%)]
• Died, n = 7 (2.5%)
• Withdrawn, n = 15 (5.3%)
• Could not contact, n = 5 (1.8%)
• Moved out of area, n = 4 (1.4%)
• Too unwell, n = 1 (0.4%)
• Lost at site, n = 1 (0.4%)
• Refused to complete, n = 1 (0.4%)
 Analysed at 6 months
 (n = 250)
Analysed at 6 months
  (n = 242)
 Analysed at 12 months
 (n = 221)
Analysed at 12 months
  (n = 222)
Lost to follow-up 
[n = 86/308 (27.9%)]
• Died, n = 21 (6.8%)
• Withdrawn, n = 42 (13.6%)
• Could not contact, n = 15 (4.9%)
• Moved out of area, n = 5 (1.6%)
• Refused to complete, n = 1 (0.3%)
• Other, n = 2 (0.7%)
Lost to follow-up 
[n = 64/285 (22.5%)]
• Died, n = 17 (6.0%)
• Withdrawn, n = 22 (7.7%)
• Could not contact, n = 12 (4.2%)
• Moved out of area, n = 5 (1.8%)
• Too unwell, n = 4 (1.4%)
• Refused to complete, n = 2 (0.7%)
• Unwilling for visit, n = 1 (0.4%)
• Other, n = 1 (0.4%)
Categories are not mutually exclusive
FIGURE 4 Screening flow diagram for the DARS trial. a, Initial screening category. Reproduced with permission
from Ford et al.119 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
4.0 license (https://creativecommons.org/licenses/by/4.0/).
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The majority of participants underwent digital imaging [263 co-careldopa participants (88.0%) and 250
placebo participants (89%)] and more participants underwent CT than MRI [299 co-careldopa participants
(97.1%) and 281 placebo participants (98.6%)] (Table 8).
Overall, 46 patients (7.8%) had also participated in another study: 27 in the co-careldopa group (8.8%)
and 19 in the placebo group (6.7%).
TABLE 4 Characteristics of screened and randomised participants
Patient characteristic
Participant
Screened (N= 19,509) Randomised (N= 593)
Days from stroke
Mean (SD), missing 6.4 (9.45), 767 11.6 (10.36), 5
Median (range) 3 (0–180) 8 (0–72)
Age (years)
Mean (SD), missing 73.6 (14.28), 130 68.1 (13.17), 6
Median (range) 76 (18–105) 70 (20–98)
Sex: male, n (%), missing (%) 9297 (47.7), 90 (0.5) 364 (61.4), 0 (0.0)
Ethnicity, n (%)
White 17,197 (88.1) 543 (91.6)
Other 767 (3.9) 32 (5.4)
Not stated or missing 1545 (7.9) 18 (3.0)






Drug doses taken Therapy sessions
Placebo Unable to comply with treatment
schedule
No 0 0
Not randomised within specified
time period post stroke
Yes 53 48
Not randomised within specified
time period post stroke
Yes 24 28
Not randomised within specified
time period post stroke
Yes 8 5
Not randomised within specified
time period post stroke
Yes 24 25
Co-careldopa Incorrect diagnosis of stroke Yes 37 46
Incorrect diagnosis of stroke Yes 2 2
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The majority of participants had at least one current or ongoing medical condition: 284 in the
co-careldopa group (92.2%) and 265 in the placebo group (93.0%), with a mean of 3.5 and
3.3 conditions, respectively.
Carer baseline characteristics
Eighty-four carers (27.3%) of participants in the co-careldopa group and 81 carers (28.4%) of participants
in the placebo group consented to participate in the trial, and their baseline characteristics are presented in
Table 9.
Participant withdrawals
Ninety-one participants (51.3%) withdrew from the trial: 58 (18.8%) in the co-careldopa group and
33 (11.6%) in the placebo group (Table 10). The majority of withdrawals occurred within 8 weeks of
TABLE 6 Summary of baseline demographic characteristics
Baseline characteristic
Treatment group
Total (N= 593)Co-careldopa (N= 308) Placebo (N= 285)
Patient age (years) at randomisation
Mean (SD) 67.5 (13.65) 69.6 (12.68) 68.5 (13.22)
Median (range) 69 (20–94) 71 (31–98) 70 (20–98)
Missing (n) 0 0 0
Patient sex, n (%)
Male 187 (60.7) 177 (62.1) 364 (61.4)
Female 121 (39.3) 108 (37.9) 229 (38.6)
Patient ethnicity, n (%)
White 289 (93.8) 270 (94.7) 559 (94.3)
Mixed: white and black Caribbean 1 (0.3) 0 (0.0) 1 (0.2)
Mixed: white and Asian 1 (0.3) 0 (0.0) 1 (0.2)
Other mixed background 0 (0.0) 1 (0.4) 1 (0.2)
Asian: Indian 4 (1.3) 3 (1.1) 7 (1.2)
Asian: Pakistani 2 (0.6) 3 (1.1) 5 (0.8)
Other Asian background 3 (1.0) 2 (0.7) 5 (0.8)
Black: Caribbean 1 (0.3) 5 (1.8) 6 (1.0)
Black: African 1 (0.3) 0 (0.0) 1 (0.2)
Other black background 1 (0.3) 0 (0.0) 1 (0.2)
Chinese 2 (0.6) 1 (0.4) 3 (0.5)
Other ethnic group 3 (1.0) 0 (0.0) 3 (0.5)
Education, n (%)
≤ 12 years 134 (43.5) 139 (48.8) 273 (46.0)
> 12 years 168 (54.5) 140 (49.1) 308 (51.9)
Missing 6 (1.9) 6 (2.1) 12 (2.0)
Reproduced with permission from Ford et al.119 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access
article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
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TABLE 7 Hospital admission and current stroke characteristics
Patient demographics
Treatment group
Total (N= 593)Co-careldopa (N= 308) Placebo (N= 285)
Days from stroke to randomisation
Mean (SD) 17.4 (9.91) 18.0 (10.23) 17.7 (10.06)
Median (range) 14 (3–50) 15 (3–59) 15 (3–59)
Missing (n) 0 0 0
Days in hospital up to randomisation
Mean (SD) 16.9 (10.10) 17.4 (10.34) 17.1 (10.21)
Median (range) 14 (2–50) 14 (3–59) 14 (2–59)
Missing (n) 0 0 0
Days in stroke unit up to randomisation
Mean (SD) 15.7 (9.89) 16.5 (9.97) 16.1 (9.93)
Median (range) 13 (1–50) 14 (1–55) 13 (1–55)
Missing (n) 0 0 0
Type of stroke, n (%)
Infarction 270 (87.7) 238 (83.5) 508 (85.7)
Primary haemorrhage 38 (12.3) 47 (16.5) 85 (14.3)
If infarction, classification, n (% out of those with infarction)
TACI 98 (36.3) 63 (26.5) 161 (31.7)
LACI 58 (21.5) 58 (24.4) 116 (22.8)
PACI 87 (32.2) 91 (38.2) 178 (35.0)
POCI 27 (10.0) 25 (10.5) 52 (10.2)
Missing 0 (0.0) 1 (0.4) 1 (0.2)
Thrombolysis received, n (%)
Yes 62 (23.0) 59 (24.8) 121 (23.8)
No 208 (77.0) 178 (74.8) 386 (76.0)
Missing 0 (0.0) 1 (0.4) 1 (0.2)
TABLE 8 Baseline neuroimaging characteristics
Neuroimaging details
Treatment group
Total (N= 593)Co-careldopa (N= 308) Placebo (N= 285)
Days from stroke to imaging
Mean (SD) 1.0 (3.44) 0.6 (2.68) 0.8 (3.10)
Median (range) 0 (–2a to 32) 0.0 (–36b to 13) 0 (–36 to 32)
Missing (n) 0 1 1
Type of imaging, n (%)
CT brain 299 (97.1) 281 (98.6) 580 (97.8)
Brain MRI 9 (2.9) 4 (1.4) 13 (2.2)
Digital scans, n (%)
Yes 263 (88.0) 250 (89.0) 513 (88.4)
No 35 (11.7) 31 (11.0) 66 (11.4)
Missing (n) 1 (0.3) 0 (0.0) 1 (0.2)
a One patient had a second stroke.
b This date was queried with the site and confirmed correct by the site.
TRIAL RESULTS
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randomisation. Patient withdrawal accounted for most of the withdrawals: 33 (10.7%) in the co-careldopa
group and 12 (4.2%) in the placebo group. The PI withdrew 13 patients (4.2%) and nine patients in
the co-careldopa (3.2%) and placebo groups, respectively. A participant’s health and/or an AE were the
most common reasons given for withdrawal, although a large proportion did not provide a reason.
Approximately half of the withdrawals from treatment were for a clinical reason, with a higher proportion
in the placebo group (n = 7, 63.6%) than in the co-careldopa group (n = 8, 40.0%).
Carer withdrawals
Ten carers (1.7%) withdrew: eight (2.6%) were carers of co-careldopa participants and two (0.7%) were
carers of placebo participants. The majority of withdrawals occurred between 6 and 12 months following
randomisation (Table 11).
TABLE 9 Carer baseline characteristics
Carer characteristics
Treatment group
Total (N= 165)Co-careldopa (N= 84) Placebo (N= 81)
Carer age at randomisation (years)
Mean (SD) 60.5 (15.33) 58.9 (13.62) 59.7 (14.49)
Median (range) 62 (20–85) 60 (21–87) 61.5 (20.2–87)
Missing (n) 2 1 3
Carer sex, n (%)
Male 23 (27.4) 24 (29.6) 47 (28.5)
Female 61 (72.6) 57 (70.4) 118 (71.5)
Carer ethnicity, n (%)
White 82 (97.6) 77 (95.1) 159 (96.4)
Asian: Indian 1 (1.2) 0 (0.0) 1 (0.6)
Asian: Pakistani 1 (1.2) 1 (1.2) 2 (1.2)
Other Asian background 0 (0.0) 1 (1.2) 1 (0.6)
Black: Caribbean 0 (0.0) 2 (2.5) 2 (1.2)
Carer-preferred language, n (%)
English 84 (100.0) 81 (100.0) 165 (100.0)
Patient–caregiver relationship, n (%)
Partner (married/never married/divorced/separated) 66 (78.6) 56 (69.1) 122 (73.9)
Daughter/son (including in-law, stepchild) 15 (17.9) 20 (24.7) 35 (21.2)
Grandchild 0 (0.0) 1 (1.2) 1 (0.6)
Parent 2 (2.4) 0 (0.0) 2 (1.2)
Other relative 0 (0.0) 3 (3.7) 3 (1.8)
Friend/neighbour 1 (1.2) 1 (1.2) 2 (1.2)
Provided care pre stroke, n (%)
Yes 36 (42.9) 43 (53.1) 79 (47.9)
No 48 (57.1) 38 (46.9) 86 (52.1)
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TABLE 10 Participant withdrawals
Participant withdrawals
Treatment group, n (%)
Total (N= 593)Co-careldopa (N= 308) Placebo (N= 285)
Withdrawals 58 (18.8) 33 (11.6) 91 (15.3)
Time of withdrawal from randomisation
Up to 8 weeks 40 (13.0) 24 (8.4) 64 (10.8)
From 8 weeks to 6 months 6 (1.9) 4 (1.4) 10 (1.7)
From 6 months to 12 months 12 (3.9) 5 (1.8) 17 (2.9)
Not withdrawn 250 (81.2) 252 (88.4) 502 (84.7)
Person who withdrew consent for further trial treatment
Patient 33 (10.7) 12 (4.2) 45 (7.6)
PI 13 (4.2) 9 (3.2) 22 (3.7)
Multidisciplinary team 0 (0.0) 1 (0.4) 1 (0.2)
N/A – trial treatment completed 12 (3.9) 11 (3.9) 23 (3.9)
If patient withdrew consent, is the patient still willing to be followed up?
Yes 11 (33.3) 6 (50.0) 17 (37.8)
No 22 (66.7) 6 (50.0) 28 (62.2)
If not, are they willing to have therapy forms collected?
Yes 6 (27.3) 0 (0.0) 6 (21.4)
No 7 (31.8) 2 (33.3) 9 (32.1)
NA – forms already collected 9 (40.9) 4 (66.7) 13 (46.4)
Patient reason for withdrawal
Participant health/AE 14 (42.4) 8 (66.7) 22 (48.9)
No continuity of rehabilitation 0 (0.0) 1 (8.3) 1 (2.2)
Missing 19 (57.6) 3 (25.0) 22 (48.9)
If PI withdrew consent, is the patient still willing to be followed up?
Yes 6 (46.2) 5 (55.6) 11 (50.0)
No 7 (53.8) 4 (44.4) 11 (50.0)
If not, are they willing to have therapy forms collected?
Yes 0 (0.0) 2 (50.0) 2 (18.2)
No 5 (71.4) 1 (25.0) 6 (54.5)
NA – forms already collected 2 (28.6) 1 (25.0) 3 (27.3)
PI reason for withdrawal
Participant health/AE 7 (53.8) 5 (55.6) 12 (54.5)
No continuity of rehabilitation 1 (7.7) 1 (11.1) 2 (9.1)
Missing 5 (38.5) 3 (33.3) 8 (36.4)
Clinically relateda
Yes 8 (40.0) 7 (63.6) 15 (48.4)
No 12 (60.0) 4 (36.4) 16 (51.6)
N/A, not applicable.
a Applies only to participants who have withdrawn from treatment, not follow-up.
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Participant assessments
The time between randomisation and completion of questionnaires is shown in Figure 5. The median
time between randomisation and follow-up assessments was 56 days for the 8-week primary outcome,
183 days for 6-month secondary outcomes and 370 days for 12-month secondary outcomes. At 8 weeks,
six participants completed questionnaires later than the agreed timelines (five in the co-careldopa group
and one in the placebo group). At 6 months, this increased to 16 participants (11 in the co-careldopa
group and five in the placebo group). At 12 months, 25 questionnaires were completed late (16 in the
co-careldopa group and nine in the placebo group).
Table 12 shows the number of questionnaires completed at each follow-up assessment, together with reasons
for non-completion. Loss to follow-up was balanced between treatment arms at 8 weeks and 12 months;
however, at the secondary outcome assessment at 6 months, more participants in the co-careldopa group
than in the placebo group did not complete the assessments (21.4% and 12.3%, respectively). A comparison
between randomised groups of the characteristics of those who did not respond to the 6-month questionnaire
revealed no differences in sex, age, stroke type, RMI score at baseline, ability to walk independently at 8 weeks
or BI at baseline. However, among participants who did not respond to the 6-month questionnaire, those in
the co-careldopa group had a statistically significantly higher NEADL mean score at baseline (59.6 points, 95%
CI 57.4 to 61.7 points) than those in the placebo group (52.5 points, 95% CI 47.4 to 57.5 points; p= 0.012).
TABLE 11 Carer withdrawals
Carer withdrawals
Treatment group, n (%)
Total (N= 593)Co-careldopa (N= 308) Placebo (N= 285)
Withdrawals 8 (2.6) 2 (0.7) 10 (1.7)
Time of carer withdrawal from randomisation
Up to 8 weeks 2 (0.6) 0 (0.0) 2 (0.3)
From 8 weeks to 6 months 3 (1.0) 0 (0.0) 3 (0.5)
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FIGURE 5 Time between randomisation and completion of RMI at each follow-up assessment.
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TABLE 12 Number of questionnaires completed at follow-up assessments and reasons for non-completion
Questionnaire completion at
follow-up assessments
Time point, n (%)




















Yes 271 (88.0) 261 (91.6) 532 (89.7) 242 (78.6) 250 (87.7) 492 (83.0) 222 (72.1) 221 (77.5) 443 (74.7)
No 37 (12.0) 24 (8.4) 61 (10.3) 66 (21.4) 35 (12.3) 101 (17.0) 86 (27.9) 64 (22.5) 150 (25.3)
Reason for non-completion
Died 6 (2.0) 1 (0.4) 7 (1.2) 13 (4.2) 7 (2.5) 20 (3.4) 21 (6.8) 17 (6.0) 38 (6.4)
Withdrawn 24 (7.8) 11 (3.9) 35 (5.9) 30 (9.7) 15 (5.3) 45 (7.6) 42 (13.6) 22 (7.7) 64 (10.8)
Cannot get hold of participant 0 (0.0) 2 (0.7) 2 (0.3) 10 (3.3) 5 (1.8) 15 (2.5) 15 (4.9) 12 (4.2) 27 (4.6)
Moved out of area 1 (0.3) 1 (0.4) 2 (0.3) 4 (1.3) 4 (1.4) 8 (1.3) 5 (1.6) 5 (1.8) 10 (1.6)
Too unwell 1 (0.3) 2 (0.7) 3 (0.5) 4 (1.3) 1 (0.4) 5 (0.8) 0 (0.0) 4 (1.4) 4 (0.7)
Lost in post 0 (0.0) 1 (0.4) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Lost at site 4 (1.3) 0 (0.0) 4 (0.7) 0 (0.0) 1 (0.4) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Refused to complete 0 (0.0) 2 (0.7) 2 (0.3) 1 (0.3) 1 (0.4) 2 (0.3) 1 (0.3) 2 (0.7) 3 (0.5)
Unwilling for visit 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 1 (0.2) 0 (0.0) 1 (0.4) 1 (0.2)
Other 1 (0.3) 2 (0.7) 3 (0.5) 2 (0.7) 0 (0.0) 2 (0.3) 2 (0.7) 1 (0.4) 3 (0.5)















Table 13 summarises the participant assessments at baseline and 8 weeks, 6 months and 12 months post
randomisation. Further description is provided in the following sections.
Rivermead Mobility Index
The mean baseline researcher-completed RMI score was 2.2 points in the co-careldopa group and 2.3 points
in the placebo group. Participant-completed baseline RMI scores were similar, although 10 participants
(3.2%) in the co-careldopa group and seven (2.5%) in the placebo group considered themselves able to
walk independently. At the 8-week follow-up, patient-reported RMI scores showed a considerable increase,
compared with baseline, in the proportion of participants who considered themselves to be able to walk
independently: 125 (40.6%) in the co-careldopa group and 127 (44.6%) in the placebo group. A further
increase in the proportion of participants who were able to walk was observed at 6 months, reaching
159 (51.6%) in the co-careldopa group and 152 (53.3%) in the placebo group; however, these figures
remained relatively stable at 12 months, with no increase in the co-careldopa group and only a slight
increase in the placebo group [162 participants (56.8%)].
Nottingham Extended Activities of Daily Living
The mean baseline (pre-stroke) NEADL score was 59.0 points in the co-careldopa group and 58.6 points
in the placebo group. As expected, NEADL scores at 8 weeks post randomisation were considerably
worse than the pre-stroke scores; the mean score was 21.0 points in the co-careldopa group and
20.0 points in the placebo group. Scores were higher at 6 months: the mean score was 27.2 points in the
co-careldopa group and 27.3 points in the placebo group. A further moderate increase was observed at
12-month follow-up: the mean score was 30.4 points in the co-careldopa group and 29.8 points in the
placebo group.
Barthel Index
The mean BI score at baseline was 7.7 points in the co-careldopa group and 7.8 points in the placebo
group. A greater degree of functional independence was indicated at the 8-week follow-up, when the
mean BI score was 12.9 points in the co-careldopa group and 13.2 points in the placebo group. The mean
BI score was higher at 6 months than at 8 weeks but levelled off at 12 months.
The ABILHAND Manual Ability Measure
The mean ABILHAND score (pre stroke) was 3.1 logits in the co-careldopa group and 3.2 logits in the
placebo group. Scores at the 8-week follow-up were predictably worse than pre-stroke scores but
improved at later follow-ups, particularly in the co-careldopa group.
Musculoskeletal – symptoms/signs and pain manikin
The proportion of participants reporting pre-stroke pain was approximately balanced between treatment
arms. A total of 129 participants (41.9%) and 107 participants (37.5%) in the co-careldopa and placebo
group, respectively, said that they had joint, neck or back pain in at least one area. Musculoskeletal pain
was more prevalent in both randomised groups at the 8-week follow-up but was experienced by fewer
participants at 6 months and 12 months.
General Health Questionnaire 12-item version
The mean GHQ-12 score at baseline was 19.4 points in the co-careldopa group and 19.3 points in the
placebo group, with a large proportion of participants reporting severe problems and psychological stress:
117 (38.0%) in the co-careldopa group and 115 (40.4%) in the placebo group. At the 8-week follow-up,
the mean GHQ-12 score was lower in both randomised groups and the proportion of participants
reporting severe problems and psychological distress decreased to 26% in the co-careldopa group and to
22% in the placebo group. A mild improvement in mean GHQ-12 score continued in the co-careldopa
group at 6 months and 12 months, whereas an improvement was not seen in the placebo group until
12 months.
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TABLE 13 Summary of participant assessment outcomes
Assessment
Time point
Baseline 8 weeks 6 months 12 months
Co-careldopa Placebo Co-careldopa Placebo Co-careldopa Placebo Co-careldopa Placebo
Researcher-reported RMI score (points)
Mean (SD) 2.2 (1.8) 2.3 (1.8)
0–3, n (%) 237 (76.9) 223 (78.2) – – – – – –
> 3 but < 7, n (%) 71 (23.1) 62 (21.8) – – – – – –
Patient-reported RMI score (points)
Mean (SD) 2.4 (2.2) 2.5 (2.2) 6.8 (4.2) 7.0 (4.2) 8.3 (4.6) 8.1 (4.5) 8.7 (4.7) 8.5 (4.6)
Able to walk independently, n (%) 10 (3.2) 7 (2.5) 125 (40.6) 127 (44.6) 159 (51.6) 152 (53.3) 159 (51.6) 162 (56.8)
NEADL score (points), mean (SD) 59.0 (11.0) 58.6 (12.4) 21.0 (17.7) 20.0 (15.8) 27.2 (18.2) 27.3 (18.1) 30.4 (19.4) 29.8 (18.9)
BI score (points), mean (SD) 7.7 (3.8) 7.8 (3.7) 12.9 (5.1) 13.2 (4.9) 14.0 (5.1) 14.4 (5.1) 14.4 (5.4) 14.6 (5.1)
ABILHAND, mean (SD) logits 0.8 (3.9) 0.3 (1.8) 0.2 (2.3) 0.4 (2.2) 0.1 (2.4) 0.3 (2.5) 0.2 (2.6) 0.4 (2.6)
MSK-SSP manikin, n (%)
Joint, neck or back pain 129 (41.9) 107 (37.5) 206 (66.9) 191 (67.0) 188 (61.0) 187 (65.6) 152 (49.4) 146 (51.2)
Pain in upper limbs 60 (19.5) 54 (18.9) 165 (53.6) 159 (55.8) 148 (48.1) 138 (48.4) 113 (36.7) 108 (37.9)
Pain in lower limbs 82 (26.6) 72 (25.3) 127 (41.2) 113 (39.6) 126 (40.9) 130 (45.6) 117 (38.0) 100 (35.1)
Right central post-stroke pain 6 (1.9) 2 (0.7) 14 (4.5) 11 (3.9) 10 (3.2) 13 (4.6) 11 (3.6) 10 (3.5)
Left central post-stroke pain 3 (1.0) 1 (0.4) 19 (6.2) 22 (7.7) 19 (6.2) 17 (6.0) 19 (6.2) 14 (4.9)
Central post-stroke pain 7 (2.3) 3 (1.1) 31 (10.1) 32 (11.2) 26 (8.4) 30 (10.5) 29 (9.4) 22 (7.7)
Right thumb, hand, finger or wrist joint pain 5 (1.6) 3 (1.1) 16 (5.2) 20 (7.0) 8 (2.6) 13 (4.6) 17 (5.5) 6 (2.1)
Left thumb, hand, finger or wrist joint pain 6 (1.9)a 3 (1.1)a 37 (12.0) 33 (11.6) 22 (7.1) 18 (6.3) 17 (5.5) 13 (4.6)
Any thumb, hand, finger or wrist joint pain 8 (2.6)a 5 (1.8)a 52 (16.9) 48 (16.8) 29 (9.4) 31 (10.9) 32 (10.4) 18 (6.3)

















Baseline 8 weeks 6 months 12 months
Co-careldopa Placebo Co-careldopa Placebo Co-careldopa Placebo Co-careldopa Placebo
GHQ-12 score (points)
Mean (SD) 19.4 (6.7) 19.3 (7.0) 16.9 (7.2) 16.4 (6.6) 15.1 (7.00) 16.3 (6.80) 14.0 (6.77) 14.4 (7.16)
No sign of psychological distress, n (%) 91 (29.5) 94 (33.0) 128 (41.6) 121 (42.5) 139 (45.1) 125 (43.9) 152 (49.4) 133 (46.7)
Evidence of distress, n (%) 85 (27.6) 68 (23.9) 60 (19.5) 72 (25.3) 46 (14.9) 58 (20.4) 32 (10.4) 46 (16.1)
Severe problems and psychological distress, n (%) 117 (38.0) 115 (40.4) 79 (25.6) 62 (21.8) 56 (18.2) 64 (22.5) 37 (12.0) 39 (13.7)
FAS score (points) mean (SD) – – 25.1 (7.6) 24.8 (7.4) 25.9 (8.1) 25.4 (7.6) 24.9 (8.3) 24.5 (8.2)
mRS score, n (%)
0 – – 3 (1.0) 1 (0.4) 1 (0.3) 2 (0.7) – –
1 – – 15 (4.9) 11 (3.9) 29 (9.4) 25 (8.8) – –
2 – – 24 (7.8) 30 (10.5) 23 (7.5) 30 (10.5) – –
3 – – 101 (32.8) 114 (40.0) 123 (39.9) 128 (44.9) – –
4 – – 95 (30.8) 79 (27.7) 41 (13.3) 47 (16.5) – –
5 – – 34 (11.0) 34 (11.9) 27 (8.8) 16 (5.6) – –
6 – – 6 (1.9) 1 (0.4) 6 (1.9) 4 (1.4) – –
MoCA score (points)
Mean (SD) 20.0 (6.6) 20.5 (6.0) 22.4 (6.3) 22.9 (5.5) 23.1 (6.2) 23.6 (5.5) 23.1 (5.9) 23.5 (5.6)
Normal (≥ 26 points), n (%) 57 (18.5) 63 (22.1) 106 (34.4) 95 (33.3) 110 (35.7) 104 (36.5) 95 (30.8) 96 (33.7)
Cognitive impairment (< 26 points), n (%) 242 (78.6) 218 (76.5) 160 (51.9) 165 (57.9) 132 (42.9) 142 (49.8) 124 (40.3) 119 (41.8)
a Pre-stroke score.
Note
RMI, higher score indicates increasing ability to walk independently; NEADL, higher score indicates greater independence; BI, higher score indicates greater degree of functional
independence; ABILHAND, raw scores are converted into a linear measure and expressed as logits, higher number logit indicates greater patient-perceived ability; GHQ-12, higher score
indicates worse health; FAS, higher scores indicate more severe fatigue; mRS, higher scores indicate greater levels of current functional independence, patients who die are given a score of
6; MoCA, score of < 26 points indicates cognitive impairment.












































































































































































The mean baseline MoCA score was 20.0 points in the co-careldopa group and 20.5 points in the placebo
group, and the majority of participants were found to have cognitive impairment: 218 (78.6%) and 218
(76.5%) in the co-careldopa and placebo groups, respectively. Although the mean score stayed relatively
stable for all of the follow-up assessments, in both randomised groups, the proportion of participants with
cognitive impairment was lower at the 8-week, 6-month and 12-month follow-ups than at baseline.
Fatigue Assessment Scale
The mean FAS scores at 8 weeks indicated similar levels of fatigue in the co-careldopa and placebo groups
(25.1 and 24.8 points, respectively) and remained relatively unchanged at the 6- and 12-month follow-ups.
Modified Rankin Scale
The mRS indicated good functional independence at 8 weeks (i.e. a score of ≤ 2) in 42 participants
(13.7%) in the co-careldopa group and 42 participants (14.8%) in the placebo group. This improved to
53 participants (17.2%) in the co-careldopa group and 57 participants (20.0%) in the placebo group at the
6-month follow-up.
Carer assessments
Table 14 summarises the category and total scores for CBS at all time points. At the 8-week follow-up,
carers of participants in both arms reported moderate to severe burden, although those in the placebo
group reported higher mean total scores than those in in the co-careldopa group: 46.6 points compared
with 43.0 points, respectively, with strain, emotional burden and disappointment accounting for the greatest
differences between the groups. The score at 6 months increased slightly in both groups, to 44.6 points
in the co-careldopa group and to 49.1 points in the placebo group, whereas, at 12 months, the mean
score remained stable in the co-careldopa group (44.6 points) but increased slightly in the placebo group
(51.8 points). The participant characteristics for the subsample with a consenting carer are shown in
Table 15 and appear similar between arms.
Primary end point
Intention-to-treat analysis
Table 16 presents the summary statistics by ability to walk independently at 8 weeks and presents the ORs
and 95% CIs for the ITT analysis.
TABLE 14 Summary of secondary carer end points: CBS
Assessment
Time point













Total CBS score (points),
mean (SD)
43.0 (13.4) 46.6 (13.9) 44.6 (13.6) 49.1 (14.7) 44.6 (15.1) 51.8 (15.3)
Strain, mean (SD) 17.3 (6.1) 18.8 (6.4) 18.3 (5.9) 19.7 (6.4) 18.4 (6.7) 21.1 (6.6)
Isolation, mean (SD) 6.3 (2.5) 6.9 (2.4) 6.5 (2.4) 7.1 (2.3) 6.1 (2.4) 7.4 (2.5)
Disappointment, mean (SD) 10.4 (3.8) 11.1 (3.6) 10.5 (3.7) 11.9 (3.9) 10.6 (3.9) 12.3 (4.2)
Emotional, median (IQR) 10 (5–20) 11 (5–20) 4 (3–12) 4.0 (3–12) 4 (3–10) 4 (3–12)
Environment, mean (SD) 5.0 (2.3) 5.3 (2.1) 5.0 (2.2) 5.6 (2.5) 4.9 (2.0) 6.1 (2.3)
IQR, interquartile range.
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There was no evidence of a statistically significant difference between treatment groups in the proportion
of participants able to walk independently at 8 weeks [125 (40.6%) in the co-careldopa group vs.
127 (44.6%) in the placebo group; OR 0.780, 95% CI 0.528 to 1.153; see Table 16] (Table 17).
The ability to walk independently did not differ between males and females [169 (46.4%) vs. 83 (36.2%),
respectively; OR 0.900, 95% CI 0.599 to 1.353]. Participants who had suffered an infarction were significantly
less likely to be able to walk than those who had a primary haemorrhage [206 (40.6%) vs. 46 (54.1%),
respectively; OR 0.382, 95% CI 0.219 to 0.667]. The ability to walk independently at 8 weeks was associated
with higher baseline scores for RMI (OR 1.522, 95% CI 1.313 to 1.764), NEADL (OR 1.026, 95% CI 1.006
to 1.046) and BI (OR 1.110, 95% CI 1.034 to 1.191). There was an inverse relationship between walking at
8 weeks and age (OR 0.980, 95% CI 0.965 to 0.995), and number of days between stroke and randomisation
(OR 0.945, 95% CI 0.925 to 0.965).
Per-protocol analysis
The per-protocol population excluded the following participants: (1) non-eligible patients; (2) patients not
receiving the treatment they were randomised to including treatment crossovers; (3) those receiving no
IMP prior to rehabilitation therapy; (4) patients not strictly complying with protocol (i.e. randomised drug
taken 45–60 minutes before therapy, involving ≥ 20 minutes of motor therapy for ≥ 80% of the sessions);
and (5) patients completing the 8-week follow-up primary end point outside 7–9 weeks. Figure 6 shows
TABLE 15 Characteristics of patients with carers consenting to the DARS trial
Characteristic of patients with carers
Treatment group
Total (N= 165)Co-careldopa (N= 84) Placebo (N= 81)
Patient sex: male, n (%) 55 (65.5) 55 (67.9) 110 (66.7)
Patient ethnicity: white, n (%) 82 (97.6) 76 (93.8) 158 (95.8)
Education, n (%)
≤ 12 years 41 (48.8) 48 (59.3) 89 (53.9)
> 12 years 41 (48.8) 30 (37.0) 71 (43.0)
Missing 2 (2.4) 3 (3.7) 5 (3.0)
Type of stroke, n (%)
Infarction 73 (86.9) 67 (82.7) 140 (84.8)
Primary haemorrhage 11 (13.1) 14 (17.3) 25 (15.2)
If infarction, then classification, n (%)
TACI 29 (34.5) 21 (25.9) 50 (30.3)
LACI 15 (17.9) 13 (16.0) 28 (17.0)
PACI 23 (27.4) 28 (34.6) 51 (30.9)
POCI 6 (7.1) 5 (6.2) 11 (6.7)
Patient walking independently (binary), n (%)
Baseline (yes) 3 (3.6) 3 (3.7) 6 (3.6)
8 weeks (yes) 33 (39.3) 33 (40.7) 66 (40.0)
6 months (yes) 42 (50.0) 39 (48.1) 81 (49.1)
12 months (yes) 46 (54.8) 46 (56.8) 92 (55.8)
Patient-reported RMI score (points) (continuous), mean (SD), missing
Baseline 2.3 (2.27), 3 2.4 (2.31), 2 2.3 (2.28), 5
8 weeks 6.4 (3.96), 7 6.5 (4.19), 4 6.5 (4.07), 11
6 months 8.0 (4.84), 14 7.6 (4.57), 5 7.8 (4.69), 19
12 months 8.5 (4.76), 20 7.8 (4.56), 12 8.2 (4.65), 32
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TABLE 16 Descriptive statistics of variables included in the primary end-point ITT analysis, by ability to walk
independently at 8 weeks
Variable in the primary end-point analysis
Able to walk independently at 8 weeks
Yes (N= 252) No (N= 341) Total (N= 593)
Randomised allocation, n (%)
Co-careldopa 125 (40.6) 183 (59.4) 308 (100.0)
Placebo 127 (44.6) 158 (55.4) 285 (100.0)
Patient sex, n (%)
Male 169 (46.4) 195 (53.6) 364 (100.0)
Female 83 (36.2) 146 (63.8) 229 (100.0)
Age (years)
Mean (SD) 65.5 (14.12) 70.7 (12.07) 68.5 (13.22)
Median (range) 66 (20–96) 72 (21–98) 70 (20–98)
Type of stroke, n (%)
Infarction 206 (81.7) 302 (88.6) 508 (85.7)
Primary haemorrhage 46 (18.3) 39 (11.4) 85 (14.3)
RMI score at baseline (points)
Mean (SD) 3.1 (1.79) 1.6 (1.49) 2.3 (1.79)
Median (range) 3 (0–6) 1 (0–6) 2 (0–6)
NEADL score at baseline (points)
Mean (SD) 60.7 (10.00) 57.4 (12.61) 58.8 (11.68)
Median (range) 66 (0–66) 63 (0–66) 63 (0–66)
Missing (n) 7 6 13
BI score at baseline (points)
Mean (SD) 9.3 (3.44) 6.5 (3.44) 7.7 (3.70)
Median (range) 9 (3–19) 6 (0–20) 7 (0–20)
Missing (n) 5 8 13
Days between stroke and randomisation
Mean (SD) 15.0 (9.55) 19.7 (9.98) 17.7 (10.06)
Median (range) 12 (3–59) 17 (3–55) 15 (3–59)
Reproduced with permission from Ford et al.119 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access
article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
TABLE 17 Primary end-point analysis estimates with 95% CIs from stepwise multilevel logistic regression analysis
for ability to walk independently at 8 weeks in the ITT population
Model parameter OR (95% CI) p-value
Treatment group: co-careldopa vs. placebo 0.780 (0.528 to 1.153) 0.212
Sex: female vs. male 0.900 (0.599 to 1.353) 0.612
Stroke type: infarction vs. primary haemorrhage 0.382 (0.219 to 0.665) 0.001
RMI score at baseline 1.522 (1.313 to 1.764) 0.000
Age (years) 0.980 (0.965 to 0.995) 0.010
NEADL score at baseline 1.026 (1.006 to 1.046) 0.011
BI score at baseline 1.110 (1.034 to 1.191) 0.004
Days between stroke and randomisation 0.945 (0.925 to 0.965) 0.000
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the number of exclusions at each step. The final sample size of the per-protocol population was 54
(9.1% of the ITT population), representing 9.7% of the co-careldopa group and 8.4% of the placebo
group. Table 18 presents the descriptive statistics of the per-protocol population. Owing to the small
sample size, no analyses were conducted on this population.
A number of sensitivity analyses were conducted to test the robustness of the assumption that patients
who died or were lost to follow-up were categorised as unable to walk independently. Descriptive statistics
and estimates with 95% CIs and p-values are presented in Appendix 3 for the following analyses:
1. Analysis with the assumption that patients who died, were lost to follow-up or their RMI score could
not be imputed were able to walk independently at 8 weeks (see Tables 69 and 70).
2. Complete-case analysis (see Tables 71 and 72).
3. Using patient-completed RMI score at baseline: descriptive statistics as for sensitivity analysis (see Table 73).
4. Using researcher-completed RMI score at baseline in place of score at 24-hour randomisation
(see Tables 74 and 75).
5. Including only participants for whom the 8-week questionnaire was received by 12 weeks post
randomisation (see Tables 76 and 77).
6. Assuming participants with no primary outcome data because they were too unwell were unable to
walk independently, and participants who had died, withdrawn, were unwilling to be visited, refused
to completed the questionnaire, had moved out of the area, those we could not get hold of and
questionnaires that were lost at site or in the post were classed missing (see Tables 78–80).
The results for a sensitivity analysis when centre was included as a fixed effect in the model is not











































1. Breached eligibility criteria
2. Did not receive treatment as 
    randomised treatment
3. No IMP
4a. Did not receive sufficient 
      motor therapy
4b. Did not conform to strict 
      compliance (IMP not taken
      45–60 minutes before 
      therapy) for ≥ 80% of the 
      sessions
5. Follow-up outside time frame
FIGURE 6 Flow chart of exclusions to obtain per-protocol population.
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None of the sensitivity analyses affected the estimates: the ORs were not statistically different from those
in the primary ITT analysis.
Patient secondary end points
Estimates and 95% CIs for the patient secondary end points are presented in Tables 19–24. At all follow-up
assessments, there was no evidence of statistically significant differences between the randomised groups in
patient secondary end points, with the exception of GHQ-12 score. Participants in the co-careldopa group
had a significantly lower GHQ-12 score than those in the placebo group at the 6-month follow-up.
Rivermead Mobility Index
Results of the stepwise multilevel linear regression analysis suggest that there was no evidence of statistically
significant differences in RMI scores (continuous scores) between treatment arms at any follow-up time
points; RMI scores were higher (not statistically) at 8 weeks and lower (not statistically) at 6 and 12 months
in the placebo group compared with intervention. Model was adjusted for stratification variables and
additionally for age, baseline NEADL, BI, MoCA scores and days between stroke and randomisation
(Table 19). Infarction was associated with lower MoCA score at 8 weeks and 12 months than primary
haemorrhage, higher age and number of days between stroke and randomisation were associated with
lower RMI scores at all time points.
Analysis of the long-term trajectory of RMI over the follow-up period revealed no differences between
randomised groups in change of outcome over time [adjusted mean difference (MD) for intervention vs.
placebo 0.274, 95% CI –0.039 to 0.586; p = 0.086].
Montreal Cognitive Assessment
Results of the stepwise multilevel regression analysis suggest that there was no evidence of statistically
significant differences in MoCA scores between treatments at any follow-up time points; MoCA scores were
higher (not statistically) in the placebo group in all time points. Model was adjusted for stratification variables
and additionally for age, baseline NEADL, ABILHAND, MoCA and number of days between stroke and
randomisation (Table 20). Infarction, higher age and number of days between stroke and randomisation
TABLE 18 Descriptive statistics for the per-protocol population, by ability to walk independently at 8 weeks
Participant characteristics
Able to walk independently at 8 weeks
Yes (N= 24) No (N= 30) Total (N= 54)
Randomised allocation, n (%)
Co-careldopa 14 (46.7) 16 (53.3) 30 (100.0)
Placebo 10 (41.7) 14 (58.3) 24 (100.0)
Patient sex, n (%)
Male 13 (48.1) 14 (51.9) 27 (100.0)
Female 11 (40.1) 16 (59.9) 27 (100.0)
Type of stroke, n (%)
Infarction 22 (44.9) 27 (55.1) 49 (100.0)
Primary haemorrhage 2 (40.0) 3 (60.0) 5 (100.0)
RMI score at baseline (points)
Mean (SD) 2.8 (1.58) 1.8 (1.24) 2.3 (1.48)
Median (range) 3.0 (0.0–6.0) 2.0 (0.0–4.0) 2.0 (0.0–6.0)
Q1, Q3 (points) 1.5, 4.0 1.0, 3.0 1.0, 3.0
Q1, quartile 1; Q3, quartile 3.
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TABLE 19 Estimates with 95% CIs from stepwise multilevel linear regression analysis for RMI (continuous variable)
at 8-week, 6-month and 12-month follow-up
Model parameter
Follow-up




























































Baseline MoCA score (points) NSa NSa 0.084
(0.012 to 0.144)
0.007









MD, adjusted mean difference; NS, not significant.
a NS and, therefore, excluded from the model.
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were associated with lower MoCA scores. Baseline MoCA and NEADL scores were positively associated with
MoCA scores at all time points.
Barthel Index
There was no evidence of statistically significant differences in BI scores between treatment arms at any
follow-up time points; BI scores were higher (not statistically) in the placebo group at all time points. Stepwise
multilevel linear regression model was adjusted for stratification variables and additionally for age, baseline BI,
MoCA and NEADL scores and number of days between stroke and randomisation (Table 21). Infarction was
associated with lower MoCA scores at 8 weeks and 12 months, age and number of days between stroke and
randomisation were associated with lower BI scores; RMI score, baseline BI, MoCA (except for 6 months) and
NEADL scores were positively associated with MoCA scores.
ABILHAND Manual Ability Measure
There was no evidence of statistically significant differences in ABILHAND logit scores between treatment
arms at any follow-up time points; ABILHAND scores were higher (not statistically) in the placebo group in
all time points. Stepwise multilevel linear regression model contained stratification variables and baseline
ABILHAND, BI, MoCA and NEADL scores and number of days between stroke and randomisation (Table 22).
Infarction and baseline BI score were associated with lower ABILHAND score at all time points.
TABLE 20 Estimates with 95% CIs from stepwise multilevel linear regression analysis for MoCA at 8-week, 6-month
and 12-month follow-up (continued )
Model parameter
Follow-up














Baseline ABILHAND score (logits) NSa NSa 0.162
(0.036 to 0.288)
0.012










a NS and, therefore, excluded from the model.
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TABLE 21 Estimates with 95% CIs from stepwise multilevel linear regression analysis for BI at 8-week, 6-month and
12-month follow-up (continued )
Model parameter
Follow-up









































a NS and, therefore, excluded from the model.
TABLE 22 Estimates with 95% CIs from stepwise multilevel linear regression analysis for ABILHAND (logits) at
8-week, 6-month and 12-month follow-up
Model parameter
Follow-up























































Baseline MoCA score (points) NSa 0.044
(0.009 to 0.079)
0.015 NSa
Baseline NEADL score (points) NSa NSa 0.022
(0.003 to 0.042)
0.026








a NS and, therefore, excluded from the model.
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Nottingham Extended Activities of Daily Living
There was no evidence of statistically significant differences in NEADL scores between treatment arms at
any follow-up time points. Stepwise multilevel linear regression model was adjusted for stratification
variables and age, baseline NEADL, MoCA and BI scores and days between stroke and randomisation
(Table 23). Baseline scores were positively associated with NEADL scores at all time points; age and days
between stroke were negatively associated with NEADL scores.
General Health Questionnaire 12-item version
There were no statistically significant differences in GHQ-12 scores between treatment arms at 8 weeks
[adjusted score was higher (not statistically) in intervention than placebo] and 12 months follow-up
[adjusted score was higher (not statistically) in placebo than intervention]. There was evidence of
statistically significant difference in GHQ-12 scores at 6 months (difference of 1.33 points, higher in
placebo than intervention, p-value of 0.035). This requires careful interpretation due to multiple testing.
Baseline GHQ-12 score was positively associated with GHQ-12 scores at all time points (Table 24).
Modified Rankin Scale
There was no significant difference between treatment arms at either follow-up assessment (Table 25).
Although the test score to check the proportional odds assumption of the mRS analysis was significant at
8 weeks and 6 months, this is a liberal test that tends to reject the null hypothesis more than it should.
A graphical assessment of the proportional odds assumption was acceptable (see Appendix 4, Figures 15
and 16) and mRS was analysed as an ordinal variable using a stepwise regression model.

















































































a NS and, therefore, excluded from the model.
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TABLE 24 Estimates with 95% CIs from stepwise multilevel linear regression analysis for GHQ-12 at 8-week,
6-month and 12-month follow-up
Model parameter
Follow-up






























































a NS and, therefore, excluded from the model.




8 weeks 6 months
OR (95% CI) p-value OR (95% CI) p-value
Treatment group:
co-careldopa vs. placebo
0.871 (0.629 to 1.206) 0.404 0.808 (0.571 to 1.142) 0.226
Sex: female vs. male 1.053 (0.746 to 1.486) 0.769 1.122 (0.777 to 1.621) 0.539
Stroke type: infarction vs.
primary haemorrhage
1.601 (1.403 to 1.828) 0.001 1.313 (1.145 to 1.506) 0.638
RMI score on 24-hour
randomisation system (points)
1.018 (1.003 to 1.033) 0.000 0.976 (0.962 to 0.990) 0.000
Age (years) NSa 1.020 (1.005 to 1.035) 0.001
Baseline NEADL score (points) 1.164 (1.093 to 1.239) 0.018 1.176 (1.100 to 1.257) 0.011
Baseline BI score (points) 0.952 (0.936 to 0.969) 0.000 0.958 (0.941 to 0.975) 0.000
Days between stroke and
randomisation
0.429 (0.263 to 0.700) 0.000 0.883 (0.526 to 1.483) 0.000
NS, not significant.
a NS and, therefore, excluded from the model.
Note
mRS categories are 0–1, 2, 3, 4 and 5–6.
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Carer secondary end points
Owing to small numbers, a single-level model was conducted for carer secondary end points (i.e. centre was
not fitted as a random effect). Adjusted MDs in CBS scores were statistically significantly higher in carers of
those in the placebo group than in carers of those in the co-careldopa group (Table 26), indicating higher
levels of burden in the placebo group. Female carers reported greater burden than males at each follow-up
time and older carers had lower scores at 12 months.
Safety
Adverse events
Overall, 365 participants reported a total of 1299 AEs. There was no evidence of a difference in levels of
AEs reported between the two groups: 195 participants (63.3%) in the co-careldopa group had an
average of 3.5 AEs each and 170 participants (59.6%) in the placebo group had an average of 3.6 AEs
each (Table 27).




8 weeks 6 months 12 months





















































a NS and, therefore, excluded from the model.
TABLE 27 Summary of AEs, by treatment group
Adverse event characteristic
Treatment group
Total (N= 593)Co-careldopa (N= 308) Placebo (N= 285)
Number of AEs reported 688 611 1299
Participants reporting AEs, n (%) 195 (63.3) 170 (59.6) 365 (61.6)
Number of AEs per participant
Mean (SD) 3.5 (3.06) 3.6 (3.11) 3.6 (3.08)
Median (range) 2 (1–15) 2 (1–15) 2 (1–15)
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
52
Serious adverse events
A total of 57 participants (18.5%) reported 74 SAEs in the co-careldopa group and 50 participants
(17.5%) reported 58 SAEs in the placebo group, with a mean of just over 1 SAE per participant occurring
in each group. The majority of SAEs reported in both the co-careldopa group and the placebo group
were not suspected to be related to the IMP (Table 28). Table 29 provides details of those SAEs that were
attributable to the trial medication and Table 30 summarises the MedDRA System Organ Classification
of SAEs. The majority were categorised as vascular disorders, nervous system disorders, respiratory
disorders and infections/infestations, with those in the co-careldopa group experiencing proportionally
more vascular disorders and infections and those in the placebo group experiencing more nervous system
and respiratory disorders.
TABLE 28 Summary of SAEs, by treatment group
Serious adverse event characteristic
Treatment group
Total (N= 593)Co-careldopa (N= 308) Placebo (N= 285)
Number of SAEs reported 74 58 132
Participants with one or more SAEs, n (%) 57 (18.5) 50 (17.5) 107 (18.0)
Number of SAEs per participant
Mean (SD) 1.3 (0.68) 1.2 (0.42) 1.2 (0.58)
Median (range) 1 (1–4) 1 (1–3) 1 (1–4)
Suspected to be related to trial medication, n (%)
Yes 2 (2.7) 1 (1.7) 3 (2.3)
No 72 (97.3) 57 (98.3) 129 (97.7)
Reproduced with permission from Ford et al.119 © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access
article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).











Co-careldopa Male 71 During PT, patient became
sweaty/clammy/faint. Therapist
called an ambulance. Symptoms
resolved after 10–15 minutes.
Seen by PI in A&E. Discharged






Placebo Male 59 During PT, patient became
pale then his body was rigid,
eyes rolled, lips blue, lasted
2–3 minutes. BP 96/71 mmHg.







Co-careldopa Female 66 Symptoms commenced within








BP, blood pressure; HR, heart rate.
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‘Other’ illnesses were the biggest cause of SAEs, accounting for around 50% in both the co-careldopa
group and the placebo group (Table 31). Stroke accounted for a greater proportion of SAEs in the
co-careldopa group than the placebo group.
With regard to the seriousness criteria of the reported SAEs, the largest proportion required hospitalisation;
10 SAEs (13.5%) in the co-careldopa group and six (10.3%) in the placebo groups resulted in death (Table 32).
However, the majority of participants who experienced a SAE recovered by the time of final follow-up: 77% of
co-careldopa group participants and 81% of placebo group participants (Table 33).
TABLE 30 Summary of MedDRA System Organ Classification of SAEs
Serious adverse events as per MedDRA System
Organ Classification
Treatment group, n (%)
Total





Blood and lymphatic system disorders 1 (1.4) 0 (0.0) 1 (0.8)
Cardiac disorders 6 (8.1) 2 (3.4) 8 (6.1)
Gastrointestinal disorders 4 (5.4) 3 (5.2) 7 (5.3)
General disorders and administration site conditions 0 (0.0) 1 (1.7) 1 (0.8)
Hepatobiliary disorders 1 (1.4) 2 (3.4) 3 (2.3)
Infections and infestations 10 (13.5) 6 (10.3) 16 (12.1)
Injury, poisoning and procedural complications 4 (5.4) 3 (5.2) 7 (5.3)
Metabolism and nutrition disorders 2 (2.7) 1 (1.7) 3 (2.3)
Musculoskeletal and connective tissue disorders 1 (1.4) 0 (0.0) 1 (0.8)
Neoplasms benign, malignant and unspecified
(including cysts and polyps)
2 (2.7) 3 (5.2) 5 (3.8)
Nervous system disorders 10 (13.5) 11 (19.0) 21 (15.9)
Psychiatric disorders 2 (2.7) 0 (0.0) 2 (1.5)
Renal and urinary disorders 2 (2.7) 1 (1.7) 3 (2.3)
Reproductive system and breast disorders 1 (1.4) 3 (5.2) 4 (3.0)
Respiratory, thoracic and mediastinal disorders 8 (10.8) 12 (20.7) 20 (15.2)
Social circumstances 4 (5.4) 0 (0.0) 4 (3.0)
Vascular disorders 16 (21.6) 10 (17.2) 26 (19.7)
TABLE 31 Summary of cause of SAEs, by treatment group
Serious adverse event causes
Treatment group, n (%)
Total





Treatment medication 2 (2.7) 1 (1.7) 3 (2.3)
Concomitant medications 4 (5.4) 3 (5.2) 7 (5.3)
Ischaemic or haemorrhagic stroke 20 (27.0) 10 (17.2) 30 (22.7)
Ischaemic or haemorrhagic stroke and other illness 5 (6.8) 4 (6.9) 9 (6.8)
Other illness 37 (50.0) 28 (48.3) 65 (49.2)
Missing 6 (8.1) 12 (20.7) 18 (13.6)
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No SAEs satisfied the criteria of being suspected unexpected serious adverse reactions.
Mortality
A total of 39 participants (6.6%) died within 12 months of randomisation: 22 (7.1%) in the co-careldopa
group and 17 (6.0%) in the placebo group. More participants in the co-careldopa group died within
8 weeks than in the placebo group: six (1.9%) and one (0.4%), respectively. The highest proportion of
deaths occurred between 6 and 12 months [nine (2.9%) in the co-careldopa group and nine (3.2%) in the
placebo group], and the majority occurred in hospital [14 (4.5%) in the co-careldopa group and 12 (4.2%)
in the placebo group] (Table 34). The cause of death of the seven participants who died during treatment
is presented in Table 35 and a graphical representation of the time between randomisation and death is
presented in Figure 7. There were no carer deaths.
New significant medical or surgical events
The most frequently occurring new significant medical or surgical events from 8 weeks to 6 months and from
6 to 12 months were falls, infection, elective/pre-planned treatment, cardiac problems and gastrointestinal
problems. The proportion of participants experiencing new events was similar between randomisation arms,
with the exception of falls, of which there was a higher proportion in the placebo group at both time points;
gastrointestinal problems, which were experienced by a greater proportion of those in the placebo group
between 8 weeks and 6 months; and cardiac problems, which were experienced by a significantly greater
number of participants in the co-careldopa group. The median time from randomisation to event was
27 days in both groups for those that occurred between 8 weeks and 6 months, and 53 days for events
between 6 and 12 months (Table 36).
TABLE 32 Summary of seriousness criteria of SAEs, by treatment group
Serious adverse events seriousness criteria
Treatment group, n (%)
Total, n (%)Co-careldopa Placebo
Death 10 (13.5) 6 (10.3) 16 (12.1)
Life-threatening illness 13 (17.6) 9 (15.5) 22 (16.7)
Required or prolonged hospitalisation 58 (78.4) 43 (74.1) 101 (76.5)
Persistent or significant disability/incapacity 4 (5.4) 3 (5.2) 7 (5.3)
Patient jeopardised (i.e. intervention required to prevent one of the above) 10 (13.5) 12 (20.7) 22 (16.7)
Total number of events 74 (100.0) 58 (100.0) 132 (100.0)
Note
The categories are not mutually exclusive; hence, the numbers in each category may not be equal to the total number of events.
TABLE 33 Outcome of SAEs, by treatment group
Serious adverse event outcome
Treatment group, n (%)
Total (N= 132), n (%)Co-careldopa (N= 74) Placebo (N= 58)
Recovered 57 (77.0) 47 (81.0) 104 (78.8)
Recovered with sequelae 6 (8.1) 5 (8.6) 11 (8.3)
Condition improving 1 (1.4) 0 (0.0) 1 (0.8)
Death 10 (13.5) 6 (10.3) 16 (12.1)
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TABLE 34 Summary of participant deaths, by treatment group
Participants deaths
Treatment group, n (%)
Total (N= 593), n (%)Co-careldopa (N= 308) Placebo (N= 285)
Number of deaths 22 (7.1) 17 (6.0) 39 (6.6)
Time death occurred
Up to 8 weeks 6 (1.9) 1 (0.4) 7 (1.2)
From 8 weeks to 6 months 7 (2.3) 7 (2.5) 14 (2.4)
From 6 months to
12 months
9 (2.9) 9 (3.2) 18 (3.0)
Place of death
Home 2 (0.6) 4 (1.4) 6 (1.0)
Hospital 14 (4.5) 12 (4.2) 26 (4.4)
Institutional care 5 (1.6) 2 (0.7) 7 (1.2)
Unknown 3 (1.0) 2 (0.7) 5 (0.8)
TABLE 35 Cause of death for participants who died within 6 weeks of randomisation
Randomised allocation Cause of death
Co-careldopa Cause of death for participants who died during treatment
NSTEMI, respiratory arrest
Pneumonia
Deterioration from initial stroke
Re-admitted to acute stroke unit from community rehabilitation unit
with having had another stroke
Peritonitis, bowel perforation
Placebo Aspiration pneumonia
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FIGURE 7 Time between randomisation and death.
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TABLE 36 New significant medical or surgical events from 8 weeks to 6 months and from 6 months to 12 months
New significant medical or
surgical events
Time period













Elective/pre-planned treatment, n (%)
Yes 22 (7.1) 24 (8.4) 46 (7.8) 21 (6.8) 20 (7.0) 41 (6.9)
No 224 (72.7) 225 (78.9) 449 (75.7) 204 (66.2) 204 (71.6) 408 (68.8)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
New stroke, n (%)
Yes 4 (1.3) 1 (0.4) 5 (0.8) 3 (1.0) 3 (1.1) 6 (1.0)
No 242 (78.6) 248 (87.0) 490 (82.6) 222 (72.1) 221 (77.5) 443 (74.7)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
Fits, n (%)
Yes 9 (2.9) 6 (2.1) 15 (2.5) 14 (4.5) 8 (2.8) 22 (3.7)
No 237 (76.9) 243 (85.3) 480 (80.9) 211 (68.5) 216 (75.8) 427 (72.0)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
Infection, n (%)
Yes 52 (16.9) 43 (15.1) 95 (16.0) 44 (14.3) 43 (15.1) 87 (14.7)
No 194 (63.0) 206 (72.3) 400 (67.5) 181 (58.8) 181 (63.5) 362 (61.0)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
Falls, n (%)
Yes 58 (18.8) 65 (22.8) 123 (20.7) 59 (19.2) 73 (25.6) 132 (22.3)
No 188 (61.0) 184 (64.6) 372 (62.7) 166 (53.9) 151 (53.0) 317 (53.5)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
Cardiac problem, n (%)
Yes 17 (5.5) 6 (2.1) 23 (3.9) 16 (5.2) 3 (1.1) 19 (3.2)
No 229 (74.4) 243 (85.3) 472 (79.6) 209 (67.9) 221 (77.5) 430 (72.5)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
Orthopaedic surgery, n (%)
Yes 4 (1.3) 4 (1.4) 8 (1.3) 3 (1.0) 1 (0.4) 4 (0.7)
No 242 (78.6) 245 (86.0) 487 (82.1) 222 (72.1) 223 (78.2) 445 (75.0)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
Diabetes mellitus related, n (%)
Yes 6 (1.9) 5 (1.8) 11 (1.9) 6 (1.9) 4 (1.4) 10 (1.7)
No 240 (77.9) 244 (85.6) 484 (81.6) 219 (71.1) 220 (77.2) 439 (74.0)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
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Vomiting between the investigational medicinal product dose and end of therapy
During 12,078 motor therapy sessions, only 27 participants (4.6%, 27/593) in 37 motor therapy sessions
(0.3%) vomited between taking the IMP dose and the end of therapy: 19 participants in 28 sessions (0.5%) in
the co-careldopa group and nine participants in nine sessions (0.1%) in the placebo group (see Appendix 5,
Table 81). Of the 28 participants who vomited, eight withdrew (seven in the co-careldopa group and one in
the placebo group). In the co-careldopa group, two withdrawals were directly related to nausea and vomiting;
one withdrawal was related to ‘. . . postural drop in line with taking medications (for trial)’.
Pregnancy
Notification of pregnancy was provided for one participant 48 days after they were randomised; a medical
termination was carried out 14 days later.
Content of occupational and physical therapy
Discharge from hospital
Table 37 summarises all participant discharges from hospital. The median number of days from randomisation
to discharge was 25 days in the co-careldopa group and 27 days in the placebo group, and median time from
stroke to discharge was 44 days in the co-careldopa group and 47 days in the placebo group. The majority
of participants were discharged to their own home or a relative’s home [174 (56.5%) in the co-careldopa
group and 170 (59.6%) in the placebo group], mostly to live with identified carers or others as opposed to
living alone.
Table 38 summarises the details of those who were discharged to the community during treatment:
115 (37.3%) in the co-careldopa group and 122 (42.8%) in the placebo group (median 13 and 16 days
from randomisation to discharge in the co-careldopa and placebo groups, respectively). The majority of
participants were discharged to their own home or to a relative’s home: 88 (76.5%) in the co-careldopa
TABLE 36 New significant medical or surgical events from 8 weeks to 6 months and from 6 months to 12 months
(continued )
New significant medical or
surgical events
Time period













Gastrointestinal problem, n (%)
Yes 16 (5.2) 28 (9.8) 44 (7.4) 19 (6.2) 18 (6.3) 37 (6.2)
No 230 (74.7) 221 (77.5) 451 (76.1) 206 (66.9) 206 (72.3) 412 (69.5)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
Other, n (%)
Yes 30 (9.7) 31 (10.9) 61 (10.3) 29 (9.4) 23 (8.1) 52 (8.8)
No 216 (70.1) 218 (76.5) 434 (73.2) 196 (63.6) 201 (70.5) 397 (66.9)
Missing 62 (20.1) 36 (12.6) 98 (16.5) 83 (26.9) 61 (21.4) 144 (24.3)
Weeks to event from randomisation
Mean (SD) 27.0 (3.70) 26.8 (2.56) 26.9 (3.18) 53.9 (4.83) 53.2 (3.68) 53.6 (4.30)
Median (range) 26 (15–49) 26 (20–41) 26 (15–49) 53 (45–84) 53 (45–83) 53 (45–84)
Missing, (n) 62 36 98 83 61 144
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Days from randomisation to discharge
Mean (SD) 35.2 (33.59) 34.5 (28.17) 34.8 (31.00)
Median (range) 25 (–5 to 209)a 27 (–1 to 166)a 26 (–5 to 209)
Date of discharge unknown (n) 68 50 118
Days from stroke to discharge
Mean (SD) 52.6 (36.21) 51.7 (31.25) 52.1 (33.82)
Median (range) 44 (6–227) 47 (9–186) 45.0 (6–227)
Date of discharge unknown (n) 68 50 118
Discharge location, n (%)
Home 174 (56.5) 170 (59.6) 344 (58.0)
Lives alone 26 (14.9) 43 (25.3) 69 (20.1)
Cohabits with identified carer 76 (43.7) 66 (38.8) 142 (41.3)
Cohabits with other 72 (41.4) 60 (35.3) 132 (38.4)
Missing 0 (0.0) 1 (0.6) 1 (0.3)
Nursing/residential/care home 23 (7.5) 19 (6.7) 42 (7.1)
Community hospital/rehabilitation centre/intermediate care 34 (11.0) 32 (11.2) 66 (11.1)
Other 0 (0.0) 2 (0.7) 2 (0.3)
Missing/not applicable 77 (25.0) 62 (21.8) 139 (23.4)
a Two participants were discharged before randomisation (one to intermediate care and one to a rehabilitation centre).









Discharged during treatment, n (%)
Yes 115 (37.3) 122 (42.8) 237 (40.0)
No 122 (39.6) 110 (38.6) 232 (39.1)
Died before end of treatment 1 (0.3) 1 (0.4) 2 (0.3)
Withdrew before end of treatment 10 (3.2) 5 (1.8) 15 (2.5)
No treatment received 11 (3.6) 4 (1.4) 15 (2.5)
Unknown 49 (15.9) 43 (15.1) 92 (15.5)
Days from randomisation to dischargea,b
Mean (SD) 15.1 (9.99) 17.9 (10.14) 16.6 (10.14)
Median (range) 13 (–5 to 42) 16 (–1 to 43) 15 (–5 to 43)
Missing, (n) 0 0 0
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group and 95 (77.9%) in the placebo group. Two participants were discharged before randomisation
(one on the day before randomisation and the other 5 days before randomisation). The delay in
randomising the latter participant was due to the therapist working off-site, trying to fit in with the
participant’s other activities and the weekend. One participant randomised to the co-careldopa group
commenced therapy 6 days post discharge.
Therapy sessions
A total of 14,551 therapy sessions were delivered during the trial. The mean number of therapy sessions
provided was 23.2 and 24.8 per patient with an average length of 42.8 and 43.1 minutes in the co-careldopa
and placebo groups, respectively (Table 39). The mean number of minutes spent on motor/non-motor activities
was 40.8/15.8 in the co-careldopa group and 40.8/17.3 in the placebo group.
The proportion of participants who received sufficient motor therapy (at least 20 minutes of motor therapy
in at least 80% of therapy sessions) was higher in the placebo group than in the co-careldopa group:
257 (90.2%) and 259 (84.1%), respectively (Table 40).
Therapists present at therapy sessions
Table 41 summarises the number of sessions in which occupational therapists, physiotherapists and
rehabilitation assistants were present. At least one occupational therapist was present in 24.7% of sessions
in the co-careldopa group and and 25.5% of sessions in the placebo group. At least one physiotherapist
was present in 61.4% and 61.0% of sessions in the co-careldopa and placebo group, respectively, and at
least one rehabilitation assistant was present in 43.4% and 42.1% of sessions, respectively.
Intensity of therapy sessions by location
The total mean length of the therapy session was 41.5 minutes in the hospital setting and 45.4 minutes
in the community. The mean time of motor and non-motor therapy was 40.1 and 16.4, respectively, in the
hospital setting, and 41.9 and 16.7, respectively, in the community setting (Table 42).









Discharge location,a n (%)
Home 88 (76.5) 95 (77.9) 183 (77.2)
Nursing/residential/care home 5 (4.3) 4 (3.3) 9 (3.8)
Community hospital/rehabilitation centre/intermediate care 18 (15.7) 18 (14.8) 36 (15.2)
Missing 4 (3.5) 5 (4.1) 9 (3.8)
Commenced therapy > 5 days post discharge,a n (%)
Yes 1 (0.9) 0 (0.0) 1 (0.4)
No 114 (99.1) 122 (100.0) 236 (99.6)
a Denominator is total number discharged before the end of treatment (n= 237).
b Two participants were discharged before randomisation (one to intermediate care and one to a rehabilitation centre).
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TABLE 40 Number of participants receiving sufficient motor therapya
Sufficient therapy for 80% of sessions
Treatment group, n (%) Total
(N= 593),
n (%)Co-careldopa (N= 308) Placebo (N= 285)
Yes 259 (84.1) 257 (90.2) 516 (87.0)
No 12 (3.9) 8 (2.8) 20 (3.4)
NA, fewer than five therapy sessions 37 (12.0) 20 (7.0) 57 (9.6)
N/A, not applicable.
a At least 20 minutes of motor therapy in at least 80% of therapy sessions.




(N= 593)Co-careldopa (N= 308) Placebo (N= 285)
Number of therapy sessions
Mean (SD) 23.2 (14.36) 24.8 (12.50) 24.0 (13.51)
Median (range) 21 (0–73) 25 (0–68) 24 (0–73)
Q1, Q3 (points) 13, 31 17, 32 15, 32
Length of therapy session (minutes)
Mean (SD) 42.8 (15.10) 43.1 (16.04) 43.0 (15.58)
Median (range) 45 (5–180) 45 (5–210) 45 (5–210)
Q1, Q3 (points) 30, 50 30, 50 30, 50
Minutes of motor therapy
Mean (SD) 40.8 (14.91) 40.8 (15.27) 40.8 (15.09)
Median (range) 40 (1–180) 40 (4–180) 40 (1–180)
Q1, Q3 (points) 30, 50 30, 50 30, 50
Minutes of non-motor therapy
Mean (SD) 15.8 (14.24) 17.3 (15.68) 16.6 (15.02)
Median (range) 10 (1–120) 10 (1–165) 10 (1–165)
Q1, Q3 (points) 5, 20 10, 20 5, 20
Q1, quartile 1; Q3, quartile 3.
TABLE 41 Therapists present during therapy session
Therapist presence
Treatment group, n (%) Total
(N= 14,551),
n (%)Co-careldopa (N= 7319) Placebo (N= 7232)
Occupational therapists present
None 5508 (75.3) 5390 (74.5) 10,898 (74.9)
1 1513 (20.7) 1492 (20.6) 3005 (20.7)
2 208 (2.8) 224 (3.1) 432 (3.0)
≥ 3 6 (0.1) 6 (0.1) 12 (0.1)
Number unknown 84 (1.1) 120 (1.6) 204 (1.4)
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Treatment compliance
Investigational medicinal product doses and motor therapy sessions
Table 43 summarises the number of IMP doses received compared with the number of motor therapy
sessions undertaken. The mean number of therapy sessions that included motor activities was 23.2 in the
co-careldopa group and 24.8 in the placebo group, and the mean number of IMP doses received by
participants was 20.7 in the co-careldopa group and 22.4 in the placebo group. The co-careldopa group
received an average of 2.6 more therapy sessions than IMP doses and the placebo group received 2.4 more
sessions than IMP doses. Around one-fifth of participants received the same number of IMP doses as therapy
TABLE 41 Therapists present during therapy session (continued )
Therapist presence
Treatment group, n (%) Total
(N= 14,551),
n (%)Co-careldopa (N= 7319) Placebo (N= 7232)
Physical therapists present
None 2825 (38.6) 2824 (39.0) 5649 (38.8)
1 3079 (42.1) 3064 (42.4) 6143 (42.2)
2 1144 (15.6) 1078 (14.9) 2222 (15.3)
≥ 3 112 (1.5) 121 (1.7) 233 (1.6)
Number unknown 159 (2.2) 145 (2.0) 304 (2.1)
Rehabilitation assistants present
None 4146 (56.6) 4185 (57.9) 8331 (57.3)
1 2726 (37.2) 2648 (36.6) 5374 (36.9)
2 339 (4.6) 275 (3.8) 614 (4.2)
≥ 3 4 (0.1) 2 (0.0) 6 (0.0)
Number unknown 104 (1.4) 122 (1.7) 226 (1.5)
TABLE 42 Length of therapy sessions, by location
Length of therapy sessions (minutes)
Location
Total
(n= 14,551)Hospital (n= 7319) Community (n= 7232)
Length of therapy session
Mean (SD) 41.5 (15.78) 45.4 (14.90) 43.0 (15.58)
Median (range) 40 (5–210) 45 (5–180) 45 (5–210)
Q1, Q3 (points) 30, 50 35, 55 30, 50
Length of motor therapy
Mean (SD) 40.1 (15.41) 41.9 (14.47) 40.8 (15.09)
Median (range) 40 (1–180) 43.0 (5–130) 40 (1–180)
Q1, Q3 (points) 30, 45 30, 50 30, 50
Length of non-motor therapy
Mean (SD) 16.4 (16.19) 16.7 (13.93) 16.6 (15.02)
Median (range) 10 (1–165) 10 (2–105) 10 (1–165)
Q1, Q3 (points) 5, 20 10, 20 5, 20
Q1, quartile 1; Q3, quartile 3.
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sessions: 58 (18.8%) in the co-careldopa group and 61 (21.4%) in the placebo group. Fourteen participants
did not receive any IMP doses or therapy; this was mainly attributable to participants withdrawing before
starting therapy, but in a few cases therapy forms were unobtainable and it was, therefore, unknown if any
therapy took place.
Table 44 summarises the time frame of the IMP dose with respect to the motor therapy sessions. The IMP
was taken as per protocol (45–60 minutes before the therapy session) in 55% of therapy sessions in both
treatment arms.
Patient refusal, ill health, cancelled or rearranged therapy session or no planned therapy session were the
main reasons for not receiving therapy (Table 45). The majority of IMP doses were not taken because a
previous dose had been taken within 3 hours or staff forgot to dispense it (Table 46).
Therapy in the community
Participants who were discharged to the community (their own or a relative’s/carer’s home, or to a
nursing, residential or care home) should have received a telephone call to remind them to take their IMP
before they received therapy. To explore the effectiveness of these reminders, the proportion of times
the drug was taken as per protocol when the participant was still in hospital and when they did or did not
receive a reminder in the community is summarised in Table 47. Approximately half of participants in both
treatment arms received the IMP as per protocol while in hospital. For those participants in the community,
TABLE 43 Summary of IMP doses and motor therapy sessions
IMP dose and motor therapy session
characteristics
Treatment group
Total (N= 593)Co-careldopa (N= 308) Placebo (N= 285)
Number of motor therapy sessions
Mean (SD) 23.2 (14.36) 24.8 (12.50) 24.0 (13.51)
Median (range) 21 (0–73) 25 (0–68) 24 (0–73)
Q1, Q3 (points) 13, 31 17, 32 15, 32
Number of IMP doses taken
Mean (SD) 20.6 (13.07) 22.4 (11.10) 21.5 (12.18)
Median (range) 19 (0–61) 23 (0–62) 22 (0–62)
Q1, Q3 (points) 12, 29 15, 29 13, 29
Difference in IMP doses and motor therapy sessions (categorical), n (%)
Same number of IMP doses and
therapy sessions
58 (18.8) 61 (21.4) 119 (20.1)
More therapy sessions than IMP doses 194 (63.0) 186 (65.3) 380 (64.1)
More IMP doses than therapy sessions 46 (14.9) 34 (11.9) 80 (13.5)
No IMP doses or therapy sessions 10 (3.2) 4 (1.4) 14 (2.4)
Difference in IMP doses and motor therapy sessions (continuous)
Mean (SD) 2.6 (5.39) 2.4 (4.40) 2.5 (4.93)
Median (range)a 1 (–33 to 31) 1 (–25 to 23) 1 (–33 to 31)
Q1, Q3 (points) 0, 4 0, 4 0, 4
Q1, quartile 1; Q3, quartile 3.
a Negative number indicates more IMP doses than therapy sessions.
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TABLE 44 Summary of time frame of IMP dose in relation to therapy sessions
Timing of IMP dose







IMP taken 45–60 minutes before motor therapy session 4030 (55.1) 3976 (55.0) 8006 (55.0)
IMP taken > 60 minutes before motor therapy session 1079 (14.7) 1074 (14.9) 2153 (14.8)
IMP taken < 45 minutes before motor therapy session 805 (11.0) 885 (12.2) 1690 (11.6)
IMP taken after start of motor therapy session 100 (1.4) 154 (2.1) 254 (1.7)
IMP taken at unknown time before/after motor therapy
session
77 (1.1) 73 (1.0) 150 (1.0)
IMP not taken before motor therapy session 1205 (16.5) 1031 (14.3) 2236 (15.4)
Missing IMP or therapy data 23 (0.3) 39 (0.5) 62 (0.4)
TABLE 45 Reasons for not receiving therapy
Reasons







Patient refused/too ill 61 (23.2) 44 (20.9) 105 (22.2)
Unscheduled/cancelled/rearranged therapy session 60 (22.8) 60 (28.4) 120 (25.3)
No planned therapy session 62 (23.6) 47 (22.3) 109 (23.0)
Not appropriate to give therapy 14 (5.3) 8 (3.8) 22 (4.6)
No evidence that therapy was given 7 (2.7) 16 (7.6) 23 (4.9)
Non-motor activity session 1 (0.4) 0 (0.0) 1 (0.2)
Patient not available 4 (1.5) 5 (2.4) 9 (1.9)
Timing issues 11 (4.2) 1 (0.5) 12 (2.5)
Staff error 14 (5.3) 2 (0.9) 16 (3.4)
Unknown 11 (4.2) 4 (1.9) 15 (3.2)
Other 17 (6.5) 17 (8.1) 34 (7.2)
Missing 1 (0.4) 7 (3.3) 8 (1.7)
TABLE 46 Reasons for not receiving IMP
Reasons







Patient refused/too ill 39 (3.2) 29 (2.8) 68 (3.0)
Unscheduled/rearranged therapy session 54 (4.5) 46 (4.5) 100 (4.5)
Previous dose taken within 3 hours 386 (32.0) 387 (37.5) 773 (34.6)
Not appropriate to give drug 80 (6.6) 16 (1.6) 96 (4.3)
No evidence that drug was taken 2 (0.2) 8 (0.8) 10 (0.4)
Temporarily stopped drug 2 (0.2) 1 (0.1) 3 (0.1)
Permanently stopped drug 0 (0.0) 2 (0.2) 2 (0.1)
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TABLE 46 Reasons for not receiving IMP (continued )
Reasons







Not aware of motor therapy 0 (0.0) 1 (0.1) 1 (0.0)
Non-motor activity session 14 (1.2) 7 (0.7) 21 (0.9)
Patient not available 10 (0.8) 2 (0.2) 12 (0.5)
Not aware patient on trial 33 (2.7) 16 (1.6) 49 (2.2)
Prescribing issues 37 (3.1) 33 (3.2) 70 (3.1)
Timing issues 57 (4.7) 75 (7.3) 132 (5.9)
Communication issues 11 (0.9) 12 (1.2) 23 (1.0)
Staff forgot 297 (24.6) 231 (22.4) 528 (23.6)
Patient forgot 105 (8.7) 83 (8.1) 188 (8.4)
Unknown 51 (4.2) 23 (2.2) 74 (3.3)
Other 26 (2.2) 46 (4.5) 72 (3.2)
Missing 1 (0.1) 13 (1.3) 14 (0.6)
TABLE 47 Summary of therapy sessions in which IMP was taken as per protocol, by location of therapy and
telephone reminder
Summary







Was IMP taken per protocol when motor therapy was received in hospital?
Yes 2327 (49.6) 2527 (52.1) 4854 (50.9)
No 2364 (50.4) 2319 (47.9) 4683 (49.1)
N= 452 N= 418 N= 870
Was IMP taken per protocol when motor therapy was received in the community and a telephone reminder was received?
Yes 316 (69.9) 317 (75.8) 633 (72.8)
No 136 (30.1) 101 (24.2) 237 (27.2)
N= 530 N= 500 N= 1030
Was IMP taken per protocol when motor therapy was received in the community and a telephone reminder was not
received?
Yes 344 (64.9) 261 (52.2) 605 (58.7)
No 186 (35.1) 239 (47.8) 425 (41.3)
N= 12 N= 30 N= 42
Was IMP taken per protocol when motor therapy was received in the community and it is unknown if a telephone reminder
was received?
Yes 4 (33.3) 6 (20.0) 10 (23.8)
No 8 (66.7) 24 (80.0) 32 (76.2)
Data were not collected for all therapy sessions conducted in the community.
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receiving a reminder was effective in ensuring that the IMP was taken as per protocol: 69.9% of
co-careldopa group participants and 75.8% of placebo group participants. When a reminder was not
received, 64.9% of the co-careldopa group and 52.2% of the placebo group took the IMP as per protocol.
Drug (kit) replacement
Four participants lost their drug kits and required a replacement: three in the co-careldopa group and one
in the placebo group. No participant received the wrong drug.
Patient perspective regarding the use of the investigational medicinal
product with rehabilitation treatment
Although many participants did not answer the questions relating to patient perspective regarding the use
of IMP, those who did answer generally found it easy to remember to take the drug and thought that the
package instructions were clear. In total, 21% of participants in both groups found it difficult to remove
the IMP from the packaging and had to ask for help, but the majority did not have problems taking the
drug (Table 48).
TABLE 48 Patient perspective regarding the use of IMP with rehabilitation treatment
Patient perspective







Remembering to take drug
Easy 147 (47.7) 142 (49.8) 289 (48.7)
Managed most of the time 37 (12.0) 39 (13.7) 76 (12.8)
Often forgot 11 (3.6) 11 (3.9) 22 (3.7)
Missing 113 (36.7) 93 (32.6) 206 (34.7)
Removal from packaging
Easy 82 (26.6) 92 (32.3) 174 (29.3)
Difficult but could do it myself 29 (9.4) 28 (9.8) 57 (9.6)
Difficult and had to ask for help 66 (21.4) 61 (21.4) 127 (21.4)
Missing 131 (42.5) 104 (36.5) 235 (39.6)
Clear instructions
Yes 122 (39.6) 112 (39.3) 234 (39.5)
Mostly 25 (8.1) 37 (13.0) 62 (10.5)
No, had to ask for help 34 (11.0) 29 (10.2) 63 (10.6)
Missing 127 (41.2) 107 (37.5) 234 (39.5)
Problems taking tablet
None 199 (64.6) 198 (69.5) 397 (66.9)
Occasionally 13 (4.2) 5 (1.8) 18 (3.0)
All the time 5 (1.6) 3 (1.1) 8 (1.3)
Missing 91 (29.5) 79 (27.7) 170 (28.7)
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Blinding
Unblinding requests and errors
A request to unblind one participant was received because the PI had concerns regarding the participant’s
blood pressure, which was low when measured using an electronic device but within range when repeated
manually. The participant was not experiencing any symptoms and felt well, and it transpired that the
telephone call was to seek advice on whether or not the site could stop treatment for the participant without
knowing the treatment allocation. The research nurse was happy that no unblinding would occur for this
participant and the participant was withdrawn from trial treatment.
Exit poll
The aim of the exit poll undertaken by the local stroke service research nurse/researcher at 12 months
(patients and therapists), using the blinding index, was to ascertain the level of masking to active drug.
A blinding index was calculated to assess whether or not blinding was successful in participants and
researchers. The blinding index has a range between –1 and 1, where a blinding index of 0 represents
complete blinding, a blinding index of –1 indicates that all guesses were incorrect and a blinding index of
1 indicates that all guesses were correct. The certainty of guesses was rated by researchers and participants
on a continuous scale (0–10), where 0 = ‘not at all’ and 10 = ‘completely sure’, and was summarised
according to the randomised arm the participant had been allocated to and by the treatment group guessed.
Blinding was successful from both the researcher perspective and the participant perspective. The blinding
index for researchers was 0.05 (95% CI –0.01 to 0.12) in the co-careldopa group and –0.06 (95% CI
–0.13 to 0.00) in the placebo group, suggesting that blinding was maintained. For participants, the
blinding index was 0.05 (95% CI –0.02 to 0.13) for those in the co-careldopa group and –0.04 (95% CI
–0.13 to 0.03) for those in the placebo group (Table 49), suggesting that blinding was maintained.
Table 50 summarises the results of the exit poll from the researcher perspective. Approximately half of
the researchers made their choice of treatment because they thought that the treatment benefited the
participant, although one-third chose a treatment arm because they thought that the treatment had no
benefit. Similar proportions were observed for reason of choice when the correct treatment group was
chosen. The certainty of guess was similar between randomised arms and by treatment group chosen.
Answers from a participant perspective are summarised in Table 51. Forty-five participants (39.1%) in the
co-careldopa group made their choice because the treatment did not work and 38 participants (33.0%)
made their choice because the treatment did work. Of the participants in the placebo group, 31 (31.0%)
chose the treatment because it did not work, whereas 41 (41.0%) chose it because it did work. Similarly,
the reasons for choice for those who answered correctly and incorrectly were mainly because the treatment
did not work [correct choice 33 (32.4%), incorrect choice 43 (38.1%)] or because the treatment did work
[correct choice 39 (38.2%), incorrect choice 40 (35.4%)]. The certainty of guesses by participants was
similar by randomised arms, treatment chosen and reason [overall mean approximately 7.0, SD 2.3)].
TABLE 49 Blinding index
Researcher and patient group Blinding index (95% CI) p-value
Researcher treatment group
Co-careldopa 0.05 (–0.01 to 0.12) 0.098
Placebo –0.06 (–0.13 to 0.00) 0.942
Participant treatment group
Co-careldopa 0.05 (–0.02 to 0.13) 0.136
Placebo –0.05 (–0.13 to 0.03) 0.835
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TABLE 50 Summary of exit poll from the researcher perspective







Treatment had no benefit 30 (34.1) 24 (30.0) 54 (32.1)
Treatment benefited patient 42 (47.7) 40 (50.0) 82 (48.8)
AE 4 (4.5) 4 (5.0) 8 (4.8)
Other reason 12 (13.6) 12 (15.0) 24 (14.3)





Treatment had no benefit 26 (31.7) 28 (32.6) 54 (32.1)
Treatment benefited patient 43 (52.4) 39 (45.3) 82 (48.8)
AE 4 (4.9) 4 (4.7) 8 (4.8)
Other reason 9 (11.0) 15 (17.4) 24 (14.3)
Certainty of choice, by randomised group Co-careldopa (N= 88) Placebo (N= 80) Total (N= 168)
Mean (SD) 6.3 (2.07) 5.9 (2.59) 6.1 (2.34)
Median (range) 6.8 (0.0–10.0) 6.5 (0.0–10.0) 6.8 (0.0–10.0)
Q1, Q3 (points) 5.0, 8.0 5.0, 8.0 5.0, 8.0
Missing (n) 0 0 0
Certainty of choice, by treatment group
chosen Co-careldopa (N= 100) Placebo (N= 68) Total (N= 168)
Mean (SD) 6.2 (2.25) 6.0 (2.47) 6.1 (2.34)
Median (range) 7.0 (0.0–10.0) 6.0 (0.0–10.0) 6.8 (0.0–10.0)
Q1, Q3 (points) 5.0, 8.0 5.0, 8.0 5.0, 8.0
Missing (n) 0 0 0
Certainty of choice, by reason Mean (SD) Median (range)
Treatment had no benefit (n= 54) 5.8 (2.48) 6.0 (0.0–9.0)
Treatment benefited patient (n= 82) 6.3 (1.95) 6.5 (0.0–10.0)
Total (N = 168) 6.1 (2.34) 6.8 (0.0–10.0)
Q1, quartile 1; Q3, quartile 3.
Certainty of choice (continuous scale from 0 = not at all to 10 = completely sure).
TABLE 51 Summary of exit poll from the participant perspective







NHS staff told me the name of the drug 0 (0.0) 1 (1.0) 1 (0.5)
Treatment did not work 45 (39.1) 31 (31.0) 76 (35.3)
Treatment worked 38 (33.0) 41 (41.0) 79 (36.7)
I had a side effect 8 (7.0) 7 (7.0) 15 (7.0)
Appearance or taste of the pill 3 (2.6) 4 (4.0) 7 (3.3)
Other 21 (18.3) 15 (15.0) 36 (16.7)
Missing 0 (0.0) 1 (1.0) 1 (0.5)
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Overall, the blinding index results and summaries from the exit poll suggest that the trial blinding
was maintained.
Further analysis
The DARS trial information DVD
Only 21 participants (6.8%) in the co-careldopa group and 25 participants (8.8%) in the placebo group
watched the DARS trial information DVD. Of these, the majority said that it helped them understand the
project (Table 52). Owing to the low number of responses, planned analyses exploring correlation between
DVD viewing and both treatment compliance and patient questionnaire completion were not conducted.
Level of assistance with patient-completed questionnaires
Help with patient questionnaire completion was monitored at each time point. At baseline, 38 co-careldopa
participants (12.3%) required no help, 200 (64.9%) required some help and 53 (17.2%) required a lot of help,
whereas 22 placebo participants (7.7%) required no help, 210 (73.7%) required some help and 43 (15.1%)
required a lot of help. Help completing the questionnaires at the 8-week follow-up was more balanced than
at baseline. More participants in the co-careldopa group were able to complete the questionnaires with no
help at 6 months than at 8 weeks [56 (18.2%)], but fewer were able to in the placebo group [40 (14.0%)].
TABLE 51 Summary of exit poll from the participant perspective (continued )





NHS staff told me the name of the drug 0 (0.0) 1 (0.9) 1 (0.5)
Treatment did not work 33 (32.4) 43 (38.1) 76 (35.3)
Treatment worked 39 (38.2) 40 (35.4) 79 (36.7)
I had a side effect 8 (7.8) 7 (6.2) 15 (7.0)
Appearance or taste of the pill 5 (4.9) 2 (1.8) 7 (3.3)
Other 17 (16.7) 19 (16.8) 36 (16.7)
Missing 0 (0.0) 1 (0.9) 1 (0.5)
Certainty of choice, by randomised group Co-careldopa (N= 115) Placebo (N= 99) Total (N= 214)
Mean (SD) 7.3 (2.31) 7.1 (2.40) 7.2 (2.35)
Median (range) 8.0 (0.0–10.0) 8.0 (0.0–10.0) 8.0 (0.0–10.0)
Q1, Q3 (points) 6.0, 9.0 5.0, 9.0 5.0, 9.0
Certainty of choice, by treatment group
chosen Co-careldopa (N= 119) Placebo (N= 95) Total (N= 214)
Mean (SD) 7.4 (2.09) 7.0 (2.62) 7.2 (2.35)
Median (range) 8.0 (0.0–10.0) 7.5 (0.0–10.0) 8.0 (0.0–10.0)
Q1, Q3 (points) 6.0, 9.0 5.0, 9.0 5.0, 9.0
Certainty of choice, by reason Mean (SD) Median (range)
NHS staff told me the name of the drug (n = 1) 7.0 (0.0) 7.0 (7.0–7.0)
Treatment did not work (n= 76) 6.9 (2.74) 7.8 (0.0–10.0)
Total (N = 214) 7.2 (2.35) 8.0 (0.0–10.0)
Q1, quartile 1; Q3, quartile 3.
Certainty of choice (continuous scale from 0 = not at all to 10 = completely sure).
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At 12 months, the ability to complete the questionnaire with no help was similar to the 8-week follow-up.
There were borderline statistically significant differences between arms at baseline and 6 months, with a
greater proportion of participants in the co-careldopa than in the placebo group needing no help (p= 0.051
and p= 0.052 at baseline and 6 months, respectively) (Table 53).
Moderator analysis
The moderator analysis explored whether or not the size of the treatment effect (irrespective of whether or
not the effect is significant) was influenced by baseline characteristics of patients. The following results are
based on exploratory analysis and should be treated with caution.
Each moderator variable was tabulated by primary outcome category and treatment group (see Appendix 6,
Tables 82 and 83). Mean baseline RMI score (regardless of reporting status) and the proportion of patients
with no lower limb pain was higher among those walking independently at 8 weeks. There was no difference
in baseline RMI score or lower limb pain between the treatment groups. There was a suggestion that both
site of MCA lesions and haemorrhage location were associated with the primary outcome and treatment
group. A higher proportion of those with no MCA lesion and those with a (subcortical) haemorrhage walked
independently at 8 weeks and belonged to the placebo group, which fits with the ITT analysis that found that
those in the placebo group have a higher odds of walking independently at 8 weeks (though not statistically
higher than those in the co-careldopa group). Scan data were available for 472 out of 593 patients (79.6%)
and patients with haemorrhage are those who had a primary haemorrhage stroke (rather than infarction).
Those without scan data were more likely to be in the co-careldopa group (58.7% without scan data vs.
50.2% with scan data) and have fewer (≤ 12) years of education (53.7% without scan data vs. 45.2% with
scan data). Hence, by not including those with scan data, the numbers in the co-careldopa arm reduces and
the ITT analysis of the primary outcome shows an OR closer to 1 (OR 0.806, 95% CI 0.521 to 1.249).
TABLE 52 The DARS trial information DVD
Participant responses to information
via DVD
Treatment group, n (%)
Total (N= 593), n (%)Co-careldopa (N= 308) Placebo (N= 285)
Watched DVD
Yes 21 (6.8) 25 (8.8) 46 (7.8)
No 255 (82.8) 241 (84.6) 496 (83.6)
Missing 32 (10.4) 19 (6.7) 51 (8.6)
Understood research project
Yes, a lot 9 (2.9) 9 (3.2) 18 (3.0)
Yes, a little 9 (2.9) 12 (4.2) 21 (3.5)
No 2 (0.6) 3 (1.1) 5 (0.8)
Missing 288 (93.5) 261 (91.6) 549 (92.6)
DVDs for future research projects
Yes 13 (4.2) 17 (6.0) 30 (5.1)
No 2 (0.6) 3 (1.1) 5 (0.8)
Not sure 6 (1.9) 4 (1.4) 10 (1.7)
Missing 287 (93.2) 261 (91.6) 548 (92.4)
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TABLE 53 Level of assistance required for patient-completed questionnaires
Help with questionnaire completion
Time point

















Questionnaire help, n (%)
No help 38 (12.3) 22 (7.7) 49 (15.9) 48 (16.8) 56 (18.2) 40 (14.0) 46 (14.9) 51 (17.9)
Some help 200 (64.9) 210 (73.7) 165 (53.6) 160 (56.1) 141 (45.8) 161 (56.5) 139 (45.1) 130 (45.6)
A lot of help 53 (17.2) 43 (15.1) 46 (14.9) 43 (15.1) 40 (13.0) 41 (14.4) 31 (10.1) 35 (12.3)
Missing 17 (5.5) 10 (3.5) 48 (15.6) 34 (11.9) 71 (23.1) 43 (15.1) 92 (29.9) 69 (24.2)
p-valuea 0.051 0.936 0.052 0.564
If help received, person who helped, n (%)
DARS trial researcher 215 (85.0) 223 (88.1) 161 (76.3) 169 (83.3) 138 (76.2) 146 (72.3) 134 (78.8) 129 (78.2)
Relative, carer or friend 29 (11.5) 25 (9.9) 37 (17.5) 28 (13.8) 36 (19.9) 44 (21.8) 24 (14.1) 31 (18.8)
Therapist 1 (0.4) 0 (0.0) 3 (1.4) 2 (1.0) 0 (0.0) 0 (0.0) 12 (7.1) 5 (3.0)
Nurse 2 (0.8) 1 (0.4) 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 6 (2.4) 4 (1.6) 9 (4.3) 4 (2.0) 7 (3.9) 12 (5.9) 12 (7.1) 5 (3.0)










































































































































































With the exception of baseline RMI score, no other baseline characteristics showed potential moderation
when accounting for covariates included in the primary analysis multilevel model (see Appendix 6, Table 84).
There was weak evidence (p = 0.069) that baseline RMI score moderates the effect of treatment on walking
independently at 8 weeks, such that there is a significant difference in the association of baseline RMI score
with the primary outcome for placebo and co-careldopa. The effect of treatment on walking independently
at 8 weeks changes as baseline RMI score increases (Figure 8). When the baseline RMI score is 0 points,
those in the placebo arm have a significantly higher chance of walking independently at 8 weeks than those
in the co-careldopa arm, but there is no evidence of a significant difference between the treatment groups at
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FIGURE 9 Predictive margins of treatment group with 95% CI.
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Departures from randomised treatment as a mediator
All patients received their treatment in accordance with their randomised allocation. Of the 593 patients with
primary outcome data, 536 had five or more therapy sessions and were included in descriptive compliance
statistics. With the exception of drug intake compliance, there was no suggestion of a difference in the
distribution of the other categories of compliance between the treatment groups (Table 54) or of a difference
between the treatment groups in the outcomes of ‘non-compliers’, where ‘non-compliers’ are defined as those
not satisfying the criteria for the compliance category (Table 55). Within the relaxed drug intake compliance
category, the proportion of compliant patients was higher in the placebo group than in the co-careldopa
group (76% vs. 68%, respectively) and the proportion of non-compliant patients walking independently at
8 weeks was higher in the placebo group than in the co-careldopa group (48% vs. 38%, respectively).
Mediator analysis
The details of the mediator analyses are shown in Appendix 7 (see Tables 85–89). In summary, there was no
evidence that any of the variables investigated mediated the effect of treatment on walking independently
at 8 weeks.
TABLE 54 Distribution of compliance, overall and by treatment group
Category of compliance
Treatment group, n (%)
Overall, n (%)Placebo Co-careldopa
Strict compliance
No 233 (87.9) 232 (85.6) 465 (86.8)
Yes 32 (12.1) 39 (14.4) 71 (13.2)
Relaxed timing compliance
No 167 (63.0) 180 (66.4) 347 (64.7)
Yes 98 (37.0) 91 (33.6) 189 (35.3)
Relaxed timing and therapy compliance
No 149 (56.2) 156 (57.6) 305 (56.9)
Yes 116 (43.8) 115 (42.4) 231 (43.1)
Relaxed drug intake compliance
No 63 (23.8) 86 (31.7) 149 (27.8)
Yes 202 (76.2) 185 (68.3) 387 (72.2)
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at 8 weeks, n (%) N
Walking independently
at 8 weeks, n (%)
Strict compliance
No 233 108 (46.3) 232 95 (41.0)
Yes 32 12 (37.5) 39 19 (48.7)
Relaxed timing compliance
No 167 71 (42.5) 180 68 (37.8)
Yes 98 49 (50.0) 91 46 (50.6)
Relaxed timing and therapy compliance
No 149 62 (41.6) 156 57 (36.5)
Yes 116 58 (50.0) 115 57 (49.8)
Relaxed drug intake compliance
No 63 30 (47.6) 86 33 (38.4)
Yes 202 90 (44.6) 185 81 (43.8)
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
Chapter 4 Economic evaluation
Sample
A total of 593 patients were recruited to the trial (308 patients to the co-careldopa group and 285 to
the placebo group). Of these, 1% died between baseline and 8 weeks, 2% died between 8 weeks and
6 months and 3% died between 6 months and 12 months. Two-thirds of those who died before the end
of the trial were from the co-careldopa group.
Missing data
A total of 122 patients had complete EQ-5D scores and costs at baseline and all follow-up periods. For
the remaining 471 participants (53% from the co-careldopa group and 47% from the placebo group),
either EQ-5D scores and/or cost data were missing for at least one of the follow-up periods. Indicatively, and
as shown in Figure 10, 99 patients from the co-careldopa group had missing EQ-5D scores at 12 months,
compared with only 19 patients at baseline; of these, 13 patients had all EQ-5D items missing at 12 months
compared with 93 at baseline. The number of patients with missing EQ-5D items increased over time, and a
majority of those with missing data did not complete the measure. Figure 11 shows the number of patients
with missing resource use items and, hence, missing costs. For example, 180 patients in the placebo group
had missing costs at baseline, compared with 228 patients at 12 months. The number of patients with






















Placebo (all items missing)
Placebo (at least one 
item missing)
Co-careldopa (all items missing)
Co-careldopa (at least one 
item missing)
Treatment group





















Placebo (all items missing)
Placebo (at least one 
item missing)
Co-careldopa (all items missing)




FIGURE 11 Total number of patients with missing total resource use costs, by treatment group.
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In addition, most of the missing costs were the result of at least one missing item rather than non-completion
of the resource use questionnaire.
Missing utility and cost data were imputed in each period using, as predictors, health status measures
(BI),120 mRS121 and GHQ-12,122 and baseline characteristics such as age, sex, ethnicity and type of stroke.
Imputation was possible for 313 patients but not for 158 patients. The latter was due to missing scores
over time for at least one of the predictor variables (BI, mRS and GHQ-12). Therefore, a total of
435 patients (216 placebo and 219 co-careldopa) were included in the primary base-case analysis.
The baseline characteristics of the patients included in the analysis sample are presented in Table 56.
Patients in the placebo group were marginally younger than those in the co-careldopa group. In both
arms, more than half of the patients were male. More than two-thirds of the patients in both arms were
admitted with an infarction stroke at baseline but did not receive thrombolysis. These results seem to be
consistent across samples (i.e. base case compared with complete case) with the exception that, in the
complete case, patients in the co-careldopa arm were slightly older than those in the placebo arm.




Placebo (N= 216) Co-careldopa (N= 219) Placebo (N= 54) Co-careldopa (N= 48)
Age (years)
Mean (SD) 71.69 (12.59) 69.91 (12.95) 68.65 (14.35) 69.60 (12.60)
Minimum 33 27 33 41
Maximum 98 97 95 90
Sex, n (%)
Male 144 (67) 127 (58) 40 (74) 26 (54)
Female 72 (33) 92 (42) 14 (26) 22 (46)
Ethnicity, n (%)
White 209 (97) 211 (96) 52 (96) 46 (96)
Non-white 7 (3) 8 (4) 2 (4) 2 (4)
Type of stroke, n (%)
Infarction 184 (85) 195 (89) 48 (89) 43 (90)
Primary haemorrhage 32 (15) 24 (11) 6 (11) 5 (10)
Classification of stroke,b n (%)
TACI 48 (26) 72 (37) 10 (21) 14 (33)
LACI 45 (25) 44 (23) 10 (21) 10 (23)
PACI 71 (39) 61(31) 25 (52) 14 (33)
POCI 19 (10) 18 (9) 3 (6) 5 (12)
Probability thrombolysis receivedc
Mean (SD) 0.214 (0.411) 0.224 (0.418) 0.167 (0.376) 0.188 (0.394)
a Patients who died before the end of the trial are excluded from this case because there are no resource use counts for
these patients in at least one of the follow-up periods.
b In the base case, this information was not available for 33 patients in the placebo group and for 24 patients in the
co-careldopa group. In the complete case, this information was not available for six patients in the placebo group and
for five patients in the co-careldopa group.
c In the complete case, this information was not available for one patient in the placebo group.
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Resource use and costs
As resource use questions for the last follow-up periods (6 months and 12 months) referred to the last
3 months, monthly face-to-face and telephone/e-mail contacts were calculated and then multiplied by 4 and 6,
respectively, to cover the period between the follow-ups. Table 57 shows the average resource use per patient
in each trial arm in the observed data only (i.e. complete case). Patients in the co-careldopa group were more
likely than those in the placebo group to use the majority of services, and that pattern persisted over time.
Any other conclusions should be tempered given the little reported resource use within the trial.
In terms of the total NHS resource use cost, the co-careldopa group used the highest number of resources
and also had the highest cost. Mean total costs from the use of primary care and community health services
(before imputation) were £5095.70 (SD £6555.99) for the placebo group and £7937.92 (SD £12,247.55)


















GP surgery visits (face-to-face contacts)
Mean (SD) 0.407 (1.000) 0.934 (2.971) 1.975 (2.454) 1.667 (2.674) 2.148 (3.293) 2.292 (3.892)
Minimum 0 0 0 0 0 0
Maximum 5 20 9 15 16 24
GP surgery visits (telephone/e-mail)
Mean (SD) 0.019 (0.136) 0.188 (0.762) 0.667 (1.505) 1.778 (8.669) 0.519 (1.563) 0.875 (2.017)
Minimum 0 0 0 0 0 0
Maximum 1 5 7 60 8 8
GP home visits
Mean (SD) 0.222 (0.572) 0.271 (0.574) 0.469 (1.104) 0.722 (1.289) 0.889 (2.793) 0.958 (1.798)
Minimum 0 0 0 0 0 0
Maximum 3 2 4 4 14 6
District nurse (face-to-face contacts)
Mean (SD) 2.167 (4.546) 3.750 (12.39) 9.358 (22.10) 6.861 (22.09) 2.593 (8.831) 2.458 (7.161)
Minimum 0 0 0 0 0 0
Maximum 22 84 133 133 60 48
District nurse (telephone/e-mail contacts)
Mean (SD) 0.481 (2.238) 0.521 (1.868) 0.049 (0.254) 0.056 (0.385) 0.296 (1.667) 0.708 (2.163)
Minimum 0 0 0 0 0 0
Maximum 13 10 1 3 12 12
Physiotherapist (face-to-face contacts)a
Mean (SD) 0.185 (1.361) 0.250 (1.466) 1.333 (5.408) 0.750 (3.086) 1.889 (7.677) 0.000 (0.000)
Minimum 0 0 0 0 0 0
Maximum 10 10 33 15 44 0
continued
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for the co-careldopa group. Mean total costs from the use of hospital and residential care services
(before imputation) were also higher for the co-careldopa group [£15,595.72 (SD £20,182.44)] than for
the placebo group [£13,619.56 (SD £14,950.22)]. There were no significant differences in costs between
the two arms using Mann–Whitney U-tests. This was the case for both the complete-case sample and the
sample after imputing for missing data. For this reason, no adjustments in costs for baseline differences
were considered necessary. Table 58 reports resource use for complete cases only as the imputation
generated total cost values rather than individual resource counts.
Quality-of-life data
Table 59 shows the mean EQ-5D scores for each period for the two arms of the trial when no scores are
imputed (i.e. complete case) and when values are imputed (i.e. base case) (Figure 12 provides a graphical
representation). In both arms, there was a considerable increase in EQ-5D scores from baseline to 8 weeks.
There are small fluctuations in the utility values between 8 weeks and 12 months for both placebo and
co-careldopa, but the improvement in utility scores is more or less maintained until the last follow-up
period (12 months).
Table 60 provides the mean EQ-5D change scores between baseline and follow-up points for the base case.
All of the observed changes are above the estimated minimally important difference (range 0.08–0.12) for
the EQ-5D.123 Independent-sample t-tests showed that there were statistically significant differences over
time in EQ-5D scores in both trial arms. Differences in EQ-5D scores between the placebo and co-careldopa
arms were significant (at the 1% level) at baseline and at 8 weeks but not at any of the other follow-up
times. This indicated that baseline adjustments are necessary and, thus, adjustments were made using an
ordinary least squares (OLS) regression of QALYs on the treatment indicator and baseline EQ-5D.124


















Hospital and residential care services
Hospital inpatient stay (days)
Mean (SD) 22.54 (25.56) 23.90 (26.70) 6.519 (24.09) 4.361 (15.80) 0.296 (2.177) 1.292 (4.237)
Minimum 0 0 0 0 0 0
Maximum 89 84 120 80 16 22
Hospital outpatient visits
Mean (SD) 0.259 (0.732) 0.542 (1.352) 2.519 (6.551) 2.694 (6.097) 2.074 (4.774) 2.333 (5.540)
Minimum 0 0 0 0 0 0
Maximum 4 8 33 32 32 34
Hospital A&E visits
Mean (SD) 0.093 (0.446) 0.125 (0.334) 0.049 (0.254) 0.083 (0.326) 0.259 (0.873) 0.417 (0.919)
Minimum 0 0 0 0 0 0
Maximum 3 1 1 1 4 4
Notes
For consistency in sample sizes across the different services and any comparisons, we use the complete cases in this table.
The table reports only the use of main services.
a There were no reported PT contacts by telephone or e-mail.
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TABLE 58 Average health-care provider costs (£), by treatment group
Cost
Time point


































Minimum 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Maximum 3460.82 3938.94 12,341.55 14,630.92 13,683.60 36,656.74 24,547.00 52,519.37

















Minimum 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Maximum 32,392.44 30,572.64 45,045.60 29,116.80 20,531.64 24,020.70 81,291.59 53,591.24

















Minimum 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00



































Minimum 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Maximum 34,449.23 35,093.59 56,462.88 59,932.10 53,600.57 59,067.19 85,957.29 122,602.5
a The cost for the co-careldopa tablets is included in these costs (£16.99 per patient).











































































































































































Table 61 shows the costs and QALYs for each of the two trial arms for the primary analysis (multiple
imputation for missing data and adjustment for baseline EQ-5D differences). It also provides the incremental
cost and benefit (expressed as QALY gains). On average, co-careldopa patients incurred higher costs and
gained fewer QALYs than placebo patients. Therefore, co-careldopa is ‘dominated’ by placebo and, hence,
the ICER was not calculated. The results indicate that co-careldopa is not cost-effective.
Figure 13 shows the cost-effectiveness plane for co-careldopa compared with placebo, based on bootstrapped
estimates of costs and QALYs. The average costs from the bootstrapped estimates were £14,531.73
(SD £1130.00) and £16,640.91 (SD £1294.21) for the placebo and co-careldopa groups, respectively.




Placebo (n= 54) Co-careldopa (n= 48) Placebo (n= 216) Co-careldopa (n= 219)
Baseline to 8 weeks 0.333 (< 0.001) 0.293 (< 0.001) 0.250 (< 0.001) 0.258 (< 0.001)
Baseline to 6 months 0.321 (< 0.001) 0.305 (< 0.001) 0.233 (< 0.001) 0.258 (< 0.001)
Baseline to 12 months 0.349 (< 0.001) 0.289 (< 0.001) 0.235 (< 0.001) 0.241 (< 0.001)




Placebo (n= 54) Co-careldopa (n= 48) Placebo (n= 216) Co-careldopa (n= 219)
Baseline 0.186 (0.351) 0.178 (0.297) 0.215 (0.327) 0.154 (0.287)
8 weeks 0.519 (0.273) 0.471 (0.320) 0.465 (0.306) 0.412 (0.317)
6 months 0.506 (0.268) 0.483 (0.339) 0.448 (0.300) 0.412 (0.342)


















FIGURE 12 Mean (unadjusted) EQ-5D scores by treatment group (base case).
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The mean number of QALYs was 0.420 (SD 0.002) for the placebo group and 0.397 (SD 0.002) for the
co-careldopa group. The simulation estimates are spread in the north-west and south-west quadrants,
suggesting that co-careldopa is unlikely to lead to better health outcomes. They also indicate that placebo is
less costly but more effective in terms of improving HRQoL. A small proportion of simulations is beneath the
diagonal cost-effectiveness threshold (£20,000 per QALY) indicating cost-effectiveness. However, in these
cases, co-careldopa is still less effective but less costly.
A CEAC is presented in Figure 14. At a threshold of £20,000 per QALY, co-careldopa has a 7% chance of
being cost-effective, decreasing to 5% when the threshold λ = £30,000. There is a negative relationship
between λ and co-careldopa’s chance of being cost-effective as placebo is more effective on average.
Net benefit regression
We calculated the NMB for each patient assuming a threshold λ = £20,000 and accounted for differences in
EQ-5D scores between trial arms at baseline. The average NMB for both groups was negative. In detail, the
NMB for the placebo group was –£6138.90 (SD £16,841.91) and for the co-careldopa group was –£9146.19
(SD £20,543.19). In Table 62 we present the results from the net benefit regression. We ran OLS regressions
of the NMB on the treatment indicator and other controls such as age, sex, type of stroke, classification of
stroke and mRS score at 8 weeks. Some of the models included also showed interactions between treatment
TABLE 61 Cost-effectiveness results (outcome measure: QALY, health-care provider perspective)
Treatment group Cost (£) QALYsa ICER (£/QALY)
Placebo, mean (SD) 14,544.52 (16,756.76) 0.420 (0.029)
Co-careldopa, mean (SD) 17,091.93 (20,507.22) 0.397 (0.031)
Treatment group comparison Incremental cost (£) Incremental QALYs
Co-careldopa vs. placebo 2547.41 –0.023 Co-careldopa dominated


























FIGURE 13 Cost-effectiveness plane for co-careldopa compared with placebo (outcome measure: QALY, health-care
provider perspective).
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TABLE 62 Net benefit regression estimates
Explanatory variables
Model














































































Treatment × mRS – – – – – –1573.99
(1677.89)
– –
Treatment × stroke type – – – – – – –1556.32
(4817.93)
–


















R2 0.006 0.036 0.164 0.167 0.183 0.169 0.168 0.190
F-statistic (p-value) 2.79 (0.096) 5.17 (0.002) 18.35 (0.000) 15.15 (0.000) 9.50 (0.000) 12.87 (0.000) 12.84 (0.000) 8.47 (0.000)
n 435 435 427 427 371 427 427 371
*p< 0.1, **p< 0.05, ***p< 0.01.
a Reference case for type of stroke is ‘infarction’ and for classification of stroke is ‘TACI’.
Note










































































































































































and mRS, treatment and type of stroke, and treatment and stroke classification. In the majority of the models,
treatment was not found to be a significant predictor of net benefit. On two occasions, the treatment
coefficient was significant at the 10% level and negative, suggesting that co-careldopa was associated with
lower net benefit than placebo.
As mentioned in the results section, a per-protocol analysis was not considered feasible because only a few
patients met the strict compliance criteria (i.e. patient received tablet 45–60 minutes before therapy for
≥ 80% of the sessions) set by the trial team. However, as a sensitivity analysis, and to see whether or not
patient non-compliance was a driver of results, we relaxed the strict compliance criterion (i.e. 80%).
In particular, we looked at 75%, 65%, 55%, 50%, 45% and 40% compliance and ran OLS regressions
of NMB on treatment and other controls, each time on the population that met the specific compliance
percentage. The results are presented in Table 63. In all cases, except when compliance is 40%, the
treatment coefficient is not significant, suggesting that the lower monetary benefits of co-careldopa than
placebo were not due to the non-compliance of the patients.
Sensitivity analyses
To account for uncertainty around mean incremental costs and effectiveness, we conducted sensitivity
analyses and non-parametric bootstrapping (Table 64). We added and subtracted 20% from the costs in
both arms and assessed the subsequent impact on the ICER. We also looked at the case of no adjustment
for baseline EQ-5D differences as well as only the complete cases. Furthermore, we examined the case of
adjusting for baseline costs and the use of a different resource use count for PT and OT sessions. In all cases
except one, the conclusion was unchanged and co-careldopa was dominated by placebo. Furthermore,
the average incremental cost and QALY estimates from the bootstrapping were similar to those of the
deterministic base-case scenario.
Secondary analysis
Table 65 shows the costs and the proportion (in percentages) of those who achieved a score of ≥ 7 points
on the RMI at 8 weeks. It also shows the incremental cost and proportion (expressed as increase in
percentage of population), as well as the ICER. More patients in the placebo group than in the co-careldopa
group achieved a score of ≥ 7 points on the RMI at 8 weeks. In addition, the cost to the health-care provider
at 8 weeks is higher for the placebo group, which yields an ICER of £307.81. As co-careldopa is less effective
and cheaper than placebo, this is interpreted as the costs saved by one person not achieving a RMI score of
≥ 7 points.
Supplementary analyses
Supplementary analyses using a wider perspective for costs were also conducted. Costs were considered to
be the sum of the costs to the health-care provider and patients’ costs (Table 66). In this case, co-careldopa
was still more expensive than placebo and less effective in terms of QALY gains.
Table 67 shows the cost-effectiveness results when the wider cost perspective also encompassed caregiver
costs. As before, co-careldopa was less effective (i.e. led to worse health outcomes) and more expensive
than placebo. However, we should be cautious about any interpretations of the latter result given the
small number of carers in the trial and questionable data quality.
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Other controlsa Yes Yes Yes Yes Yes Yes Yes Yes
n 190 225 255 288 309 349 364 386
Compliance Strict compliance
for ≥ 75% of the
sessions
Strict compliance
for ≥ 70% of the
sessions
Strict compliance
for ≥ 65% of the
sessions
Strict compliance
for ≥ 60% of the
sessions
Strict compliance
for ≥ 55% of the
sessions
Strict compliance
for ≥ 50% of the
sessions
Strict compliance
for ≥ 45% of the
sessions
Strict compliance
for ≥ 40% of the
sessions
*p < 0.1.
a The extra controls are sex and age at baseline.
Note










































































































































































TABLE 64 Sensitivity analyses (outcome measure: QALY, health-care provider perspective)
Co-careldopa vs. placebo Incremental cost (£) Incremental QALYs ICER (£/QALY)
Without adjusting for baseline EQ-5D
differences
2547.41 –0.046 Co-careldopa dominated
Adjusting for baseline cost differencesa 1903.90 –0.023 Co-careldopa dominated
Alternative PT and OT countsa,b –166.44 –0.023 7211.06
Complete case (without imputation)a 883.04 –0.029 Co-careldopa dominated
20% increase in costs (in both arms)a 3056.89 –0.023 Co-careldopa dominated
20% decrease in costs (in both arms)a 2037.93 –0.023 Co-careldopa dominated
Costs are normally distributed in imputation
(adjusting for baseline differences)a
3398.69 –0.024 Co-careldopa dominated
Bootstrapped average (10,000 replications)a 2109.18 –0.023 Co-careldopa dominated
a QALYs are adjusted for EQ-5D differences at baseline.
b We used information on PT and OT sessions provided to us by the clinical team rather than patient-reported data.
TABLE 65 Cost-effectiveness results (outcome measure: RMI, health-care provider perspective)
Treatment group
Costs at 6 weeks (£),a
mean (SD)
RMI at 8 weeks,
proportion (%) with
RMI ≥ 7 points ICER (£/RMI)
Placebo 4447.59 (7368.05) 54.76
Co-careldopa 3197.89 (4993.56) 50.70
Incremental cost (£) Incremental RMI
Co-careldopa vs. placebo –1249.70 –4.06 307.81
a Costs are different from those reported earlier because we used a different sample for this analysis, (i.e. only those with
an RMI score of ≥ 7 points at 8 weeks in either trial arm).
TABLE 66 Cost-effectiveness results (wider perspective for costs, i.e. includes health-care provider costs and
patient costs)
Treatment group Costs (£), mean (SD) QALYs,a mean (SD) ICER (£/QALY)
Placebo 15,266.73 (16,987.16) 0.421 (0.030)
Co-careldopa 17,484.66 (18,579.82) 0.407 (0.281)
Incremental cost (£) Incremental QALYs
Co-careldopa vs. placebo 2217.93 –0.022 Co-careldopa dominated
a QALYs are adjusted for EQ-5D differences at baseline.
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Discussion
The primary CEAs indicated that co-careldopa was not cost-effective compared with placebo. Indeed,
co-careldopa was more expensive, and less effective in terms of QALY gains, than placebo.
Both trial arms showed an increased mean EQ-5D score over 12 months, and the increase was significant
at the 1% level. EQ-5D score differences between groups were significant at baseline and at 8 weeks. The
former may be explained by the fact that the proportions of different stroke infarct types were not equally
distributed across arms. For example, more patients in the co-careldopa group suffered a total anterior
infarct. We adjusted for these baseline differences in the CEAs using simple linear regression techniques.
In the primary analysis, we used a health and social services perspective for costs. Costs from this perspective
were higher in the co-careldopa group than in the placebo group because the former reported a higher use
of resources such as GP visits, face-to-face contacts with the district nurse and hospital inpatient stays. That
said, differences in costs were not significant between groups or over time. Higher costs were also incurred
by the co-careldopa group when adopting a wider perspective (costs to the patients or caregivers) and after
controlling for baseline differences between arms.
A limitation of this analysis was the high proportion of missing data. Even though missing EQ-5D scores
were present in the data set, of greater concern was that about two-thirds of the patients in the trial had
missing resource use data. This was primarily driven by missing items in the resource use questionnaire
rather than by failure to attempt to complete the questionnaire. Some of the missing values can perhaps be
explained by patient morbidity and the fact that the average age of participants in the trial was 71 years.
To deal with the missing utility and cost data, we had to impute the values using the multiple imputation
method. Although an accepted method, it is clearly suboptimal and less reliable the greater the proportion
of data to be imputed. Analysis of complete-case data, although limited by the small sample, yielded the
same conclusion as the primary analysis. Economic evaluations in trials of patients who may struggle to
complete questionnaires as a result of failing recall, frailty or other morbidity should strive to capture
health-care resource use data from central records such as Hospital Episode Statistics whenever possible.
This would minimise missing data, allow greater confidence in results and reduce responder burden
on patients.
Despite the missing data, we can be relatively confident in the QALY results, and these were not in favour
of co-careldopa. However, there was some suggestion that the results may be influenced by the degree to
which the protocol was followed in intervention delivery. The net benefit regression is also of interest, and
a significant interaction was found between treatment arm and infarct type. The trial was not powered for
such subgroup analysis, but further investigation may be warranted to determine whether this finding is
spurious or highlights a real differential treatment effect by stroke type.
TABLE 67 Cost-effectiveness results (wider perspective for costs, i.e. includes health-care provider costs, patient and
caregiver costs)
Treatment group Costs (£), mean (SD) QALYs,a mean (SD) ICER (£/QALY)
Placebo 57,740.67 (59,077.52) 0.422 (0.026)
Co-careldopa 60,965.02 (66,242.36) 0.398 (0.027)
Incremental cost Incremental QALYs
Co-careldopa vs. placebob 3224.35 –0.024 Co-careldopa dominated
a These are patient QALYs adjusted for EQ-5D differences at baseline.
b In this analysis, 94 patients and carers were included.
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Conclusions
On the basis of the DARS trial, the conclusion is that co-careldopa is not cost-effective for improving
rehabilitation after stroke. Indeed, the results indicate that it is more expensive and less effective than
placebo alone. This was the conclusion after conducting several sensitivity and supplementary analyses.
Although there were missing data for resource use and strict treatment non-compliance in many patients,
this conclusion is robust given the lack of treatment effect of co-careldopa. Further analysis is required to
explore the impact of trial arm imbalance, treatment compliance and missing data on the trial results.
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The DARS trial found no benefit of combining dopaminergic therapy with occupational and physical motor
therapy during early rehabilitation following acute stroke in improving walking ability or other motor function.
Just over 10% of patients were lost to follow-up at 8 weeks and < 10% of patients met the strict
per-protocol analysis criteria. Despite this, the findings are robust and generalisable to patients with limited
mobility in the first few weeks after stroke.
The proportion of patients in the placebo arm who achieved the primary outcome of independent
walking at 8 weeks was greater than was anticipated from results of the Scheidtmann et al.52 study, used
to determine the DARS trial sample size (44% in DARS vs. 26%52). This is most likely attributable to the
recruitment of participants at an earlier time point after stroke in the DARS trial than in the Scheidtmann
et al.52 study. Patients in the Scheidtmann et al.52 study were randomised, on average, 43 days after stroke
onset, compared with 18 days after stroke onset in the DARS trial. In any recovery study in stroke, the extent
of potential recovery is greater the earlier patients are recruited after becoming medically stable after the
acute management stage.
Analysis of the moderators of recovery in the DARS trial found that only baseline RMI was weakly
associated with recovery of independent walking, which is an expected finding as patients with less
impairment would be more likely to achieve independent walking.
A range of secondary outcomes in the DARS trial showed no suggestion of benefit on arm function,
disability, activities of daily living and cognition. Cognition showed a recovery pattern seen in other studies,
with significant early improvement and continuing improvement in cognitive functioning during the
12 months following stroke. Carers of patients in the co-careldopa group reported less burden at 6 months
and 12 months. We consider that this may reflect an imbalance between the two carer groups prior to
stroke, which we were unable to measure, rather than a treatment effect of co-careldopa on trial participants
that was not apparent in the other outcome measures. Carers were identified opportunistically by research
teams in discussion with patients after they had experienced a stroke at the time of trial consent. Carer input
prior to, and after, stroke was not measured in the trial; therefore, change in carer burden could not be
analysed in relation to care delivered. One possible contributory factor to carer burden may have been the
better general health reported by patients in the co-careldopa group at 6 months. However, no difference in
general health status was seen between groups at 8 weeks and 12 months, and the finding at 6 months is
unlikely to be due to an effect of co-careldopa therapy and more likely to be due to the play of chance. The
health economic analysis of the DARS trial demonstrated that dopaminergic therapy with co-careldopa is
associated with increased health-care resource utilisation with lower QALY gain and is, therefore, clearly
not cost-effective.
Strengths and weaknesses
In designing the DARS trial, levodopa in the form of co-careldopa was chosen from a number of drug
therapies that were considered, including amphetamines and SSRIs. Levodopa was chosen because it has a
good safety profile and is generally well tolerated by an older population with Parkinson’s disease. The
previously published small trials also suggested an efficacy signal.52–54,56–58,63 In contrast, other potential
therapies, such as amphetamines, were known to have significant safety problems, such as hypertension
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and delirium, and, with other agents such as cholinesterase inhibitors, the pre-existing clinical trial
database was much weaker.
The strengths of the trial are the double-blind, placebo-controlled design (and the results suggest that
the blinding was maintained), the recruitment of a large of number of participants from multiple NHS
stroke services and good adherence to study treatment and therapy sessions, with > 80% of participants
receiving at least 20 minutes of motor therapy in > 80% of therapy sessions. However, < 10% of patients
met the per-protocol analysis criteria, and this analysis was consequently severely underpowered. The main
reason for lack of compliance with the per-protocol analysis was failure of participants to take the IMP
45–60 minutes prior to therapy. This time frame was chosen with the aim of achieving peak serum and
brain levodopa concentrations at the time of therapy but may have been unnecessarily narrow. These
criteria were, in retrospect, too strict for a multicentre trial involving multiple therapy teams, often in
individual patients. We cannot absolutely exclude the possibility that, had high levels of strict compliance
with optimal timing of therapy following drug administration been achieved, a benefit of co-careldopa
may have been shown. It is also possible that the trial included too many patients who were going to
make a good recovery; although, because fewer than half of participants in the placebo group achieved
the primary mobility end point and there was no suggestion of benefit in patients with more impairment
at trial baseline, this seems unlikely. Future trials of combined timed drug and therapy might consider
using less strict criteria for per-protocol analyses.
Participant characteristics appear reasonably representative of a typical inpatient stroke population able to
engage with routine stroke therapy who were independently mobile prior to stroke and able to consent
to participate in research. Patients who had reduced mobility prior to their stroke or significant cognitive
impairment were not included in the DARS trial. It is unlikely that this group would have shown a different
therapeutic response, but they may have been more vulnerable to AEs of co-careldopa.
A weakness of the trial is the loss to follow-up at 8 weeks of just over 10% of participants. Excluding
deaths, 8.1% of placebo participants and 10.3% of co-careldopa participants had no outcome at 8 weeks,
with participant withdrawal from the trial being the main cause. The potential for incomplete follow-up in
all randomised patients to bias the results of RCTs is well recognised, and patients with less good outcomes
may be more likely to withdraw from follow-up. However, the primary analysis made the assumption that
those participants with missing outcome data did not achieve a positive primary outcome (i.e. they were
assumed to be unable to walk independently), and sensitivity analyses testing the robustness of this assumption
did not contradict the primary ITT conclusion. It is possible that the differential loss to follow-up between
groups may have led to bias, and this would probably have been in favour of placebo if participants who were
lost to follow-up were less well. Considerable efforts were made by the trial management team and sites to
reduce loss to follow-up, but some patients found the follow-up requirements of the trial demanding. This
emphasises the importance of designing recovery trials with robust mechanisms to capture follow-up outcomes
that minimise demands on patients and their carers.
Generalisability
Overall, despite these limitations, the main finding of the DARS trial of no benefit on independent walking
at 8 weeks appears robust and generalisable to the typical stroke population in the UK and other countries
with developed health-care systems.
Safety
Treatment with co-careldopa after stroke had an acceptable safety profile. Twelve-month mortality was,
as expected, low for a stroke population recruited after acute phase and was not significantly increased
with co-careldopa treatment. More patients in the co-careldopa group died within the first 8 weeks of the
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trial than in the placebo group when the study IMP was administered (n = 6, co-careldopa group; n = 1
placebo group). The cause of death in these patients was reveiwed and was not considered to be due to
co-careldopa treatment. The rate of reported SAEs was not increased in the co-careldopa group and SAEs
were not typical AEs of co-careldopa but mostly considered to be related to the underlying stroke or
complications. Vomiting during therapy sessions after study drug administration was uncommon but more
frequent in the co-careldopa group than in the placebo group (0.5% vs. 0.1%, respectively) and may have
been drug related.
Intensity of therapy
The findings of the mediator analysis suggested that both the amount of therapy and the number of IMP
doses, placebo or co-careldopa, received were associated with walking independently at 8 weeks. As IMP
administration and therapy were highly correlated through trial design, this observation suggests that the
amount of therapy received may be an important determinant of recovery. However, interpretation of these
associations when the amount of therapy was not subject to randomisation is complex, as intercurrent
illness, mood problems or clinical deterioration may prevent patients participating in therapy and impaired
recovery may be related to these factors rather than the amount of received therapy alone. Further research
is required to identify optimal therapy input in the acute and recovery stages of stroke. The lack of current
knowledge on optimal type and intensity of therapy in different populations of stroke patients presents
challenges in the design of combined drug therapy trials.
Stroke subtype
No difference was seen in the response of patients’ subcortical and cortical stroke to co-careldopa therapy.
However, categorisation of patients had to be undertaken on the basis of imaging obtained in routine
clinical care, which was obtained at different times after stroke onset, and was generally with CT brain
imaging rather than MRI. There are theoretical reasons why patients whose motor deficit is due to basal
ganglia lesions might respond differently to dopaminergic therapy to those with cortical strokes. Initially,
the researchers had intended to undertake functional MRI (fMRI) studies to examine changes in functional
brain responses during motor therapy in a subset of patients at sites where this imaging was available.
However, this proved impractical to establish within a multicentre trial. Given the overall lack of response
seen in a heterogeneous stroke population to dopaminergic therapy, it would be appropriate to undertake
studies that examine in well-defined subgroups of stroke patients whether or not dopaminergic or other
drug therapies can modify motor cortex activation following stroke, before undertaking clinical studies
utilising impairment and disability measures.
Intermittent versus sustained dosing
Another possible explanation for the lack of response to co-careldopa is the use of intermittent dosing of
the IMP rather than sustained daily dosing, as was used in some previous trials including the Scheidtmann
et al. trial52 of 3 weeks’ levodopa therapy. An intermittent dosing strategy was chosen with the intention
of maximising brain dopamine concentrations during therapy by administering the IMP 45–60 minutes
prior to therapy so that peak brain concentrations of dopamine would be achieved during therapy. This
dosing strategy was developed from the timing of clinical experience of response to dopaminergic therapy
in Parkinson’s disease. A strategy of daily dosing for 6 weeks may have more consistently achieved
elevated brain dopaminergic activity at the time of therapy, but would probably have resulted in an
increase in AEs and patient withdrawal, and, unless all therapy sessions had been administered in the first
2–3 hours after daily administration of the IMP, would have resulted in therapy sessions being undertaken
with relatively low levels of dopaminergic activity. It is possible that higher doses of co-careldopa might
have been beneficial. However, this would probably have produced more AEs and been less well tolerated.
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The dose used in the trial produces chemical benefits in Parkinson’s disease. Future Phase II trials of
recovery-enhancing drugs might usefully compare intermittent versus daily dosing in terms of tolerability
and clinical and/or biomarker response of recovery.
Intensity of therapy received
A possible explanation for the lack of response to co-careldopa seen in the DARS trial is that the intensity
of therapy delivered in the trial was insufficient. The therapy delivered to patients was at the discretion
of the hospital and early supported discharge therapy teams. The average number of therapy sessions
delivered to each patient was 23, with an average duration of 40 minutes of motor activities. This amount
of therapy matches that recommended in guidance produced for stroke rehabilitation by the Royal College
of Physicians.125 The study authors intended that patients would receive at least 16 hours of therapy, and
the study was based on the results of the 2004 meta-analysis of the effects of therapy time on recovery.126
This level of therapy was achieved and, although it is possible that more intensive therapy might have
been needed to see benefit from dopaminergic therapy, this would prove challenging to NHS services to
provide, and many patients might be unable to tolerate higher levels of therapy. Further interpretation is
limited within such a large multicentre trial conducted across many sites, as it was infeasible to collect
further detailed information on the content or delivery of therapy.
The DARS trial and other trials
The findings of the DARS trial appear to be consistent with those of smaller studies of dopaminergic
therapy. A formal meta-analysis of trials of dopaminergic therapy in stroke recovery has not been
undertaken and, given the wide range of different outcome measures in populations of stroke patients
recruited at different times after stroke, might not be justified. Of the seven reported randomised trials,
three showed no benefit on motor function (n = 33,63 n = 1058 and n = 25 participants53), two showed
improvements in walking speed (n = 10 participants56) or procedural motor learning (n = 18 participants57)
and one, slightly larger, study showed a slight improvement in disability (n = 100 participants54). The
one trial that showed a clinically significant effect of levodopa therapy was the Scheidtmann et al.52 study
n = 53 participants), which found a significant difference in RMI score gain of 2.3 points after 3 weeks in
those on 100 mg of levodopa compared with those receiving placebo therapy.
Practical issues
The DARS trial was a complex stroke trial and is the largest multicentre stroke rehabilitation trial to
combine timed administration of a blinded IMP with therapy sessions. The DARS trial was designed to
optimise efficacy of dopaminergic therapy and minimise AEs by using a strategy of administering oral
levodopa prior to motor therapy. This approach required a high degree of co-ordination of drug
administration with planned therapy and differs from that used in most clinical trials. This novel approach
of co-ordinating drug administration with motor therapy in a multicentre trial was successfully delivered
with support from NIHR Stroke Research Network research teams. Recruitment to trial target was achieved
and would not have been possible without the infrastructure and support provided by the network with
site co-ordinators and the eight local stroke research network leads. Strict per-protocol adherence was
achieved in 55% of therapy sessions and the IMP was administered before therapy in 85% of therapy
sessions. Transfer of patients from hospital to community rehabilitation settings was a further challenge.
The DARS trial has demonstrated that it is feasible to deliver multicentre trials of pharmacotherapy-
enhanced rehabilitation in NHS stroke services. This learning and experience is of value in informing
the design and conduct of future rehabilitation multicentre trials investigating the effect of drugs to
enhance recovery.
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Future trials
The DARS trial demonstrates no additional benefit of dopaminergic therapy to routine motor PT and OT in
improving walking and motor function after stroke. Valuable experience has been gained in the design
and conduct of combined studies of drug therapy and motor therapy that are complex and challenging in
terms of deciding the timing of the start of the intervention, timing of drug/cellular therapy with motor
therapy and intensity of motor therapy, which is highly relevant to the design of future trials of combined
studies of drug/cellular therapy and motor therapy to improve outcomes from stroke.
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Implications for health care
The results of the DARS trial indicate that there is no role for the use of dopaminergic therapy in
conjunction with PT and OT in improving walking after stroke.
Implications for research
The results of the DARS trial suggest that further clinical trials of levodopa to improve motor function in
the first few weeks after stroke should not be undertaken.
Future clinical trials of other pharmacotherapies that act on motor learning should consider comparing
strategies of continuous dosing and intermittent dosing prior to motor therapy and different doses of
drug therapy.
The DARS trial has shown that multicentre trials of pharmacotherapy and standardised rehabilitation are
feasible. Future trials should collect data on time and content of rehabilitation.
Clinical trials of pharmacotherapy to improve stroke recovery may need to consider using a greater
intensity of therapy than was used in the DARS trial.
Future clinical rehabilitation trials should arrange follow-up assessments that minimise the burden on trial
participants and carers and loss to follow-up at primary outcome assessment.
Future research should consider incorporation of emerging imaging markers, such as fMRI, as proof-of-concept
biomarkers into early-phase trials of pharmacotherapy to improve recovery from stroke.
Future research is needed into the development of more sensitive clinical markers of motor recovery that
would demonstrate proof-of-concept efficacy on neurological impairment in early-phase trials before
undertaking large pragmatic trials using disability measures as the primary trial outcome.
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Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to available
anonymised data may be granted following review.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Search strategy
Search strategy for Ovid MEDLINE (1946 to 25 September 2015)
1 exp Stroke/ 28 exp Dihydroxyphenylalanine/ 55 recover$.mp.
2 exp Stroke, Lacunar/ 29 $dopa$.mp. 56 (motor adj3 function$).mp.
3 exp Cerebrovascular Disorders/ 30 sinemet.mp. 57 (motor adj3 perform$).mp.
4 exp Cerebral Infarction/ 31 $careldopa.mp. 58 (motor adj3 skill$).mp.
5 exp Brain Infarction/ 32 madopar.mp. 59 (upper adj3 function$).mp.
6 exp Cerebrovascular
Circulation/
33 24 or 25 or 26 or 27 or 28 or
29 or 30 or 31 or 32
60 (arm adj3 function$).mp.
7 exp Arterial Occlusive Diseases/ 34 exp Rehabilitation/ 61 (upper adj3 move$).mp.
8 exp Cerebral Hemorrhage/ 35 exp “Recovery of Function”/ 62 (hand adj3 function$).mp.
9 exp Brain Ischemia/ 36 exp Physical Therapy Modalities/ 63 (hand adj3 move$).mp.
10 exp Hemiplegia/ 37 exp Walking/ 64 (hand adj3 dexter$).mp.
11 exp Paresis/ 38 exp Mobility Limitation/ 65 (upper adj3 limb$).mp.
12 stroke.mp. 39 exp “Activities of Daily Living”/ 66 (upper adj3 extrem$).mp.
13 (cerebr*vascular adj3
accident).mp.
40 exp Arm/ 67 (leg adj3 function$).mp.
14 (cerebrovascular adj3
accident).mp.
41 exp Upper Extremity/ 68 (leg adj3 move$).mp.
15 (cerebral adj2 vascular adj2
accident).mp.
42 exp Hand/ 69 (lower adj3 limb).mp.
16 CVA.mp. 43 exp Hand Strength/ 70 (lower adj3 extrem$).mp.
17 hemipleg*.mp. 44 exp Leg/ 71 physi$ therapy.mp.
18 hemipar*.mp. 45 exp Lower Extremity/ 72 physiotherapy.mp.
19 cereb* isch?emi*.mp. 46 exp Muscle Strength/ 73 occupat$ therapy.mp.
20 cerebral h?emorrhage.mp. 47 exp Locomotion/ 74 walk$.mp
21 intracerebral h?emorrhage.mp. 48 exp Gait/ 75 gait.mp.
22 parenchymal h?emorrhage.mp. 49 exp Gait Disorders, Neurologic/ 76 ambulat$.mp.
23 1 or 2 or 3 or 4 or 5 or 6 or 7
or 8 or 9 or 10 or 11 or 12 or
13 or 14 or 15 or 16 or 17 or
18 or 19 or 20 or 21 or 22
50 exp Gait Apraxia/ 77 mobil$.mp.
24 exp Dopamine/ 51 exp Motor Skills/ 78 transfer$.mp.
25 exp Dopamine Agents/ 52 exp Treatment Outcome/ 79 34 or 35 or 36 or 37 or 38 or
39 or 40 or 41 or 42 or 43 or
44 or 45 or 46 or 47 or 48 or
49 or 50 or 51 or 52 or 53 or
54 or 55 or 56 or 57 or 58 or
59 or 60 or 61 or 62 or 63 or
64 or 65 or 66 or 67 or 68 or
69 or 70 or 71 or 72 or 73 or
74 or 75 or 76 or 77 or 78
26 exp Dopamine Agonists/ 53 exp Social Participation/ 80 23 and 33 and 79
27 exp Levodopa/ 54 rehabilitat$.mp.
DOI: 10.3310/eme06050 EFFICACY AND MECHANISM EVALUATION 2019 VOL. 6 NO. 5
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Ford et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
Search strategy for EMBASE (1996 to week 42, 2014) and EMBASE Classic
(1947 to 25 September 2015)
1 exp cerebrovascular accident/ 32 21 or 22 or 23 or 24 or 25
or 26 or 27 or 28 or 29 or
30 or 31
63 exp social participation/
2 exp cerebrovascular disease/ 33 exp rehabilitation/ 64 exp social adaptation/
3 exp brain infarction/ 34 exp convalescence/ 65 exp social interaction/
4 exp brain hemorrhage/ 35 exp physiotherapy/ 66 exp occupational therapy/
5 exp hemiplegia/ 36 exp home physiotherapy/ 67 exp physical disability/
6 exp hemiparesis/ 37 exp walking/ 68 exp outcome assessment/
7 exp lacunar stroke/ 38 exp walking difficulty/ 69 exp treatment outcome/
8 exp brain ischemia/ 39 exp walking speed/ 70 exp outcomes research/
9 exp paresis/ 40 exp locomotion/ 71 exp rating scale/
10 stroke.mp. 41 exp gait/ 72 rehabilitat$.mp.
11 lacun$.mp. 42 exp gait disorder/ 73 recover$.mp.
12 ($vascular adj3 accident$).mp. 43 gait/ or exp neurologic gait
disorder/
74 arm.mp.
13 cerebrovascular accident.mp. 44 exp gait apraxia/ 75 leg.mp.
14 cerebral vascular accident.mp. 45 exp hemiplegic gait/ 76 (upper adj3 limb).mp.
15 hemipleg$.mp. 46 gait/ or exp unsteady gait/ 77 (upper adj3 extremit$).mp.
16 hemipar$.mp. 47 gait/ or exp spastic gait/ 78 (lower adj3 limb$).mp.
17 isch?emi$.mp. 48 exp limited mobility/ 79 (lower adj3 extremit$).mp.
18 CVA.mp. 49 exp patient mobility/ 80 mobil$.mp.
19 h?emorrhag$.mp. 50 exp physical mobility/ 81 walk$.mp.
20 1 or 2 or 3 or 4 or 5 or 6 or 7 or
8 or 9 or 10 or 11 or 12 or 13 or
14 or 15 or 16 or 17 or 18 or 19
51 exp daily life activity/ 82 ambulat$.mp.
21 exp dopamine/ 52 exp arm/ 83 $therapy.mp.
22 exp dopamine receptor
stimulating agent/
53 exp arm movement/ 84 outcome.mp.
23 exp levodopa/ 54 exp arm exercise/ 85 (arm adj3 function$).mp.
24 exp carbidopa plus levodopa/ 55 arm/ or exp arm weakness/ 86 (hand adj3 function$).mp.
25 exp carbidopa plus entacapone
plus levodopa/
56 exp hand/ 87 (leg adj3 function$).mp.
26 exp benserazide plus levodopa/ 57 exp hand grip/ 88 (upper limb adj3 function$).mp.
27 exp DOPA/ 58 exp hand movement/ 89 (lower limb adj3 function$).mp.
28 $dopa$.mp. 59 exp hand function/ 90 33 or 34 or 35 or 36 or 37 or
38 or 39 or 40 or 41 or 42 or
43 or 44 or 45 or 46 or 47 or
48 or 49 or 50 or 51 or 52 or
53 or 54 or 55 or 56 or 57 or
58 or 59 or 60 or 61 or 62 or
63 or 64 or 65 or 66 or 67 or
68 or 69 or 70 or 71 or 72 or
73 or 74 or 75 or 76 or 77 or
78 or 79 or 80 or 81 or 82 or
83 or 84 or 85 or 86 or 87 or
88 or 89
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29 sinemet.mp. 60 exp hand strength/ or
hand/
91 20 and 32 and 90
30 $careldopa.mp. 61 exp leg/
31 madopar.mp. 62 exp leg movement/
Search strategy for Ovid PsycINFO (1806 to 25 September 2015)
1 exp Cerebrovascular Accidents/ 23 madopar.mp. 45 exp Physical Strength/
2 exp Cerebral Ischemia/ 24 levodopa.mp. 46 exp Exercise/
3 exp Cerebrovascular Disorders/ 25 L-dopa.mp. 47 exp Treatment Outcomes/
4 exp Cerebral Hemorrhage/ 26 16 or 17 or 18 or 19 or 20
or 21 or 22 or 23 or 24 or
25
48 exp Rating Scales/
5 exp Hemiplegia/ 27 exp Rehabilitation/ 49 exp Measurement/
6 exp Hemiparesis/ 28 exp Motor Processes/ 50 rehabilitat$.mp.
7 Stroke.mp. 29 exp Motor Performance/ 51 recover$.mp.
8 lacun$.mp. 30 exp Physical Therapy/ 52 arm.mp.
9 cerebrovascular accident$.mp. 31 exp Occupational Therapy/ 53 leg.mp.
10 cerebral vascular accident$.mp. 32 exp “Activities of Daily
Living”/
54 (upper adj3 limb).mp.
11 $vascular accident$.mp. 33 exp Walking/ 55 (lower adj3 limb).mp.
12 CVA.mp. 34 exp Gait/ 56 (lower adj3 extremit$).mp.
13 hemipleg$.mp. 35 exp Physical Mobility/ 57 (upper adj3 extremit$).mp.
14 hemipare$.mp. 36 exp Disabilities/ 58 hand.mp.
15 1 or 2 or 3 or 4 or 5 or 6 or 7 or
8 or 9 or 10 or 11 or 12 or 13 or
14
37 exp Social Interaction/ 59 mobil$.mp.
16 exp Dopamine/ 38 exp Participation/ 60 walk$.mp.
17 exp Dopamine Agonists/ 39 exp Learning/ 61 ambulat$.mp.
18 exp Levodopa/ 40 exp Motor Coordination/ 62 $therapy.mp.
19 exp DOPA/ 41 exp “Arm (Anatomy)”/ 63 outcome.mp.
20 $dopa$.mp. 42 exp “Hand (Anatomy)”/ 64 27 or 28 or 29 or 30 or 31 or
32 or 33 or 34 or 35 or 36 or
37 or 38 or 39 or 40 or 41 or
42 or 43 or 44 or 45 or 46 or
47 or 48 or 49 or 50 or 51 or
52 or 53 or 54 or 55 or 56 or
57 or 58 or 59 or 60 or 61 or
62 or 63
21 sinemet.mp. 43 exp Grasping/ 65 15 and 26 and 64
22 $careldopa.mp. 44 exp “Leg (Anatomy)”/
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Appendix 2 Resource use: unit costs
TABLE 68 Resource use: unit costs
Resource type
Unit cost at
2015 prices, (£) Source Comments
GP, surgery visit
FTF 46.75 PSSRU 2013, p. 191109 Lasting 11.7 minutes (with
qualifications – including
direct care staff costs)
T/E 28.05 PSSRU 2013, p. 191109 Lasting 7.1 minutes (with
qualifications – including
direct care staff costs)
GP, home visit
FTF 118.44 PSSRU 2013, p. 191109 Lasting 23.4 minutes (with
qualifications – including
direct care staff costs)
T/E 70.69 Assume 23.4 minutes ×
0.6= 14.04 minutes
District nurse, health visitor or member of community team
FTF 39.79 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, community
health services – nursing, code: N02AF
T/E 24.03 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, community
health services – nursing, code: N02AN
Social worker
FTF 234.80 PSSRU 2013, p. 198109 Assume 60 minutes
T/E 78.26 Assume 20 minutes
Counsellor
FTF 60.00 PSSRU 2013, p. 54109 55 minutes
T/E 20.00 Assume 18.3 minutes
Home help or care
worker
24.93 PSSRU 2013, p. 202109 Based on the price
multipliers for independent
sector home care provided
for social services
Speech and language therapist
FTF 35.32 PSSRU 2013, p. 177109 Assume 60 minutes
T/E 11.77 Assume 20 minutes
Psychiatrist or psychologist
FTF 139.22 PSSRU 2013, p. 179109 Assume 60 minutes
T/E 46.41 Assume 20 minutes
Day centre 213.97 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, community
health services – day care facilities, code: DCF10
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TABLE 68 Resource use: unit costs (continued )
Resource type
Unit cost at
2015 prices, (£) Source Comments
Lunch or social
club




36.75 PSSRU 2013, p. 129109
Family or patient support or self-help groups
FTF 52.99 PSSRU 2013, p. 152109 Ongoing support from the
family support worker
(London costs)
T/E 17.66 Assume 20 minutes
Dentist 119.33 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, community
health services – medical and dental, code: M01
Nurse, general practice
FTF 13.95 PSSRU 2013, p. 188109 15.5 minutes
T/E 4.69 Assume 5.2 minutes
Occupational therapist
FTF 79.06 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, allied health
professionals, code: A06A1
T/E 26.36 Assume one-third of FTF
Paramedics 239.03 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, ambulance
services, code: ASS02
Pharmacist
FTF 36.36 PSSRU 2013, p. 180109 Assume 30 minutes
T/E 12.12 Assume one-third of FTF
Physiotherapist
FTF 52.40 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, allied health
professionals, code: A08A1
T/E 17.46 Assume one-third of FTF
Re-ablement 43.63 PSSRU 2013, p. 114109
Rehabilitation
centre
71.71 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, allied health
professionals, code: CRT1
Wheelchair service 92.46 PSSRU 2013, p. 108109
Citizens Advice
FTF 15.58 PSSRU 2013, p. 200109 Assume 30 minutes
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TABLE 68 Resource use: unit costs (continued )
Resource type
Unit cost at
2015 prices, (£) Source Comments
Chiropodist
FTF 43.55 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, allied health
professionals, code: A09
T/E 14.51 Assume one-third of FTF
Psychotherapy
FTF 60.00 Same as ‘Councellor’
T/E 20.00 Same as ‘Councellor’
Leisure facilities 5.30 www.leeds.gov.uk/sports/Documents/30.01.2014.pdf




(accessed 27 October 2015)
Clinic incontinent
FTF 87.82 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, community
health services, code: N14AF
Non-FTF 39.92 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, community
health services, code: N14AN
Hypnotherapy
FTF 60.00 Same as ‘Counsellor’
T/E 20.00 Same as ‘Counsellor’
Dietitian
FTF 73.49 National Schedule of Reference Costs 2012–13,110
NHS trusts and NHS foundation trusts, allied health
professionals, code: A03
T/E 24.50 Assume one-third of FTF
Hospital inpatient
stay
363.96 National Schedule of Reference Costs
2013–2014,111 NHS trusts and NHS foundation
trusts, elective inpatient excess bed-days, code:
AA35C
Stroke with CC score of
10–12
Hospital day centre 375.38 National Schedule of Reference Costs
2013–2014,111 NHS trusts and NHS foundation
trusts, day cases, code: AA35C




135.33 National Schedule of Reference Costs
2013–2014,111 NHS trusts and NHS foundation




112.59 National Schedule of Reference Costs
2012–2013,110 NHS trusts and NHS foundation







111.31 PSSRU 2013, p. 37109 £750 per week
CC, complication and comorbidity; FTF, face-to-face contact; T/E, telephone or e-mail contact.
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Appendix 3 Sensitivity analyses tables
TABLE 69 Descriptive statistics for sensitivity analysis
Variables used in the sensitivity analysis
Able to walk independently at 8 weeks
Yes (N= 311) No (N= 269) Total (N= 580)
Randomised allocation, n (%)
Co-careldopa 159 (53.3) 139 (46.7) 298 (100.0)
Placebo 152 (53.9) 130 (46.1) 282 (100.0)
Patient sex, n (%)
Male 202 (57.2) 151 (42.8) 353 (100.0)
Female 109 (48.0) 118 (52.0) 227 (100.0)
Type of stroke, n (%)
Infarction 252 (50.7) 245 (49.3) 497 (100.0)
Primary haemorrhage 59 (71.1) 24 (28.9) 83 (100.0)
RMI 24-hour randomisation system score
Mean (SD) 2.9 (1.83) 1.5 (1.38) 2.2 (1.78)
Median (range) 3.0 (0.0–6.0) 1.0 (0.0–6.0) 2.0 (0.0–6.0)
Age (years)
Mean (SD) 66.5 (14.06) 70.8 (11.61) 68.5 (13.14)
Median (range) 67.3 (20.2–95.6) 72.1 (41.8–98.2) 69.9 (20.2–98.2)
BI score at baseline
Mean (SD) 8.9 (3.71) 6.3 (3.19) 7.7 (3.70)
Median (range) 8.0 (1.0–19.0) 6.0 (0.0–20.0) 7.0 (0.0–20.0)
Days between stroke and randomisation
Mean (SD) 15.8 (9.54) 19.8 (10.26) 17.7 (10.08)
Median (range) 13.0 (3.0–59.0) 17.0 (5.0–55.0) 15.0 (3.0–59.0)
Note
Assumes that participants who died, were lost to follow-up or had missing RMI data that could not be imputed were able
to walk independently at 8 weeks.
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TABLE 70 Estimates with 95% CIs from stepwise multilevel logistic regression model for sensitivity analysis
Model parameter OR (95% CI) p-value
Treatment group: co-careldopa vs. placebo 0.915 (0.617 to 1.358) 0.660
Sex: female vs. male 0.770 (0.509 to 1.166) 0.217
Stroke type: infarction vs. primary haemorrhage 0.277 (0.152 to 0.505) 0.000
RMI score at baseline 1.504 (1.283 to 1.763) 0.000
Age (years) 0.978 (0.962 to 0.994) 0.007
BI score at baseline 1.094 (1.016 to 1.177) 0.017
Days between stroke and randomisation 0.958 (0.938 to 0.978) 0.000
Total number of sessions with sufficient motor therapy 0.968 (0.951 to 0.985) 0.000
Note
Assumes participants who died, were lost to follow-up or had missing RMI data that could not be imputed were able to
walk independently at 8 weeks.
TABLE 71 Descriptive statistics for the complete-case sensitivity analysis
Variables used in the complete-case sensitivity analysis
Able to walk independently at 8 weeks
Yes (N= 238) No (N= 256) Total (N= 494)
Randomised allocation, n (%)
Co-careldopa 116 (46.8) 132 (53.2) 248 (100.0)
Placebo 122 (49.6) 124 (50.4) 246 (100.0)
Patient sex, n (%)
Male 161 (53.0) 143 (47.0) 304 (100.0)
Female 77 (40.5) 113 (59.5) 190 (100.0)
Type of stroke, n (%)
Infarction 195 (45.7) 232 (54.3) 427 (100.0)
Primary haemorrhage 43 (64.2) 24 (45.8) 67 (100.0)
RMI 24-hour randomisation system score (points)
Mean (SD) 3.1 (1.78) 1.5 (1.39) 2.3 (1.79)
Median (range) 3.0 (0.0–6.0) 1.0 (0.0–6.0) 2.0 (0.0–6.0)
Age (years)
Mean (SD) 65.3 (14.14) 71.0 (11.44) 68.3 (13.11)
Median (range) 65.9 (20.2–95.6) 72.5 (41.8–98.2) 69.6 (20.2–98.2)
NEADL score at baseline (points)
Mean (SD) 60.7 (10.13) 57.6 (12.77) 59.1 (11.67)
Median (range) 66.0 (0.0–66.0) 63.0 (0.0–66.0) 63.0 (0.0–66.0)
Missing (n) 7 2 9
BI score at baseline (points)
Mean (SD) 9.3 (3.39) 6.3 (3.23) 7.7 (3.63)
Median (range) 9.0 (3.0–19.0) 6.0 (0.0–20.0) 7.0 (0.0–20.0)
Missing (n) 5 3 8
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TABLE 71 Descriptive statistics for the complete-case sensitivity analysis (continued )
Variables used in the complete-case sensitivity analysis
Able to walk independently at 8 weeks
Yes (N= 238) No (N= 256) Total (N= 494)
Days between stroke and randomisation
Mean (SD) 15.1 (9.66) 19.9 (10.29) 17.6 (10.26)
Median (range) 13.0 (3.0–59.0) 17.0 (5.0–55.0) 14.0 (3.0–59.0)
TABLE 72 Estimates with 95% CIs from stepwise multilevel logistic regression model for sensitivity analysis of
complete cases
Model parameter OR (95% CI) p-value
Treatment group: co-careldopa vs. placebo 0.809 (0.517 to 1.266) 0.352
Sex: female vs. male 0.917 (0.574 to 1.463) 0.714
Stroke type: infarction vs. primary haemorrhage 0.283 (0.143 to 0.559) 0.000
RMI score at baseline 1.684 (1.400 to 2.025) 0.000
Age (years) 0.976 (0.959 to 0.994) 0.010
NEADL score at baseline 1.024 (1.003 to 1.046) 0.027
BI score at baseline 1.116 (1.023 to 1.217) 0.013
Days from stroke to randomisation 0.945 (0.922 to 0.967) 0.000
TABLE 73 Descriptive statistics for participants in sensitivity analysis, adjusting for patient-completed RMI score at
baseline (in place of score the researcher score on the 24-hour randomisation system)
Variables used in the sensitivity analysis
Able to walk independently at 8 weeks
Yes (N= 244) No (N= 332) Total (N= 576)
Randomised allocation, n (%)
Co-careldopa 120 (40.5) 176 (59.5) 296 (100.0)
Placebo 124 (44.3) 156 (55.7) 280 (100.0)
Patient sex, n (%)
Male 164 (46.7) 187 (53.3) 351 (100.0)
Female 80 (35.6) 145 (64.4) 225 (100.0)
Type of stroke, n (%)
Infarction 199 (40.46) 294 (59.6) 493 (100.0)
Primary haemorrhage 45 (54.2) 38 (45.8) 83 (100.0)
RMI 24-hour randomisation system score (points)
Mean (SD) 3.1 (1.78) 1.6 (1.46) 2.2 (1.77)
Median (range) 3.0 (0.0–6.0) 1.0 (0.0–6.0) 2.0 (0.0–6.0)
continued
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TABLE 73 Descriptive statistics for participants in sensitivity analysis, adjusting for patient-completed RMI score at
baseline (in place of score the researcher score on the 24-hour randomisation system) (continued )
Variables used in the sensitivity analysis
Able to walk independently at 8 weeks
Yes (N= 244) No (N= 332) Total (N= 576)
Age (years)
Mean (SD) 65.5 (14.10) 70.7 (12.02) 68.5 (13.18)
Median (range) 66.0 (20.2–95.6) 72.2 (20.8–98.2) 69.9 (20.2–98.2)
NEADL score at baseline (points)
Mean (SD) 60.7 (10.01) 57.6 (12.51) 58.9 (11.61)
Median (range) 66.0 (0.0–66.0) 63.0 (0.0–66.0) 63.0 (0.0–66.0)
BI score at baseline (points)
Mean (SD) 9.3 (3.44) 6.5 (3.44) 7.7 (3.70)
Median (range) 9.0 (3.0–19.0) 6.0 (0.0–20.0) 7.0 (0.0–20.0)
Days between stroke and randomisation
Mean (SD) 15.0 (9.59) 19.6 (10.01) 17.7 (10.08)
Median (range) 12.0 (3.0–59.0) 17.0 (3.0–55.0) 15.0 (3.0–59.0)
TABLE 74 Estimates with 95% CIs from stepwise multilevel logistic regression analysis for sensitivity analysis,
adjusting for researcher-completed RMI score at baseline (in place of score on the 24-hour randomisation system)
Model parameter OR (95% CI) p-value
Treatment group: co-careldopa vs. placebo 0.784 (0.528 to 1.165) 0.229
Sex: female vs. male 0.875 (0.580 to 1.321) 0.525
Stroke type: infarction vs. primary haemorrhage 0.384 (0.219 to 0.672) 0.001
Baseline researcher RMI score 1.545 (1.323 to 1.803) 0.000
Age (years) 0.979 (0.964 to 0.994) 0.008
Baseline NEADL score 1.024 (1.004 to 1.045) 0.017
Baseline BI score 1.106 (1.030 to 1.187) 0.006
Days between stroke and randomisation 0.947 (0.927 to 0.968) 0.000
TABLE 75 Estimates with 95% CIs from multilevel stepwise logistic regression, adjusting for patient-completed RMI
score at baseline (in place of score the researcher score on the 24-hour randomisation system)
Model parameter OR (95% CI) p-value
Treatment group: co-careldopa vs. placebo 0.769 (0.518 to 1.142) 0.193
Sex: female vs. male 0.886 (0.587 to 1.337) 0.562
Stroke type: infarction vs. primary haemorrhage 0.426 (0.243 to 0.745) 0.003
RMI score on 24-hour randomisation system 1.289 (1.132 to 1.468) 0.000
Age (years) 0.978 (0.963 to 0.993) 0.005
Baseline NEADL score 1.023 (1.004 to 1.042) 0.019
Baseline BI score 1.140 (1.058 to 1.228) 0.001
Days between stroke and randomisation 0.946 (0.925 to 0.966) 0.000
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TABLE 76 Descriptive statistics for participants in sensitivity analysis, excluding participants who completed the
8-week follow-up RMI questionnaire later than 12 weeks post randomisation
Variables used in the sensitivity analysis
Able to walk independently at 8 weeks
Yes (N= 230) No (N= 261) Total (N= 491)
Randomised allocation, n (%)
Co-careldopa 110 (44.9) 135 (55.1) 245 (100.0)
Placebo 120 (48.8) 126 (51.2) 246 (100.0)
Patient sex, n (%)
Male 156 (51.7) 146 (48.3) 302 (100.0)
Female 74 (39.2) 115 (60.8) 189 (100.0)
Type of stroke, n (%)
Infarction 187 (43.9) 239 (56.1) 426 (100.0)
Primary haemorrhage 43 (66.2) 22 (33.8) 65 (100.0)
RMI 24-hour randomisation system score (points)
Mean (SD) 3.0 (1.80) 1.5 (1.37) 2.2 (1.76)
Median (range) 3.0 (0.0–6.0) 1.0 (0.0–6.0) 2.0 (0.0–6.0)
Age (years)
Mean (SD) 65.7 (14.24) 70.7 (11.61) 68.4 (13.14)
Median (range) 66.0 (20.2–95.6) 72.0 (41.8–98.2) 69.7 (20.2–98.2)
NEADL score at baseline (points)
Mean (SD) 60.6 (10.20) 57.9 (12.52) 59.1 (11.56)
Median (range) 66.0 (0.0–66.0) 63.0 (0.0–66.0) 63.0 (0.0–66.0)
BI score at baseline (points)
Mean (SD) 9.2 (3.42) 6.4 (3.16) 7.7 (3.57)
Median (range) 9.0 (3.0–19.0) 6.0 (0.0–20.0) 7.0 (0.0–20.0)
Days between stroke and randomisation
Mean (SD) 14.8 (9.61) 19.5 (10.06) 17.3 (10.11)
Median (range) 12.0 (3.0–59.0) 17.0 (5.0–50.0) 14.0 (3.0–59.0)
TABLE 77 Estimates with 95% CIs from stepwise multilevel logistic regression analysis for sensitivity analysis, excluding
participants who completed the 8-week follow-up RMI questionnaire later than 12 weeks post randomisation
Model parameter OR (95% CI) p-value
Treatment group: co-careldopa vs. placebo 0.790 (0.508 to 1.229) 0.294
Sex: female vs. male 0.924 (0.582 to 1.468) 0.737
Stroke type: infarction vs. primary haemorrhage 0.231 (0.117 to 0.457) 0.000
RMI score on 24-hour randomisation system 1.631 (1.366 to 1.947) 0.000
Age (years) 0.978 (0.960 to 0.995) 0.013
Baseline NEADL score 1.024 (1.002 to 1.046) 0.032
Baseline BI score 1.134 (1.043 to 1.233) 0.003
Days between stroke and randomisation 0.943 (0.920 to 0.966) 0.000
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TABLE 78 Descriptive statistics for participants in sensitivity analysis, assuming participants who were too unwell to
complete the 8-week follow-up questionnaire were unable to walk independently, and excluding participants with
any other reason for not completing it
Variables used in the sensitivity analysis
Able to walk independently at 8 weeks
Yes (N= 243) No (N= 295) Total (N= 538)
Randomised allocation, n (%)
Co-careldopa 120 (43.8) 154 (56.2) 274 (100.0)
Placebo 123 (46.6) 141 (53.4) 264 (100.0)
Patient sex, n (%)
Male 163 (49.4) 167 (50.6) 330 (100.0)
Female 80 (38.5) 128 (61.5) 208 (100.0)
Type of stroke, n (%)
Infarction 199 (42.5) 269 (57.5) 468 (100.0)
Primary haemorrhage 44 (62.9) 26 (37.1) 70 (100.0)
RMI 24-hour randomisation system score (points)
Mean (SD) 3.1 (1.78) 1.5 (1.41) 2.2 (1.78)
Median (range) 3.0 (0.0–6.0) 1.0 (0.0–6.0) 2.0 (0.0–6.0)
Age (years)
Mean (SD) 65.5 (14.12) 70.8 (11.78) 68.4 (13.15)
Median (range) 66.0 (20.2–95.6) 72.1 (41.8–98.2) 69.7 (20.2–98.2)
NEADL score at baseline (points)
Mean (SD) 60.7 (10.03) 57.7 (12.57) 59.0 (11.58)
Median (range) 66.0 (0.0–66.0) 63.0 (0.0–66.0) 63.0 (0.0–66.0)
BI score at baseline (points)
Mean (SD) 9.3 (3.43) 6.3 (3.24) 7.7 (3.64)
Median (range) 9.0 (3.0–19.0) 6.0 (0.0–20.0) 7.0 (0.0–20.0)
Days between stroke and randomisation
Mean (SD) 15.1 (9.60) 19.5 (10.19) 17.5 (10.17)
Median (range) 12.0 (3.0–59.0) 17.0 (5.0–55.0) 14.0 (3.0–59.0)
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TABLE 79 Reasons why participants did not return questionnaires (i.e. had no primary end-point data)
Reasons







Patient died 1 (0.3) 1 (0.4) 2 (0.3)
Patient withdrew 11 (3.2) 5 (1.8) 16 (2.5)
Cannot get hold of participant 1 (0.3) 2 (0.7) 3 (0.5)
Moved out of area 1 (0.3) 1 (0.4) 2 (0.3)
Too unwell 1 (0.3) 3 (1.1) 4 (0.7)
Lost in post 0 (0.0) 1 (0.4) 1 (0.2)
Lost at site 4 (1.3) 0 (0.0) 4 (0.7)
Withdrew after follow-up period
started
6 (1.9) 2 (0.7) 8 (1.3)
Participant refused to complete 0 (0.0) 2 (0.7) 2 (0.3)
Other 1 (0.3) 2 (0.7) 3 (0.5)
TABLE 80 Estimates with 95% CIs from stepwise multilevel logistic regression analysis for sensitivity analysis,
assuming participants who were too unwell to complete the 8-week follow-up questionnaire were unable to walk
independently, and excluding participants who moved out of area, were unwilling for visit, refused to complete,
whose questionnaires were lost at site or in post or when we could not get hold of them
Model parameter OR (95% CI) p-value
Treatment group: co-careldopa vs. placebo 0.858 (0.566 to 1.302) 0.471
Sex: female vs. male 0.948 (0.613 to 1.467) 0.811
Stroke type: infarction vs. primary haemorrhage 0.265 (0.141 to 0.498) 0.000
RMI score on 24-hour randomisation system 1.590 (1.347 to 1.876) 0.000
Age (years) 0.981 (0.965 to 0.998) 0.026
Baseline NEADL score 1.025 (1.004 to 1.047) 0.018
Baseline BI score 1.137 (1.052 to 1.230) 0.001
Days between stroke and randomisation 0.948 (0.927 to 0.970) 0.000
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FIGURE 15 Modified Rankin Scale proportional odds assumptions at the 8-week follow-up (plot of four empirical


















FIGURE 16 Modified Rankin Scale proportional odds assumptions at the 6-month follow-up.
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Appendix 5 Vomiting between the investigational
medicinal product dose and end of therapy
TABLE 81 Number of participants vomiting between the IMP dose and end of motor therapy
Vomited between IMP dose and end of therapy







Yes 27 (0.5) 9 (0.1) 36 (0.3)
No 5829 (97.7) 5861 (97.4) 11,690 (97.5)
Unknown 89 (1.5) 134 (2.2) 223 (1.9)
Missing 22 (0.4) 16 (0.3) 38 (0.3)
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Appendix 6 Moderator analysis
TABLE 82 Summary statistics of moderator variables, by primary outcome category
Moderator variable
Walking independently at 8 weeks
No (N= 341) Yes (N= 252)
Baseline RMI score (points), n; mean (SD)
24-hour randomisation 341; 1.60 (1.49) 252; 3.13 (1.79)
Researcher-reported 341; 1.60 (1.48) 252; 3.11 (1.77)
Patient-reported 322; 1.74 (1.85) 244; 3.43 (2.29)
GHQ-12 total score (points), n; mean (SD) 331; 19.68 (6.56) 239; 18.90 (7.22)
MoCA total score (points), n; mean (SD) 331; 19.11 (6.58) 249; 21.71 (5.60)
Joint, neck or back pain, n (%)
No 195 (58.0) 152 (61.5)
Yes 141 (42.0) 95 (38.5)
Pain in upper limbs, n (%)
No 270 (80.4) 199 (80.6)
Yes 66 (19.6) 48 (19.4)
Pain in lower limbs, n (%)
No 235 (69.9) 194 (78.5)
Yes 101 (30.1) 53 (21.5)
Central post-stroke pain, n (%)
No 331 (98.5) 242 (98.0)
Yes 5 (1.5) 5 (2.0)
Any thumb, hand, finger or wrist joint pain, n (%)
No 326 (97.0) 244 (98.8)
Yes 10 (3.0) 3 (1.2)
Spinal pain, n (%)
No 330 (98.2) 238 (96.4)
Yes 6 (1.8) 9 (3.6)
Patient medical history, n (%)
Cardiovascular and limiting mobility conditions
(with/without other conditions)
282 (82.7) 195 (77.4)
Other conditions only 40 (11.7) 28 (11.1)
No medical conditions reported 19 (5.6) 29 (11.5)
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TABLE 82 Summary statistics of moderator variables, by primary outcome category (continued )
Moderator variable
Walking independently at 8 weeks
No (N= 341) Yes (N= 252)
Ischaemic change in MCA territory, n (%)
Not affected 158 (59.4) 135 (68.2)
< 33% of MCA territory 72 (27.1) 43 (21.7)
> 33% of MCA territory 36 (13.5) 20 (10.1)
Site of MCA territory, n (%)
None 158 (59.4) 135 (68.2)
Cortical 40 (15.0) 28 (14.1)
Subcortical 41 (15.4) 22 (11.1)
Both (cortical and subcortical) 27 (10.2) 13 (6.6)
Any haemorrhage, n (%)
No 233 (86.9) 156 (79.2)
Yes 35 (13.1) 40 (20.8)
Haemorrhage location, n (%)
None 233 (88.9) 156 (80.0)
Cortical 11 (4.2) 10 (5.1)
Subcortical 18 (6.9) 28 (14.9)
Periventricular lucencies, n (%)
No 153 (57.1) 118 (58.7)
Yes 115 (42.9) 83 (41.3)
White matter periventricular lucency, n (%)
No lucency 153 (57.1) 118 (58.7)
Restricted to region adjoining ventricles 60 (22.4) 49 (24.4)
Entire region from lateral ventricle to cortex 55 (20.5) 34 (16.9)
Old vascular lesions, n (%)
No 200 (74.9) 145 (73.2)
Yes 67 (25.1) 52 (26.8)
Notes
GHQ-12: higher score indicates worse health.
MoCA: score of < 26 points indicates cognitive impairment.
Scan data only available for 472 patients: 270 not walking independently at 8 weeks and 202 walking independently at
8 weeks. All data measured prior to randomisation.
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TABLE 83 Summary statistics of moderator variables, by treatment group
Moderator variable
Treatment group
Placebo (N= 285) Co-careldopa (N= 308)
Baseline RMI score (points), n; mean (SD)
24-hour randomisation 285; 2.28 (1.79) 308; 2.22 (1.79)
Researcher-reported 285; 2.26 (1.76) 308; 2.23 (1.78)
Patient-reported 275; 2.50 (2.23) 291; 2.45 (2.20)
GHQ-12 total score (points), n; mean (SD) 277; 19.31 (7.02) 293; 19.40 (6.69)
MoCA total score (points), n; mean (SD) 281; 20.46 (5.96) 299; 20.01 (6.62)
Joint, neck or back pain, n (%)
No 177 (62.3) 170 (56.9)
Yes 107 (37.7) 129 (43.1)
Pain in upper limbs, n (%)
No 230 (81.0) 239 (79.9)
Yes 54 (19.0) 60 (20.1)
Pain in lower limbs, n (%)
No 212 (74.7) 217 (72.6)
Yes 72 (25.3) 82 (27.4)
Central post-stroke pain, n (%)
No 281 (98.9) 292 (97.7)
Yes 3 (1.1) 7 (2.3)
Any thumb, hand, finger or wrist joint pain, n (%)
No 279 (98.2) 291 (97.3)
Yes 5 (1.8) 8 (2.7)
Spinal pain, n (%)
No 279 (98.2) 289 (96.7)
Yes 5 (1.8) 10 (3.3)
Patient medical history (category 3), n (%)
Cardiovascular and/or limiting mobility conditions
(with/without other conditions)
229 (80.3) 248 (80.5)
Other conditions only 33 (11.6) 35 (11.4)
No medical conditions reported 23 (8.1) 25 (8.1)
Ischaemic change in MCA territory, n (%)
Not affected 155 (67.1) 138 (59.2)
< 33% of MCA territory 49 (21.2) 66 (28.3)
> 33% of MCA territory 27 (11.7) 29 (12.5)
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TABLE 83 Summary statistics of moderator variables, by treatment group (continued )
Moderator variable
Treatment group
Placebo (N= 285) Co-careldopa (N= 308)
Site and size of MCA territory, n (%)
None 155 (67.1) 138 (59.2)
Cortical 28 (12.1) 40 (17.2)
Subcortical 29 (12.6) 34 (14.6)
Both (cortical and subcortical) 19 (8.2) 21 (9.0)
Any haemorrhage, n (%)
No 187 (81.0) 202 (86.3)
Yes 44 (19.0) 32 (13.7)
Haemorrhage location, n (%)
None 187 (82.4) 202 (87.8)
Cortical 13 (5.7) 8 (3.5)
Subcortical 27 (11.9) 20 (8.7)
Periventricular lucencies, n (%)
No 137 (58.6) 134 (57.0)
Yes 97 (41.4) 101 (43.0)
White matter periventricular lucency, n (%)
No lucency 137 (58.6) 134 (57.0)
Restricted to region adjoining ventricles 54 (23.1) 55 (23.4)
Entire region from lateral ventricle to cortex 43 (18.4) 46 (19.6)
Old vascular lesions, n (%)
No 170 (73.6) 175 (74.8)
Yes 61 (26.4) 59 (25.2)
Notes
GHQ-12: higher score indicates worse health.
MoCA: score of < 26 points indicates cognitive impairment.
Scan data only available for 472 patients: 235 in the placebo group and 237 in the co-careldopa group. All data measured
prior to randomisation.
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TABLE 84 Assessment of moderators of treatment effect at 8 weeks in the ITT population: ORs and 95% CIs for the








Model 1: baseline RMI score 0.462 (0.233 to 0.918) 1.251 (0.982 to 1.594) 0.069
Model 2: baseline RMI (patient-reported) score 0.547 (0.287 to 1.042) 1.133 (0.927 to 1.384) 0.222
Model 3: GHQ-12 score 1.278 (0.388 to 4.203) 0.975 (0.912 to 1.033) 0.388
Model 4: MoCA score 0.976 (0.237 to 4.013) 0.989 (0.926 to 1.056) 0.735
Model 5: joint, neck or back pain (yes vs. no) 0.884 (0.528 to 1.480) 0.778 (0.346 to 1.749) 0.544
Model 6: pain in upper limbs (yes vs. no) 0.857 (0.550 to 1.337) 0.695 (0.260 to 1.860) 0.469
Model 7: pain in lower limbs (yes vs. no) 0.841 (0.530 to 1.335) 0.813 (0.326 to 2.028) 0.658
Model 8: central post-stroke pain (yes vs. no) 0.795 (0.533 to 1.185) 1.109 (0.045 to 27.164)a 0.949
Model 9: thumb/hand/wrist joint pain (yes vs. no) 0.819 (0.548 to 1.224) 0.360 (0.018 to 7.307)a 0.506
Model 10: spinal pain (yes vs. no) 0.852 (0.570 to 1.273) –a –
Model 11: patient medical historyb 0.702 (0.452 to 1.092) 1.663 (0.482 to 5.743) 0.615
1.627 (0.380 to 6.961)
Model 12: site of MCA territoryc 0.829 (0.477 to 1.44) 0.730 (0.198 to 2.689) 0.817
0.853 (0.231 to 3.141)
1.916 (0.336 to 10.938)
Model 13: haemorrhage (yes vs. no) 0.838 (0.517 to 1.357) 0.815 (0.253 to 2.625) 0.732
Model 14: periventricular lucencyd 0.737 (0.410 to 1.323) 1.993 (0.686 to 5.791) 0.214
0.612 (0.192 to 1.951)
Model 15: old vascular lesion (yes vs. no) 0.9997 (0.598 to 1.670) 0.462 (0.168 to 1.277) 0.137
a Numbers in model 10 were too small to assess interaction. The numbers in the treatment/pain categories in models
8 and 9 were also small; hence the large CIs for the interaction terms.
b The p-value for model 11 is the overall p-value testing each interaction simultaneously. The number of patients in each
category of treatment group and medical history was small; hence, these results should be treated with caution. The
first OR interaction term is comparing the OR for those with other medical conditions with the OR for those with
cardiovascular and/or limiting mobility conditions. The second OR interaction is comparing the OR for those with no
medical conditions with the OR for those with cardiovascular and/or limiting mobility conditions.
c The number of patients included in this analysis is 464 and the numbers in each category of treatment group and MCA
territory site is small; hence, the results should be treated with caution. Each of the interaction ORs are comparing ORs
for those with cortical, subcortical or both cortical and subcortical MCA lesions, respectively, with the OR for those with
MCA territory not affected.
d The first interaction OR is comparing the OR for those with lucency restricted to region adjoining ventricles with the OR
for no lucency. The second interaction OR is comparing the OR for those with lucency covering the entire region from
lateral ventricle to cortex with the OR for those with no lucency. The p-value for the interaction when considering
lucency as a binary variable (yes/no) was 0.709.
Notes
Potential moderators were measured at baseline and assessed by including an interaction between treatment group and
the moderator variable in the primary analysis multilevel model one at a time. The primary multilevel model adjusted for
baseline RMI score, age, sex, stroke type, baseline BI score, baseline NEADL score and days between stroke and
randomisation, and included a random intercept for site.
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Appendix 7 Mediator analysis
The mediator analysis explored the extent to which the treatment effects can be explained by anintermediate mechanistic outcome. The first step in the Baron and Kenny83 approach to establishing
mediation is to establish whether or not there is an effect that may be mediated. Since there was no
evidence of a statistically significant difference in walking independently at 8 weeks between the
treatment groups in the ITT analysis, the results below are based on exploratory analysis and should be
treated with caution.
Summary statistics of the variables being considered for mediation were tabulated by treatment group and
primary outcome category (Tables 85 and 86). There was no suggestion of any differences by treatment
group but, as might be expected, those walking independently at 8 weeks also had higher BI and NEADL
scores. There were a number of patients with missing questionnaire data at 8 weeks and examination of
the baseline and treatment characteristics of those with and without questionnaire data showed that those
missing data were more likely to be in the co-careldopa group (51% among those not missing vs. 60–63%
among those missing, depending on the questionnaire missing data), to have attended fewer therapy
sessions and to have taken fewer IMP doses (Table 87). With the exception of MoCA score, a higher
proportion of patients without questionnaire data at 8 weeks had a primary haemorrhage (87% among
those not missing vs. 76–77% among those missing, depending on the questionnaire missing data).
TABLE 85 Summary statistics of each mediator variable, by primary outcome category
Mediator variable
Walking independently at 8 weeks
No (N= 341) Yes (N= 252)
Number of (motor) therapy sessions, n; mean (SD) 341; 23.94 (14.05) 252; 23.97 (12.77)
Number of IMP doses, n; mean (SD) 341; 21.52 (13.04) 252; 21.40 (10.94)
FAS score (points), n; mean (SD) 274; 26.00 (7.67) 249; 23.84 (7.11)
MoCA score (points), n; mean (SD) 280; 21.23 (6.33) 246; 24.28 (4.90)
BI score (points), n; mean (SD) 276; 9.46 (3.88) 251; 16.94 (2.56)
NEADL score (points), n; mean (SD) 276; 10.47 (9.05) 251; 31.49 (16.52)
Joint, neck or back pain, n (%)
No 66 (23.7) 64 (25.7)
Yes 212 (76.3) 185 (74.3)
Pain in upper limbs, n (%)
No 108 (38.9) 95 (38.1)
Yes 170 (61.1) 154 (61.5)
Pain in lower limbs, n (%)
No 144 (51.8) 143 (57.4)
Yes 134 (48.2) 106 (42.6)
Central post-stroke pain, n (%)
No 240 (86.3) 242 (90.0)
Yes 38 (13.7) 5 (10.0)
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TABLE 85 Summary statistics of each mediator variable, by primary outcome category (continued )
Mediator variable
Walking independently at 8 weeks
No (N= 341) Yes (N= 252)
Any thumb, hand, finger or wrist joint pain, n (%)
No 224 (80.6) 244 (81.5)
Yes 54 (19.4) 3 (18.5)
Spinal pain, n (%)
No 275 (98.9) 246 (98.8)
Yes 3 (1.1) 3 (1.2)
Notes
FAS: score ranges from 10 to 50 points, with higher scores indicating more severe fatigue.
MoCA: a score of < 26 points indicates cognitive impairment.
BI: a measure of daily living scored from 0 to 20 points, with a higher score indicating a greater degree of functional dependence.
NEADL: score ranges from 0 to 66 points, with a higher score indicating a greater degree of independence.
All measurements were taken at 8-week follow-up.
TABLE 86 Summary statistics of each mediator variable, by treatment group
Mediator variable
Treatment group
Placebo (N= 285) Co-careldopa (N= 308)
Number of (motor) therapy sessions, n; mean (SD) 285; 24.75 (12.50) 308; 23.21 (14.36)
Number of IMP doses, n; mean (SD) 285; 22.36 (11.10) 308; 20.64 (13.07)
FAS score (points), n; mean (SD) 257; 24.85 (7.39) 266; 25.09 (7.57)
MoCA score (points), n; mean (SD) 260; 22.87 (5.51) 266; 22.44 (6.26)
BI score (points), n; mean (SD) 259; 13.17 (4.90) 268; 12.88 (5.09)
NEADL score (points), n; mean (SD) 259; 19.98 (15.83) 268; 20.97 (17.74)
Joint, neck or back pain, n (%)
No 69 (26.5) 61 (22.9)
Yes 191 (73.5) 206 (77.1)
Pain in upper limbs, n (%)
No 101 (38.9) 102 (38.2)
Yes 159 (61.1) 165 (61.8)
Pain in lower limbs, n (%)
No 147 (56.5) 140 (52.4)
Yes 113 (43.5) 127 (47.6)
Central post-stroke pain, n (%)
No 228 (87.7) 236 (88.4)
Yes 32 (12.3) 31 (11.6)
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Following the Baron and Kenny83 steps in establishing mediation, there was no evidence that any of the
variables investigated potentially mediated the effect of treatment on walking independently at 8 weeks
(Table 88). There was weak evidence that treatment group was associated with the amount of therapy
(path a) but no evidence that the amount of therapy affects walking independently at 8 weeks. Similarly,
there was also some evidence that treatment group was associated with the number of IMP doses (path a)
but not that drug dose affects the primary outcome.
TABLE 86 Summary statistics of each mediator variable, by treatment group (continued )
Mediator variable
Treatment group
Placebo (N= 285) Co-careldopa (N= 308)
Any thumb, hand, finger or wrist joint pain, n (%)
No 212 (81.5) 215 (80.5)
Yes 48 (18.5) 52 (19.5)
Spinal pain, n (%)
No 257 (98.8) 264 (98.9)
Yes 3 (1.2) 3 (1.1)
Notes
FAS: score ranges from 10 to 50 points, with higher scores indicating more severe fatigue.
MoCA: a score of < 26 points indicates cognitive impairment.
BI: a measure of daily living scored from 0 to 20 points, with a higher score indicating a greater degree of functional
dependence.
NEADL: score ranges from 0 to 66 points, with a higher score indicating a greater degree of independence.
All measurements were taken at 8-week follow-up.
TABLE 87 Number of therapy sessions and IMP doses among those with and without questionnaire data
at 8 weeks
Mediator variable Missing/not missing at 8 weeks
Therapy sessions IMP doses
n Mean (SD) n Mean (SD)
FAS score Missing 70 12.54 (12.53) 70 10.60 (11.53)
Not missing 523 25.48 (12.90) 523 22.93 (11.52)
MoCA score Missing 67 11.78 (11.92) 67 10.21 (11.33)
Not missing 526 25.50 (12.91) 526 22.90 (11.53)
BI score Missing 66 11.38 (11.26) 66 9.26 (9.79)
Not missing 527 25.53 (12.94) 527 23.0 (11.58)
NEADL score Missing 66 11.79 (11.58) 66 9.56 (10.04)
Not missing 527 25.48 (12.96) 527 22.96 (11.60)
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Path a, effect of treatment group (predictor) on the mediator variable (outcome) (i.e. whether or not treatment group is
associated with the mediator) path b, effect of the mediator on the outcome controlling for treatment group; path c, effect
of treatment group on the primary outcome, controlling for the mediator.
To be judged a mediator, paths a and b must be significant at the 5% level.
Potential mediators were measured post baseline and before assessment of the primary outcome at 8 weeks. All regression
models were based on the primary analysis multilevel model and adjusted for baseline RMI score, age, sex, stroke type,
baseline BI score, baseline NEADL score and days between stroke and randomisation, and included a random intercept
for site.
TABLE 89 Estimates with 95% CIs for the ability to walk independently at 8 weeks among compliers
Model OR (95% CI) p-value
ITT primary analysis 0.777 (0.524 to 1.151) 0.208
Strict compliance 0.868 (0.282 to 2.676) 0.806
Relaxed timing compliance 0.701 (0.354 to 1.391) 0.310
Relaxed timing and motor therapy compliance 0.769 (0.412 to 1.437) 0.411
Relaxed drug intake compliance 0.882 (0.540 to 1.440) 0.615
Notes
Treatment effect among compliers was assessed by including an interaction between treatment group and compliance in
the primary analysis multilevel model. The primary multilevel model adjusted for baseline RMI score, age, sex, stroke type,
baseline BI score, baseline NEADL score and days between stroke and randomisation, and included a random intercept
for site.
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